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IMPLANTABLE DEFIBRILLATOR TREATMENT 
Sudden cardiac death accounts for approximately 50% of mortality from cardiovascular 
disease
1
 and about 85% of these deaths are attributable to ventricular arrhythmias
2
. 
Ventricular tachycardia refers to an abnormal rapid heart rhythm that originates in the 
ventricles and may progress to ventricular fibrillation during which the ventricles quiver. 
As a consequence, effective pumping of blood is ceased, with brain and heart damage 
within minutes. 
The implantable cardioverter defibrillator (ICD) was first implanted in 1980
3
 and 
has now become the treatment of choice in patients who have experienced ventricular 
arrhythmias (secondary prevention), but also in patients at increased risk for these 
arrhythmias, due to coronary artery disease and left ventricular dysfunction (primary 
prevention)
4, 5
. Both secondary as well as primary prevention trials have shown that the 
ICD is significantly more effective in reducing the risk for sudden cardiac death as 
compared to antiarrhythmic drugs
5
. As a consequence, the number of implantations has 
increased substantially
6
. However, it is important to note that sudden cardiac death may 
still occur in a small proportion of ICD patients
7
. 
The ICD is a sophisticated device with three therapy options to terminate 
ventricular arrhythmias
8
. Ventricular fibrillation requires immediate defibrillation by 
high-energy shocks. Ventricular tachycardia is treated with antitachycardia pacing (ATP), 
which involves short bursts of pacing impulses at faster rates than the tachycardia, or low 
energy shocks (cardioversion)
8
. Due to the complex features of the ICD, its reliability has 
been questioned
9
. According to a report by Maisel et al.
9
, ICD replacement due to 
malfunctioning of devices has increased markedly by number and rate between 1996 and 
2002, with a peak in the years 2000-2002 when 26.8 per 1000 ICD implants had to be 
replaced. Most cases of ICD malfunctioning relate to hardware abnormalities, like battery 




PSYCHOLOGICAL DISTRESS FOLLOWING ICD IMPLANTATION 
Many patients adjust well to their implanted defibrillator, but a subgroup of patients 
experiences psychological problems following ICD implantation, including anxiety, 
depression, impaired quality of life, and avoidance behaviors
10-18





 indicates that diagnosable levels of anxiety and depression may be experienced by 
respectively 13%-38% and 10%-15% of ICD patients, which suggests that anxiety may be 
particularly common in this population. Levels of anxiety and depressive symptoms in 




 months after ICD implantation, although 
other studies suggest stability of these levels over various periods within 1 month and 5 
years post-implantation
14, 18, 20, 21
. 
Adaptation problems in ICD patients may be caused by several stressful 
experiences, including the experience of resuscitation, diagnosis of a life-threatening 
disease, unpredictable reoccurrence of ventricular arrhythmias, and restricted physical 
capabilities, but also by the ICD implantation itself, which involves medical examinations 
and induction and termination of ventricular fibrillation
22
. ICD indication (primary versus 
secondary prevention) does not seem to influence adjustment
12, 23
. In contrast, shocks may 
lead to increased psychological distress, although results are not conclusive
24
. A number 





and impaired quality of life
16, 26
 as compared to non-shocked patients, although other 
studies report no significant psychological differences between shocked and non-shocked 
patients
10, 17, 18
. Another device-related factor that may be associated with maladjustment 
is ICD recall
27
, which refers to a notification of ICD manufacturers that some of their 
devices may malfunction. 
Several studies have also focused on non-device related risk factors for anxiety in 





history of psychological difficulties
13
. Only a few studies have focused on personality as a 
risk factor, including Type D personality
12, 28
 (tendency to experience increased negative 
emotions paired with social inhibition
29
) and anxiety sensitivity
21, 30
 (fears of anxiety-
related sensations based on beliefs that these sensations have harmful consequences, such 




PSYCHOLOGICAL FACTORS AND RISK OF VENTRICULAR 
ARRHYTHMIAS IN ICD PATIENTS 
ICDs do not prevent ventricular arrhythmias. Given the increase in the number of ICD 
patients
6





and the notion that ICDs are not completely protective against sudden cardiac death
7
, 
knowledge of precipitating factors of ventricular arrhythmias is essential for the 
identification of high-risk patients. Clinical factors that increase the risk for ventricular 







, atrial fibrillation, and low left ventricular ejection fraction
36
. 
Despite preliminary evidence that psychological factors may play a role in the onset of 
ventricular arrhythmias
37
, only a few studies have investigated this issue in ICD  
patients
38-41
. These patients provide a good opportunity to study psychological precipitants 
of ventricular arrhythmias due to the ICD’s capacity to store arrhythmia episodes. Whang 
et al.
41
 reported that depression triggered arrhythmias, whereas Dunbar et al.
38
 found that 
anxiety was a trigger, but not depression or anger. Finally, Lampert et al.
39
 reported that 
anger may precipitate ventricular arrhythmias, but anxiety, worry, sadness, happiness, 
challenge, feeling in control, or interest may not. In addition to the role of mood states, 
personality factors may also play a role, as Burg et al.
40
 found that ICD patients with trait 
anger or trait anxiety were at increased risk to experience anger- or anxiety-triggered 
appropriate shocks, respectively. Taken together, depression, anxiety, and anger were 
precipitants of ventricular arrhythmias in some, but not all studies.  
As psychological factors may precipitate ventricular arrhythmias in patients, it is 
important to identify these patients and offer them adequate support. However, only a few 
studies have examined interventions for anxiety and depression in ICD patients. These 
studies focused on comprehensive cardiac rehabilitation
42, 43









 but not all
46-48
 
studies demonstrating an effect of the intervention on distress. 
  
THE ROLE OF PARTNERS IN ICD TREATMENT 
Partner status may also be associated with emotional distress in ICD patients. Generally, 
lack of social support may be related to increased emotional distress
51





. Therefore, not having a partner may also be associated with adverse 
outcomes, especially in Type D patients who already have fewer social ties and 





Partners of ICD patients themselves may also experience emotional distress, but 
only a few studies investigated this issue, even though anxiety levels in partners have been 
reported to be as high as levels in ICD patients
54, 55
 or even higher
15, 28
. Initially, partners 
may feel insecure and uncertain about the effectiveness of the ICD, but later on they may 




AIMS OF THIS THESIS 
The main focus of this thesis is on anxiety, as anxiety may be more prevalent in ICD 
patients as compared to depression
13
. The importance of anxiety in ICD patients may stem 
from a number of specific ICD treatment characteristics, including the experience of 
resuscitation, the diagnosis of a life-threatening disease, and the unpredictability of 
ventricular arrhythmias and ICD shocks
22
. Moreover, anxiety has been related to adverse 
outcomes across cardiovascular disease
38, 57
. In this thesis, anxiety predominantly refers to 
general symptoms of state anxiety, which refers to a transient emotional status, 
characterized by feelings of apprehension (i.e., worries and concerns) and tension as well 
as increased activity of the autonomic nervous system
58
. However, interviewer-rated 
levels of clinical anxiety as well as disease-specific anxiety are also discussed in some 
papers. 
The present thesis reports the findings of ongoing prospective research in ICD 
patients and their partners. A theoretical model of research concerning ICD patients only 
is shown in Figure 1a and an explorative model of research involving partners of patients 
is shown in Figure 1b. Following the importance of anxiety in ICD patients, the aims of 
this thesis were to i) examine vulnerability factors for anxiety in ICD patients, ii) examine 
the precipitating role of anxiety for adverse psychological and clinical outcomes, 
including ventricular arrhythmias, and iii) examine anxiety in partners of ICD patients. 





























Patients were recruited from two Dutch referral hospitals: the Catharina Hospital in 
Eindhoven (since May 2003), and the Amphia Hospital in Breda (since June 2005). 
Patients were approached during their hospitalization for ICD implantation and were 
asked to voluntarily participate in a longitudinal study on psychological reaction to ICD 
implantation. The study includes four time points, that is, baseline and 2, 12, and 18 
months post-implantation. Patients were excluded in case of significant cognitive 
ANXIETY 
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   Clinical anxiety 
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impairments (e.g., dementia), severe life-threatening comorbidities (e.g., cancer), or 
inability to read and understand Dutch. In September 2005, a substudy involving partners 
of ICD patients was started in both hospitals. Partners could only participate in this 
substudy when they were living together with the patient and the patient had already 
agreed to participate in the study. No further criteria were formulated for the partners. The 
study was approved by the Medical Ethic Committees of the participating hospitals. The 
study was conducted in accordance with the Helsinki Declaration, and all subjects 
provided written informed consent. Four of the papers in this thesis concern additional 
data from other studies. Chapter 3 includes the results of an extra measurement of anxiety 
after device recall. Chapters 4 and 7 are partially based on data from the “Mood and 
personality as precipitants of arrhythmia in patients with an Implantable cardioverter 
Defibrillator: A prospective Study (MIDAS)”, which is conducted in the Erasmus Medical 
Center in Rotterdam. Finally, the results in Chapter 10 are based on merged data, 
including this ICD population as well as a myocardial infarction population.  
 
OUTLINE OF THIS THESIS 
 
Part I Vulnerability factors for anxiety in ICD treatment 
ICD patients frequently show increased anxiety, but little is known about the determinants 
of anxiety in these patients. It is important to identify patients with increased anxiety, 
because studies on general cardiovascular patients have shown that anxiety may have a 
negative effect on quality of life and prognosis. More specifically in ICD patients, anxiety 
may be associated with an increased risk for ventricular arrhythmias. The first part of this 
thesis describes vulnerability factors for anxiety in order to identify high-risk patients.  
Chapter 2 describes the role of shocks, Type D personality, anxiety sensitivity, and 
demographic and clinical variables for anxiety in 308 ICD patients. Previous studies have 
found that shocks may lead to increased anxiety, although other studies did not find this 
association. In addition, little is known about the role of personality dispositions for 
anxiety in ICD patients. Hence, this short-term follow-up study investigated vulnerability 
factors, including shocks and personality, for self-reported as well as interviewer-rated 
anxiety at 2 months post-implantation. 
Chapter 1 
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Chapter 3 investigates the extent to which ICD recalls may lead to increased anxiety. 
Following Medtronic’s notification in 2005 on potential malfunctioning of certain ICDs, 
all patients with these ICDs had an extra device evaluation. After this evaluation, 33 
patients completed a questionnaire on anxiety because we hypothesized that ICD recall 
may lead to increased anxiety in these patients. The aim of this additional study was to 
determine whether the proportion of ICD patients with high levels of anxiety would 
increase after the extra device evaluation. 
In Chapter 4, the determinants of chronic anxiety were examined. Previous studies 
have focused on anxiety, but little is known about patients who experience chronic levels 
of anxiety. We hypothesized that these patients may differ from patients who are only 
anxious at the time of implantation. This long-term follow-up study only included the 222 
patients of the current study in combination with those of the MIDAS with increased 
anxiety at the time of implantation. Demographic, clinical, and psychological predictors 
were examined of patients who were still anxious at 12 months post-implantation versus 
patients whose anxiety had resolved at 12 months. 
Chapter 5 describes trajectories of anxiety and depressive symptoms over a 12-
month period as well as determinants of these trajectories in 312 ICD patients. Only a few 
studies have examined the course of anxiety and depressive symptoms in ICD patients. 
However, all of these studies examined overall mean scores, which does not allow for the 
identification of trajectories of subgroups of patients with different levels of symptoms. 
 
Part II The role of anxiety in the outcome of ICD treatment 
While part I of this thesis focused on the effect of ICD implantation on anxiety, part II 
focuses on the role of anxiety for clinical outcomes in ICD patients. 
The focus of Chapter 6 is on the predictive value of general anxiety versus disease-
specific anxiety for poor perceived health at 2 months post-implantation in 205 ICD 
patients. Most of the studies on anxiety in ICD patients have focused on general anxiety, 
but attention may also be directed towards specific disease-related anxiety as this type of 
anxiety may be differentially related to outcomes as compared to general anxiety. The 
outcomes in this study comprise self-reported feelings of disability, cardio-pulmonary 
symptoms, and concerns about the ICD, but also interviewer-rated clinical anxiety. The 
Chapter 1 
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psychometric characteristics of the disease-specific anxiety measure we used (Cardiac 
Anxiety Questionnaire), are also examined. 
Chapter 7 reports the results of a large prospective study in 565 ICD patients from 
the current study as well as the MIDAS that investigated the role of anxiety as predictor of 
appropriate ICD therapies (ATPs and shocks) within 12 months following ICD 
implantation. Two previous studies by others also investigated the role of anxiety as a 
trigger of ventricular arrhythmias, but as one study found a significant relationship 
whereas the other study did not, more research is warranted on this topic. 
Chapter 8 also focuses on psychological precipitants of ventricular arrhythmias 
within 12 months post-implantation, but this study (N = 324) included anxiety as well as 
depressive symptoms, Type D personality, and their interaction terms. Until now, Type D 
personality has not been investigated in relation to ventricular arrhythmias and more 
research is needed to examine the relative importance of anxiety, depression, and 
personality as potential predictors of ventricular arrhythmias. 
Chapter 9 reports a review of studies on psychological interventions in ICD 
patients. As stated before, a subgroup of patients experiences psychological problems, 
which may be decreased by means of psychological treatment. Several studies have 
addressed possible interventions for these patients and our aim was to give an overview of 
these studies and to evaluate their efficacy. Another aim was to provide recommendations 
for future research. 
 
Part III The role of partners in ICD treatment 
Partners may also play a role in psychological well-being of ICD patients. Moreover, 
anxiety in partners of ICD patients may be as high as in patients themselves. However, 
little is known about these issues. Therefore, the last part of this thesis focuses on research 
involving partners of ICD patients. 
Chapter 10 reports the results of a short-term follow-up study on the influence of 
not having a partner in combination with a Type D personality for emotional distress. 
Type D personality is associated with morbidity and mortality, but not all Type D patients 
are at risk. We hypothesized that not having a partner may enhance the detrimental effects 
General Introduction 
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of Type D personality on anxiety and depressive symptoms. The results of this study are 
based on ICD patients as well as MI patients (N = 554). 
Chapter 11 presents the findings of a short-term prospective study on anxiety and 
posttraumatic stress in 182 partners of ICD patients. Prospective studies investigating 
anxiety in partners of ICD patients are sparse, even more so for determinants of anxiety in 
partners. Therefore, the aims of this study were to examine the prevalence of anxiety and 
posttraumatic stress in partners, as well as to determine the influence of i) Type D 
personality, anxiety sensitivity, gender, and age of the partner and ii) the patient variables 
ICD indication and shocks. 
Chapter 12 describes the influence of adding a partner substudy on participation 
rates of patients, especially Type D patients (N = 507). We also examined partner 
nonparticipation rates among Type D patients (N = 276). Generally, study participants 
may systematically differ from non-participants. However, nonparticipation may also be 
influenced by the addition of a substudy on partners. As mentioned before, the partner 
study started only in September 2005. Therefore, we were able to examine characteristics 
of participants before and after the start of the substudy on partners, more specifically we 
examined whether addition of a partner substudy was associated with participation rates of 
patients with a Type D personality. A secondary aim was to examine whether Type D 
personality of patients was associated with participation rates of partners. A potential 
selection bias may influence the results of studies involving partners, thereby threatening 
the generalizability of findings. 
 
General discussion and summary 
The thesis will be closed with a general discussion and summary (Chapter 13). The main 
findings of this thesis will be summarized and integrated. Next, clinical implications, 
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Background Studies have examined the relationship between shocks and anxiety, but 
little is known about the role of personality. Our aim was to examine the determinants of 
self-reported and interviewer-rated anxiety following implantable cardioverter 
defibrillator (ICD) implantation. 
Methods At baseline, that is, 0-3 weeks following ICD implantation, 308 ICD patients 
(82% men, mean age = 62.6 years) completed the DS14 (Type D personality) and ASI 
(anxiety sensitivity). The STAI (self-reported symptoms of state-anxiety) was assessed at 
baseline and follow-up, which was 2 months following ICD implantation. At this follow-
up, the HAM-A interview (interviewer-rated anxiety) was assessed in a subsample (57%); 
the occurrence of ICD shocks was deduced from medical records.  
Results ANCOVA for repeated measures showed a significant interaction effect between 
time and shocks (F = 9.27, p = .003), with patients who had experienced a shock 
experiencing higher levels of self-reported anxiety at follow-up. The main effects of Type 
D personality (F = 33.42, p < .0001) and anxiety sensitivity (F = 66.31, p < .0001) were 
significant, indicating that these patients scored higher on self-reported anxiety across 
time points. Multivariable linear regression analyses yielded Type D personality (β = .18, 
p = .021) and anxiety sensitivity (β = .19, p = .016), but not shocks, as independent 
predictors of interviewer-rated anxiety. Covariates included gender, marital status, 
education, age, ICD indication, cardiac history, and comorbidity. 
Conclusions Type D personality and anxiety sensitivity were independent predictors of 
both self-reported and interviewer-rated anxiety outcomes while ICD shocks were related 
to an increase in levels of self-reported anxiety only. Identification and support of ICD 
patients with Type D personality, increased anxiety sensitivity, or shocks is important.  
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INTRODUCTION 
Despite the medical benefits of the implantable cardioverter defibrillator (ICD), several 
psychological problems following ICD implantation have been described, including 
anxiety, with the prevalence of clinically relevant levels ranging from 13% to 38% in ICD 
patients
1
. Symptoms of anxiety refer to a variety of worries and fears as well as 
physiological arousal. ICD discharges may enhance the levels of anxiety, although studies 
report inconsistent results, with some studies finding a significant association between 
shocks and anxiety
2, 3
, but other studies not
4, 5
. These inconsistencies may be due to 
differences in measurements and time points, but also due to the low power to detect 
differences, because of small samples or a low prevalence of shocks. In this context, the 
role of personality may be important, since personality may mediate the relationship 
between discharges and anxiety. Furthermore, some studies have found that anxiety may 
also precipitate ventricular arrhythmias
6, 7
. Due to this untoward effect of anxiety in ICD 
patients, it is important to identify patients who are at risk for experiencing anxiety.  
Although studies have examined the relationship between shocks and anxiety, little 
is known about the role of personality in ICD patients. Personality traits, including     
Type D personality and anxiety sensitivity, may play a central role in the identification of 
ICD patients at risk for experiencing increased levels of anxiety. Type D personality refers 
to the combination of two personality traits; that is, negative affectivity (the tendency to 
experience negative emotions across time and situations) and social inhibition (the 
tendency to inhibit the expression of emotions due to fears of how others will react)
8
. 
Type D patients tend to experience increased negative emotions (e.g., they tend to worry 
and have a gloomy view of life), and they tend to inhibit the expression of these 
emotions
8
. The prevalence of Type D personality varies from 23% to 27% in ICD 
patients
5, 9, 10
 to 53% in hypertensive patients
11
. Type D personality has been associated 
with an increased risk for morbidity and mortality in patients with coronary heart 
disease
11
, as well as increased feelings of anxiety
5, 11
. The relationship between Type D 
personality and anxiety in ICD patients has been evaluated in two studies
5, 12
, with the 
cross-sectional study reporting an independent association between Type D personality 
and anxiety
5
 and the prospective study reporting a large effect of Type D personality on 





Anxiety sensitivity is a personality trait that refers to the fears of anxiety-related 
sensations based on beliefs that these sensations have harmful consequences, such as 
illness, embarrassment, or additional anxiety
13, 14
. For example, persons with high anxiety 
sensitivity may believe that heart palpitations indicate a heart attack, whereas those with 
low anxiety sensitivity experience these sensations as unpleasant but nonthreatening. This 
misinterpretation of sensations may lead to a vicious cycle, where higher levels of anxiety 
may cause further anxiety-related sensations that may be misinterpreted again, and so on. 
Hence, the experience of shocks as well as personality traits may play an important role in 
anxiety in ICD patients. 
The aim of the current study was to examine whether shocks, Type D personality, 
and anxiety sensitivity were predictors of self-reported symptoms of anxiety as well as 
interviewer-ratings of anxiety, independent of each others’ effects and of those of possible 
confounders, such as indication for ICD implantation. 
 
METHODS 
Patient population and design 
Patients who had an ICD implanted in two large Dutch referral hospitals between May 
2003 and January 2007 were included. Inclusion criteria were implantation with an ICD 
and age between 18 and 80 years. Patients were excluded when they were unable to read 
or understand Dutch. 
The study was approved by the Medical Ethics Committees of the participating 
hospitals. The study was conducted in accordance with the Helsinki Declaration, and all 
patients provided written informed consent. 
 
Clinical characteristics  
Demographic variables included sex, age, marital status, and low educational level (less 
than 13 years of education, that is, secondary education or less). Clinical variables 
included shocks (no shocks versus ≥ 1 shock), ICD indication (primary versus secondary 
prevention), comorbidity (lung disease, renal disease, rheumatic disease, or diabetes 
mellitus), and ischemic heart disease (previous myocardial infarction, percutaneous 
coronary intervention, or coronary artery bypass graft surgery). 
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Personality: Type D and anxiety sensitivity  
At baseline, which was between 0 and 3 weeks after ICD implantation, patients completed 
self-report measures on Type D personality and anxiety sensitivity. Table 1 provides an 
overview of the study measurements. 
 
Table 1. Description of measures 





  Type D scale 
  (DS14) 
Type D 
personality 
Tendency to experience 




   
Anxiety Sensitivity 
  Index  





Tendency to be sensitive 







   
  State-Trait       
  Anxiety    
  Inventory  




Feelings of apprehension 
and tension; increased 




   
  Hamilton Anxiety  
  Rating Scale  







Anxious mood, tension, 







Type D personality.  
The 14-item Type D personality Scale (DS14) was used to assess Type D personality
8
. 
The DS14 consists of the 7-item subscales negative affectivity (e.g., “I often feel 
unhappy”) and social inhibition (e.g., “I am a ‘closed’ person”). Items are answered on a 
five-point Likert scale ranging from 0-false to 4-true. Total scores on both subscales range 
from 0 to 28. Patients scoring high on both subscales, that is, equal to or above 10, are 
classified as Type D. Internal consistency is high with Cronbach’s α values of 0.88 for 
negative affectivity and 0.86 for social inhibition
8
. The temporal stability of Type D 
personality has been confirmed by means of test-retest correlations, which were 0.72 and 





Anxiety sensitivity.  
Anxiety sensitivity was measured using the 16-item Anxiety Sensitivity Index (ASI), 
designed to assess sensitivity and fear of anxiety symptoms
14
. Items are rated on a five-
point Likert scale from 0-very little to 4-very much. Total scores are obtained by summing 
the scores on the 16 items, that is, total scores range from 0 to 64, with higher scores 
reflecting greater sensitivity and fear of anxiety symptoms. Examples of items are: ‘It 
scares me when I feel faint’ and ‘When I am nervous, I worry that I might be mentally ill’. 
In our study, the reliability of the ASI was good, with Cronbach’s α = 0.88. Since there is 
no standardized cut-off for the ASI, we used the upper quartile score (i.e., ASI ≥ 19) to 
dichotomize ASI scores. As a final point, it is important to distinguish anxiety sensitivity; 
that is, the beliefs that anxiety symptoms have negative effects, from anxiety; that is, the 




Outcome: symptoms and ratings of anxiety 
The anxiety outcomes comprise both self-reported and interviewer-ratings of anxiety. 
Self-reported anxiety refers to subjective feelings of anxiety as experienced and reported 
by the patient, whereas interviewer-ratings denote the interviewer’s assessment of the 
severity of anxiety, which may be rated as a psychiatric diagnosis. At baseline, self-
reported symptoms of anxiety were assessed. Two months following implantation, 
assessment of self-reported symptoms of anxiety as well as interviewer-ratings of anxiety 
was realized. Interviews were administered in the hospital and the questionnaires were 
subsequently completed at home and returned via mail. This procedure was applied till 
August 2006 (interview group; n = 199). Due to logistic reasons, interviews could not be 
administered after August 2006. Patients who had their 2 month follow-up time point after 
this date, received the questionnaires via mail (mail only group; n = 169). 
 
Self-reported symptoms of anxiety.  
The state version of the State-Trait Anxiety Inventory (form Dutch Y-1; STAI) is a 20-
item self-report measure. The STAI was used to assess the current presence of general 
symptoms of state anxiety
15
. This form of anxiety refers to a transient emotional status, 
characterized by feelings of apprehension (i.e., worries and concerns) and tension as well 
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as increased activity of the autonomic nervous system
15
. Items are scored on a 4-point 
Likert scale from 1-not at all to 4-very much so. Scores range from 20, that is, low level of 
state-anxiety to 80, that is, high level of state-anxiety. The STAI has been demonstrated to 
have adequate validity and reliability, with Cronbach’s α ranging from 0.87 to 0.92
15
. To 
indicate clinically elevated levels of general anxiety, a cut-off ≥ 40 was used. This cut-off 
was previously used in studies on ICD
16




Interviewer ratings of anxiety.  
The Hamilton Rating Scale for Anxiety (HAM-A) is a 14-item semi-structured interview 
and is a psychiatric standard for the assessment of current severity of anxiety
18
. The items 
comprise the symptoms of anxiety, including anxious mood, tension, insomnia, and 
several somatic symptoms. The severity of the symptoms is rated by the interviewer on a 
scale from 0-not present to 4-very severe/incapacitating. Scores range from 0 to 56, with a 
score above 17 indicating clinically elevated anxiety
18
. The validity and reliability are 
good, with Cronbach’s α ranging from 0.82 to 0.92, and interrater reliability (i.e., 
intraclass coefficient) ranging from 0.74 to 0.98
18-20
. The HAM-A has been used as an 





Patients with and without complete data were compared regarding baseline demographic 
and clinical variables, using a Chi-square
 
test for nominal variables and Student’s t-test for 
continuous data. To investigate differences between baseline and follow-up levels of 
anxiety and the proportion of patients with clinically relevant anxiety, a paired t-test and 
the McNemar test were used, respectively. A t-test for independent samples was 
performed to determine the association between Type D personality and anxiety 
sensitivity. Next, a biserial correlation coefficient was calculated to examine the 
plausibility of multicollinearity between these personality characteristics. To examine the 
influence of shocks and personality for self-reported anxiety at baseline and 2 months 
follow-up, and for changes in anxiety, an ANCOVA for repeated measures was 
performed. To examine whether interviewer-rated anxiety at follow-up differed as a 
function of shocks, Type D, or increased anxiety sensitivity a number of t-tests for 
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independent samples were applied. Next, a series of linear regression analyses were 
performed to determine the predictive value of personality and shocks for interviewer-
ratings of anxiety. In ANCOVA for repeated measures and linear regression analyses, we 
adjusted for the effects of the other predictors, including sex, marital status, age, 
education, indication for ICD, comorbidity, and history of cardiac disease. A p-value < 
0.05 was considered to be statistically significant. All statistical analyses were performed 




Of the initial 368 patients who were included at baseline, 308 (84%) patients completed 
the study at 2 months follow-up (mean = 64.07±15.82 days, range 29-139 days). Reasons 
for not completing the study were death (n = 6), loss to follow-up and refusal to further 
participate (n = 27), and missing data on self-report measures or medical data (n = 27). 
Patients without complete data were more likely to be Type D (36% versus 20%, p = .008) 
and to be without a partner (23% versus 11%, p = .007). Furthermore, these patients had 
higher levels of anxiety sensitivity (p = .001) and general anxiety (p = .001) at baseline 
compared to included patients. 
The interview group (who also received questionnaires) eventually comprised 176 
(57%) patients and the mail only group comprised 132 (43%) patients. These groups were 
compared on all variables included in this study, except for HAM-A scores. Results only 
showed differences regarding shocks (2.8% versus 8.3%, p = .032) and primary 
prevention (46.6% versus 64.4%, p = .002). The results regarding shocks must be 
interpreted with caution because of reduced power. The higher percentage of primary 
prevention patients in the mail only group was expected, since indications for ICD 
implantation have been expanded in recent years, with nowadays relatively more primary 
prevention reasons being applied. Table 2 shows the demographic, clinical, and 
personality characteristics of the 308 study participants, as well as the mean scores and 
prevalences of clinically elevated levels of both self-reported and interviewer-rated 
anxiety. A total number of 57 appropriate as well as inappropriate shocks were 
experienced by 16 patients (5%), including 1 patient who had experienced an electrical 
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storm of 33 shocks. The prevalences of Type D personality and anxiety sensitivity were 
consistent with previous literature
5, 9, 22
. Levels of self-reported anxiety diminished 
significantly from baseline to follow-up (p < .0001). Similarly, the proportion of patients 
with clinically elevated scores of self-reported anxiety decreased significantly from 
baseline to follow-up (p < .002). 
 
Table 2. Patient characteristics (N = 308)
 
 % (N) Mean (SD) Range 
Demographics    
   Female 18 (54)   
   No partner 11 (33)   
   Low education
* 
48 (147)   
   Age  62.6 (10.1) 24-79 
    
Clinical variables    
   Secondary prevention 46 (141)   
   ≥ 1 shock since implantation 5 (16)   
   Ischemic heart disease
† 
71 (220)   
   Comorbidity
‡
 36 (112)   
    
Personality    
   Type D personality 20 (61)   
   Anxiety sensitivity score  13.5 (9.2) 0-47 
   Anxiety sensitivity ≥ 19
 
26 (79)   
    
Mean anxiety levels    
   Self-reported anxiety score at baseline  38.6 (11.4) 20-76 
   Self-reported anxiety score at follow-up  36.3 (10.8) 20-69 
   Interviewer-rated anxiety at follow-up
§ 
 4.7 (5.5) 0-24 
    
Clinically elevated anxiety (≥ cut-off)    
   Self-reported anxiety at baseline ≥ 40
 
46 (140)   
   Self-reported anxiety at follow-up ≥ 40
 
36 (110)   
   Interviewer-rated anxiety at follow-up ≥ 17§ 
 
13 (24)   
Measures: Type D personality: Type D Scale (DS14), Anxiety sensitivity: Anxiety 
Sensitivity Index (ASI), Self-reported symptoms of anxiety: State-Trait Anxiety Inventory 
(STAI), Interviewer-ratings of anxiety: Hamilton Anxiety Rating Scale (HAM-A). 
*
 Secondary education or less; 
†
 Previous myocardial infarction, percutaneous coronary 
intervention, and/or coronary artery bypass graft; 
‡
 Lung, renal, and/or rheumatic disease, 
and/or diabetes; 
§
 n = 176 
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Type D personality was significantly related to anxiety sensitivity, with Type D 
patients scoring higher on anxiety sensitivity than non-Type D patients (18.8±10.2 versus 
12.1±8.5, p < .0001). Similarly, significantly more Type D patients reported increased 
feelings of anxiety sensitivity compared to non-Type Ds (48% versus 22%, p < .0001). 
However, the biserial correlation coefficient between Type D personality and anxiety 
sensitivity was 0.42, indicating no multicollinearity and permitting these variables to be 
included simultaneously in the regression model. 
 
Personality and self-reported symptoms of anxiety  
Repeated measures ANCOVA analysis showed no significant effect of time (Wilks’ 
Lambda = 0.99, F (1, 298) = 2.75, p = .098), indicating that baseline levels of anxiety did 
not differ from follow-up levels, adjusting for anxiety sensitivity, Type D personality, 
shocks, gender, marital status, education, ICD indication, and age. Two interaction effects 
were found. First, a significant time by shocks effect (Wilks’ Lambda = 0.97, F (1, 298) = 
9.27, p = .003) was found, with the plot in Figure 1 showing almost equal levels of 
anxiety at baseline, but at follow-up higher levels for the patients who had experienced a 
shock. Second, the time by age (Wilks’ Lambda = 0.98, F (1, 298) = 4.82, p = .029) effect 
was significant. Additional analysis using the dichotomized variable age ≤ 65 instead of 
the continuous variable age showed that younger patients experience similar levels of 
anxiety across time points, but older patients experience less anxiety at baseline and equal 
levels at follow-up. Both Type D personality (Wilks’ Lambda = 0.99, F (1, 298) = 1.93,   
p = .17) and anxiety sensitivity (Wilks’ Lambda = 1.0, F (1, 298) = 0.26, p = .61) did not 
interact with time nor was there a significant interaction between time and any of the other 
variables. 
The main effect of Type D personality was significant (F (1, 298) = 33.42,              
p < .0001), with Type Ds scoring significantly higher on self-reported anxiety as 
compared to non Type Ds across both time points. Similarly, the main effect of anxiety 
sensitivity was significant (F (1, 298) = 66.31, p < .0001). In contrast, the main effect of 
shocks was not significant (F (1, 298) = 1.07, p = .30). Low education was associated with 
higher anxiety levels across time points (F (1, 298) = 8.62, p = .004). None of the other 
variables displayed a main effect. 

















Figure 1. Estimated marginal means of self-reported anxiety as a function the experience 
















Personality and interviewer-ratings of anxiety  
Mean levels of interviewer-rated anxiety varied as a function of Type D personality and 
anxiety sensitivity, but not of shocks (Figure 2). A series of univariable linear regression 
analyses were used to examine the predictive value of personality and shocks for 
interviewer-ratings of anxiety. Type D personality (ß = .24, p = .001) and anxiety 
sensitivity (ß = .24, p = .001) were significant predictors of interviewer-ratings of anxiety, 
whereas shocks were not (ß = .04, p = .59). These two personality variables also predicted 
interviewer-rated anxiety in multivariable analyses (Table 3). None of the covariates were 
significantly associated with interviewer-rated anxiety at follow-up. It is important to note 
that this interview group comprised only 5 patients who had experienced a shock. 
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Figure 2. Levels of interviewer-rated anxiety at follow-up, stratified by shocks, Type D 
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DISCUSSION 
This short-term follow-up study in ICD patients examined personality type and ICD 
shocks in relation to anxiety. Anxiety is an important issue in ICD patients, since over one 
third of the patients in this study still experienced clinically elevated levels of anxiety two 
months following the ICD implantation. Both self-reported anxiety as well as interviewer-
rated anxiety were independently predicted from Type D personality and anxiety 
sensitivity, whereas shocks did not exert a significant main effect on either anxiety 
outcome. However, levels of self-reported anxiety at baseline were equal for shocked 
versus non-shocked patients, but at two months follow-up, the shocked patients 
experienced higher levels of self-reported anxiety as compared to the non-shocked 
patients.  
Previous studies regarding the role of shocks for anxiety have reported inconsistent 
results
2-5
. Personality may play a role in this relationship, but this could not be examined 
in this study due to the low number of shocks and consequently reduced power. Our 
results indicate that patients who have experienced one or more shocks may develop 
symptoms of anxiety (as measured by the STAI), although the severity of these symptoms 
may not be on the level of a clinical diagnosis of anxiety (as measured by the HAM-A). 
These results should be interpreted with caution because of the short-term follow-up 
period and subsequent reduced number of shocks, especially in the interview group. 
It is important to note that the decreased prevalence of shocks, as well as the 
number of shocks per patient, may have influenced our results. The declined prevalence of 
shocks may in part be due to an increasing proportion of primary ICD implantations. 
Moreover, increasing use of antitachycardia pacing as initial therapy for ventricular 
tachycardias will diminish the occurrence of shocks
23
. In general, in our population we 
programmed antitachycardia pacing for slow and fast VT in all ICD patients. The 
prevalence of patients who have experienced ≥ 1 shocks between implantation and 2 
months follow-up was 5% only, which implies reduced power to detect differences. 
Besides the prevalence and consequently reduced power, the number of shocks may also 
be of importance in predicting anxiety. The CIDS trial found that receiving ≥ 5 shocks 
was related to poorer emotional functioning, whereas < 5 shocks was not
24
. Because of the 
small number of participants receiving a shock, we used the distinction of 0 shocks versus 
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≥ 1 shocks, which may have influenced the results. Therefore, future research should 
further focus on the role of shocks for anxiety, using different distinctions. 
Our results regarding personality factors are in line with and expand previous 
research, with one previous cross-sectional study showing an independent association 
between Type D personality and symptoms of anxiety, independent of shocks
5
 and 
another study showing a large effect size (> 0.8) for the impact of Type D personality on 
anxiety
12
. Our study also showed an independent risk of anxiety sensitivity for state 
anxiety, which has not been described before. Moreover, the effects of Type D personality 
and anxiety sensitivity were independent of each other, indicating that both personality 
constructs have their own effect on symptoms of anxiety. Therefore, in future research on 
anxiety, it is important to take into account the role of personality.  
The level as well as the proportion of patients experiencing high levels of anxiety 
significantly diminished from baseline to 2 months following the implantation. However, 
ANCOVA for repeated measures showed no significant change in anxiety levels across 
time points. Previous studies also have shown that anxiety did not significantly decrease 
from implantation to follow-up, which was 12 months in these studies
25, 26
. However, one 
study did show that the proportion of patients experiencing clinically elevated levels of 
anxiety decreased from 61% to 42% at 12 months follow-up
25
. In these studies, the 
increased number of shocks or the worsening of the clinical status of the patient may 
account for the nonsignificant decrease in anxiety over the 12 month period. Hence, levels 
of anxiety may decrease in the ICD population, indicating that patients can gain some 
relief with an ICD. Future studies may further investigate this issue. 
Secondary prevention was not associated with anxiety. A few studies have 
investigated the relationship between ICD indication and anxiety, reporting also no 
difference between primary and secondary prevention
2, 27
. Similarly, primary and 
secondary prevention ICD patients did not differ on health-related quality of life following 
ICD implantation
9, 27, 28
. Considering the paucity of studies, future research is warranted to 
further examine the relationship between indication and psychological well-being. 
This study has a number of limitations. First, a follow-up period of two months is 
rather short and our results should be replicated in studies using a longer follow-up period. 
Next, the prevalence of shocks was only 5% (n = 16), which may indicate insufficient 
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power to find a major effect for shocks. Similarly, the relationship between anxiety and 
the experience of shocks could not be examined. Future studies with a longer follow-up 
period may have adequate power to research the influence of shocks. Finally, the attrition 
rate (16%), as well as the significant differences between patients with and without 
complete data may indicate limited generalizability. In addition, the limited 
generalizability also applies for the results of the interviewer-ratings of anxiety, although 
with the exception of shocks and secondary prevention, no systematic differences were 
found between the interview and mail only group. Despite these limitations, this is the 
first study to show that Type D personality and anxiety sensitivity exert major 
independent effects on both self-reported as well as interviewer-rated anxiety, while 
shocks contributed to an increase in self-reported anxiety. 
Important clinical implications can be inferred from these results. Identification of 
patients with a Type D personality or high in anxiety sensitivity is important, because 
these patients are at increased risk to experience anxiety and anxiety may precipitate 
ventricular arrhythmias
6, 7
. In cardiology practice, the DS14 may be used to screen for 
Type D personality, because this is a short questionnaire and easy to score with well-
defined cut-off points to determine the presence of Type D personality
8
. Regarding 
anxiety sensitivity, the 16-item ASI may be used
14
, but there are no established cut-off 
points to determine the presence of increased anxiety sensitivity. Future research may 
focus on the ASI and its cut-offs. Furthermore, the importance of self-reported anxiety 
was stressed with this study, since prevalences of self-reported anxiety were higher as 
compared to prevalences of interviewer-rated anxiety. Hence, interviewer-rated anxiety 
may result in an underestimation of anxiety problems. 
A recent review on psychological interventions in ICD patients showed that a 
multi-factorial approach including a cognitive behavioral component paired with exercise 
training is likely to be most successful
29
. However, appropriate psychosocial interventions 
for Type D personality and anxiety sensitivity per se have not been examined to date. 
Since our results showed that the experience of shocks may lead to an increase in 
symptoms of anxiety, it may be essential to support patients who have experienced a 
shock in order to diminish the risk that they develop symptoms of anxiety. Sears and 
colleagues
30
 recently showed that structured interventions including ICD education and 
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cognitive-behavioral strategies may reduce psychological distress in ICD patients who 
received a shock. 
In conclusion, both Type D personality and anxiety sensitivity were independent 
predictors of self-reported anxiety at baseline and 2 months following ICD implantation as 
well as interviewer-rated levels of anxiety at 2 months following ICD implantation. The 
experience of a shock was related to an increase in self-reported symptoms of anxiety 
from baseline to 2 months following ICD implantation, but not to interviewer-rated levels 
of anxiety at 2 months follow-up. Identification and support of ICD patients with Type D 
personality, increased anxiety sensitivity, and shocks is very important. Future research on 
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Background Psychological problems following implantable cardioverter defibrillator 
(ICD) implantation are diverse and include increased levels of anxiety. Anxiety may even 
rise further when possible malfunctioning of an ICD is announced, with a higher risk of 
serious ventricular arrhythmias and death as a consequence. Following the public 
statement of Medtronic, all patients in the Netherlands with the specific Medtronic ICD 
were contacted for extra device evaluation. The aim of this exploratory study was to 
determine whether the proportion of ICD patients with high levels of anxiety would 
increase after this extra device evaluation.  
Methods Patients were recruited from an ongoing prospective study on psychological 
effects of ICD implantation. Thirty-three patients completed the State subscale of the 
State-Trait Anxiety Inventory (STAI) before and after extra device evaluation. The STAI 
can identify patients with high levels of anxiety. 
Results A high level of anxiety was experienced by 2 patients (6.1%) at baseline and 8 
patients (24.2%) at follow-up (p = .031). Hence, ICD patients were significantly more 
likely to experience high levels of anxiety following the public statement of potential 
malfunctioning of their device.  
Conclusion A public statement regarding device safety may increase levels of anxiety 
among ICD patients. Given the potential triggering effect of high levels of anxiety on 
arrhythmias, psychological support may be considered for some of the ICD patients after 








Implantation of implantable cardioverter defibrillators (ICDs) is increasingly common in 
patients who have experienced serious ventricular arrhythmias or in those patients who are 
at risk for such arrhythmias
1
. Psychological problems following ICD implantation are 
diverse and include increased levels of anxiety
2-4
. However, symptoms of anxiety may 
even rise further when possible malfunction of an ICD is announced. Recently, the safety 
of ICDs has been questioned
5
; for example, Medtronic (Minneapolis, MN, USA) sent out 
a news report regarding the possibility of rapid battery depletion in some models of the 
Marquis and Maximo series
6
. Patients may have different psychological reactions to these 
public statements about the safety of devices and to the options or advice regarding 
replacement. Some patients may experience acute stress and anxiety, with a higher risk of 
ventricular arrhythmias as a consequence
7
. 
In the Netherlands all patients with an ICD of the Marquis or Maximo series were 
contacted for extra device evaluation. The aim of this exploratory study was to determine 
whether the number of ICD patients with high levels of anxiety would increase after this 




In the Catharina Hospital in Eindhoven, the Netherlands, ICD patients were approached, 
who (i) had been called for the extra device evaluation of their Medtronic Marquis series 
ICD, and (ii) were enrolled in a larger ongoing 18-month prospective study on 
psychological effects of ICD implantation, which started in May 2003 (N = 39). Of these 
patients, 35 (90%; 28 men and 7 women) returned their questionnaire; two patients were 
excluded from analyses because of missing data. This procedure resulted in a final sample 
of 33 patients. After the extra device evaluation, 5 (15%) had their ICD replaced and the 
remaining patients were recommended to perform regular self-checks of their device by a 
handheld magnet. Criteria for ICD replacement were: (i) having experienced an ICD 
shock the year prior to the extra device evaluation and/or (ii) pacemaker-dependency. The 
study was approved by the medical ethics committee of the participating hospital. The 
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study was conducted in accordance with the Helsinki Declaration, and all patients 
provided written informed consent. 
 
Self-report measures and procedure 
At baseline, that is, following ICD implantation, patients completed the State subscale of 
the State-Trait Anxiety Inventory (STAI)
8
 as part of the ongoing study. After the extra 
device evaluation, patients completed the STAI scale once again. This self-report scale 
measures the current presence of symptoms of anxiety. The scale consists of 20 statements 
that ask people to describe how they feel at a particular moment in time (e.g., ‘I feel 
upset’, ‘I feel calm’), which can be rated on a 4-point intensity scale ranging from 1-not al 
all to 4-very much so. Ten items are positively worded and 10 items are negatively 
worded. Scores can range from 20, that is, low level of state-anxiety to 80, that is, high 
level of state-anxiety. The Dutch version of the STAI has good reliability (α ranges from 
0.87 to 0.92) and validity
8
. The STAI was also used in recent studies on (i) the influence 
of psychological distress on ICD patients' report of atrial fibrillation symptoms
9
, and (ii) 





Given the relatively small sample and wide ranges of anxiety scores, we used a 
nonparametric test (i.e., McNemar’s Chi-Square test) to compare the proportion of 
patients with high levels of anxiety at baseline and after extra device evaluation. The 
upper quartile score on the STAI (≥ 56) was used to identify patients with markedly 
increased anxiety scores following extra device evaluation. In previous research
11
, we 
found that a score of 56 on the state-scale of the STAI corresponds to the 90% percentile 
in patients who were recovering from an acute coronary event. Moreover, this score is at 
least half a standard deviation above the mean STAI-state scores obtained among panic 
disorder patients
12






The mean time between assessment of anxiety at baseline and after device evaluation was 
14 ±4 months with a range from 5 to 20 months. Sociodemographic and clinical baseline 
characteristics of the patients are shown in Table 1. The mean age in this patient group 
was 60 ±11 years. Of these 33 patients, 29 (88%) had a partner, 15 (46%) had received 
higher education, and 25 (76%) had a history of ischemic heart disease.  
 
Table 1. Sociodemographic and clinical characteristics 
Age, mean (SD) 60 (±11) 
Female 6 (18%) 
Partner  29 (88%) 
High education 15 (46%) 
Employment 7 (21%) 
Current smoking 5 (15%) 
History of ischemic heart disease
*
 25 (76%) 
Indication for ICD 
     Primary prevention 




Months since implant and Medtronic’s news report, mean (SD) 14 (±4) 
*
 e.g., previous AMI, PCI or CABG 
 
The mean level of anxiety rose from 39.1 (±10.73) at baseline to 42.0 (±15.34) 
after extra device evaluation. The mean anxiety level after device evaluation corresponds 
to the upper quintile of the Dutch general population
8
, and indicates clinically relevant 
symptoms of anxiety. High levels of anxiety were experienced by 2 patients (6.1%) at 
baseline and by 8 patients (24.2%) at follow-up (p = .031) (Figure 1). Hence, ICD patients 
were significantly more likely to experience high levels of anxiety following the public 
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DISCUSSION 
Significant differences were found in ICD patients regarding levels of anxiety before and 
after the extra device evaluation following a public statement from Medtronic about the 
possibility of a short-circuit in the battery; that is, a larger proportion of ICD patients was 
found to have high levels of anxiety after extra device evaluation as compared to their 
baseline anxiety level. Psychological distress, including anxiety, has been shown to 
predict ventricular arrhythmias requiring shocks in ICD patients
7, 13, 14
. In addition, 





may decrease the risk of ventricular arrhythmias in these patients. Psychological distress 
and anxiety are at least as strong as ICD shocks in reducing quality of life post-ICD 
implantation
17
. Anxiety may also increase atrial fibrillation symptoms, causing a further 
decline in quality of life
9
. Given the detrimental effects of anxiety on ventricular 
arrhythmias and quality of life, ICD patients should be monitored more frequently after an 
anxiety-evoking event such as a news report about the safety of an ICD.  
Although cardiologists or nurses may not feel very comfortable in managing 
anxiety problems in ICD patients
18
, our findings indicate that managing these problems 
may be important in patients who are being called for extra device evaluation because of 
potential malfunctioning. There is evidence that specific behavioral intervention may be 
p = .031 





















indicated for ICD patients with high levels of anxiety. For example, a structured nursing 
intervention resulted in a significant and stable reduction in anxiety post-ICD 
implantation
10
. Cognitive behavioral therapy may also be an effective way of reducing 
anxiety
19
 and ventricular arrhythmias
15
 among ICD patients. 
The present findings should be interpreted with some caution because of the small 
number of patients. The strength of this explorative study is the fact that patients are 
participating in an ongoing study, so that baseline data were available. To the best of our 
knowledge, no other studies including such data have been published. 
Currently, a number of steps are being taken to provide clear guidelines for the 
notification of medical device malfunctioning. These steps should result in the reassurance 
of patients that ICD therapy is reliable and effectively regulated
20
. In his commentary, 
Maisel has proposed a number of changes to this notification process, e.g., “manufacturers 
should annually publish detailed data on device reliability”
21
. In addition, the Heart 
Rhythm Society (HRS) has formed a task force on device performance and in September 
2005 a conference was organized about the current policy and possible improvements. In 
April 2006, a document regarding recommendations on performance policies for 
pacemakers and ICDs was released by the HRS
22
. In a report issued on March 20, 2006, a 
Guidant-commissioned panel made recommendations to “strengthen postmarket 
surveillance of the products, to actively pursue any potential device-related problems and 
be completely open with clinicians and the public about safety issues”
23
. The present data 
suggest that this policy also needs to account for possible psychological consequences for 
patients of making news regarding safety of devices public.  
 
CONCLUSION 
ICD patients were significantly more likely to experience high levels of anxiety after a 
public statement about possible malfunctioning of ICDs as compared to their baseline 
anxiety level. Given the potential triggering effect of anxiety on arrhythmias and its 
detrimental effect on quality of life, psychological support may be considered for some of 
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Background Little is known about the prevalence of chronic anxiety in patients with an 
implantable cardioverter defibrillator (ICD). In a multi-center study, we examined 1) the 
prevalence of patients with chronic anxiety, and 2) the predictors of chronic anxiety at 12 
months.  
Methods ICD patients (N = 222; 81.1% males; mean±SD age = 60.8±10.4 years) 
recruited from three hospitals, who were anxious at the time of implantation, comprised 
the sample for the current study. Patients completed the Type D Scale at baseline and the 
State-Trait Anxiety Inventory (state measure) at baseline and 12 months. A cut-off ≥ 40 
on the STAI was used to indicate probable levels of clinical anxiety.  
Results At 12 months, 51.8% (115/222) patients were still anxious. Diabetes (OR = 4.57; 
95% CI 1.65-12.66; p = .003) and Type D personality (OR = 2.81; 95% CI 1.48-5.36;       
p = .002) were independent predictors of 12-month anxiety, adjusting for demographic 
and clinical variables including appropriate ICD therapy during follow-up. The prevalence 
of anxiety at 12 months in the 118 patients with no risk factors was 39.8%, whereas the 
prevalence was 65.4% in the 104 patients with either diabetes or Type D (p < .001).  
Conclusions More than 50% of ICD patients anxious at the time of implantation were still 
anxious at 12 months, indicating a high level of chronicity. Diabetes and Type D 
personality were independent predictors of chronic anxiety. ICD patients anxious at the 
time of implantation should be closely monitored and offered adjunctive psychosocial 







Implantable cardioverter defibrillator (ICD) therapy for the treatment of life-threatening 
arrhythmias is generally well accepted by patients, although a subgroup experiences 
probable clinical levels of anxiety and depression
1-4
. Anxiety seems to be more prevalent 
in cardioverter-defibrillator patients than depression, with prevalence rates of anxiety 
reported from 24-87% compared to 24-33% for depressive symptoms
1
. In the general 
cardiovascular literature, anxiety has been associated with adverse health outcomes, 
including decreased quality of life
5,6
 and increased morbidity and mortality
7,8
. There is 
also evidence to suggest that general psychological distress and anxiety may precipitate 
arrhythmic events
9-12
. Therefore, it is important to know the determinants of anxiety 
following ICD implantation in order to identify high-risk patients and optimize secondary 
prevention.  
Psychological distress may decrease in the first year following implantation with an 
ICD
1-13
, indicating that patients adapt to ICD therapy over time. However, examining 
changes in overall mean scores over time may mask variability in intraindividual changes 
and impede the identification of patients who experience chronic levels of distress and 
potentially may have a greater risk of adverse health outcomes
14
. Importantly, ICD 
patients who experience anxiety both at the time of implantation and at later follow-up 
may be distinctly different from those whose anxiety levels may resolve. We are not 
aware of any studies in ICD patients that have examined patients who are prone to 
experience chronic anxiety. 
Therefore, in a multi-center study focusing on patients who were anxious at the 
time of implantation, we examined 1) the prevalence of chronic anxiety at 12-month 





Patients implanted with an ICD (N = 222; 81.1% males; mean±SD age = 60.8±10.4 years) 
between May 2003 and December 2006 at the Erasmus Medical Center, Rotterdam, 
Catharina Hospital, Eindhoven, and Amphia Hospital, Breda, The Netherlands, comprised 
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the sample for the current study. Patients included in the Erasmus Medical Center were 
part of the ongoing Mood and personality as precipitants of arrhythmia in patients with 
an Implantable cardioverter Defibrillator: A prospective Study (MIDAS)
15
. Exclusion 
criteria were significant cognitive impairments (e.g., dementia), life-threatening 
comorbidities (e.g., cancer), a history of psychiatric illness other than affective/anxiety 
disorders, and insufficient knowledge of the Dutch language.  
Initially, 587 ICD patients agreed to participate, but 22 (3.7%) were not included in 
the analyses due to missing data on self-report measures or clinical variables. These 
excluded patients were compared with the remaining 565 patients on all demographic and 
clinical variables, but no statistically significant differences were found. For the purpose 
of the current study, we included 273 patients who were anxious at baseline, as measured 
by a score ≥ 40 on the STAI. Of these patients, 18 died during follow-up and 33 patients 
had no score on the STAI at 12 months, leaving 222 patients in the analyses.  
The study protocol was approved by the medical ethic committees of the 
participating hospitals. The study was conducted in accordance with the Helsinki 
Declaration, and all patients provided written informed consent. 
 
Measures 
Demographic and clinical variables  
Demographic variables included gender, age, marital status (single versus having a 
partner) and low education (secondary education or less). Information on clinical variables 
included ICD indication (primary versus secondary), etiology (ischemic versus non-
ischemic), cardiac resynchronization therapy (CRT), diabetes, smoking, cardiac 
medication, and appropriate ICD therapy (i.e., both antitachycardia pacing episodes and 
shocks) for ventricular arrhythmias (i.e., ventricular tachycardia or ventricular fibrillation) 
during the 12-month follow-up period. Information on these variables was obtained from 
the patients’ medical records, with the exception of smoking which was obtained by 






Symptoms of anxiety were assessed with the 20-item state scale of the State-Trait Anxiety 
Inventory (STAI)
16,17
. Each item is rated on a 4-point Likert scale from 1-not al all to 4-
very much so, with a score range of 20 to 80. A high score indicates high levels of anxiety, 
with a score ≥ 40 indicating probable levels of clinical anxiety
18,19
. The STAI is a valid 
and reliable scale, with Cronbach’s α ranging from 0.87 to 0.92
16
. The STAI state scale 
was administered at baseline (i.e., between 1 day prior to ICD implantation and 3 weeks 
post implantation) and at 12 months.  
 
Type D personality  
Type D personality was assessed with the 14-item Type D Scale (DS14)
20
. Items are 
answered on a 5-point Likert scale ranging from 0-false to 4-true. The 14 items contribute 
to two subscales, negative affectivity (e.g., ‘I often feel unhappy’; 7 items) and social 
inhibition (e.g., ‘I am a closed kind of person’; 7 items). A standardized cut-off ≥ 10 on 
both subscales identifies patients with a Type D personality
20,21
. The DS14 was originally 
developed in cardiac patients and is a valid and reliable measure, with Cronbach’s alpha 
of 0.88/0.86 and 3-month test-retest reliability r = 0.72/0.82 for the negative affectivity 
and social inhibition subscales, respectively
20
. The stability of Type D personality has 
been confirmed in a large sample of patients with acute myocardial infarction
22
. It is the 
combination of a high score on both negative affectivity and social inhibition that incurs 
an increased risk of adverse clinical events rather than the single traits
23
. In addition, Type 
D is not confounded by cardiac disease severity and measures of anxiety and  
depression
22, 24
. The DS14 was administered at baseline. 
 
Statistical analyses 
The Chi-square test (Fisher’s exact test when appropriate) was used to examine between 
group differences on dichotomous variables and Student's t-test for independent samples 
for differences on continuous variables. Multivariable logistic regression analysis was 
used to determine predictors of 12-month anxiety, adjusted for gender, age, education, 
marital status, Type D personality, diabetes, etiology, ICD indication, CRT, smoking, and 
appropriate ICD therapy during follow-up. In a secondary multivariable analysis, we also 
Chapter 4 
62 
adjusted for cardiac medication (i.e., amiodarone, beta-blockers, diuretics, ACE-
inhibitors, statins, and digoxin) to examine whether this would change the results, 
although this model was essentially over fitted due the large number of covariates relative 
to the number of patients with anxiety at 12-month follow-up. All tests were two-tailed, 
and a p-value < .05 was used to indicate statistical significance. For the results of the 
logistic regression analysis, odds ratios (OR) and their corresponding 95 percent 
confidence intervals (CI) are reported. All data were analyzed using SPSS.14.0 for 




At 12 months, 51.8% (115/222) patients were still anxious. Patient demographic and 
clinical baseline characteristics stratified by anxiety at 12 months are presented in Table 1. 
Patients with chronic anxiety were more likely to have diabetes (20.2% versus 8.7%;        
p = .029) and a Type D personality (44.7% versus 28.0%; p = .015) than patients whose 
anxiety remitted by 12 months. There was a trend for CRT (p = .06), appropriate ICD 
therapy for ventricular arrhythmias (p = .055) and age (p = .08), with patients with chronic 
anxiety more likely receiving CRT, having experienced ICD therapy for ventricular 
arrhythmias during follow-up, and being older.  
 
Independent predictors of 12-month anxiety  
The independent predictors of 12-month anxiety are presented in Table 2. Diabetes (OR = 
4.57; 95% CI 1.65-12.66; p = .003) and Type D personality (OR = 2.81; 95% CI        
1.48-5.36; p = .002) were independent predictors of 12-month anxiety, adjusting for all 
other demographic and clinical variables. The overall results did not change when adding 
cardiac medication (i.e., amiodarone, beta-blockers, diuretics, ACE-inhibitors, statins, and 
digoxin) to the multivariable analysis (results not shown), apart from the use of ACE-










(n = 115) 
Non-anxious 
(n = 107) 
 
p 
    
Demographics    
   Male gender 80.9 81.3 1.00 
   Age, mean ±SD 62.0 ±9.6 59.5 ±11.0 .08 
   Single/no partner 13.9 9.3 .40 
   Lower education
1 
60.9 61.5 1.00 
    
Clinical     
   Smoking 19.1 14.0 .40 
   Diabetes 20.2 8.7 .029 
   Secondary indication 48.7 45.8 .77 
   Ischemic etiology  71.3 70.1 .96 
   CRT 38.1 25.5 .06 
   Appropriate ICD therapy during follow-up 25.0 13.6 .055 
    
Medication    
   Amiodarone 25.7 25.5 1.00 
   Beta-blockers 78.8 84.9 .32 
   Diuretics 64.6 58.5 .43 
   ACE-inhibitors 69.9 75.5 .44 
   Statins 69.8 69.0 1.00 
   Digoxin 15.9 12.3 .56 
    
Psychological    
   Type D personality 44.7 28.0 .015 
Results are presented as percentages unless otherwise indicated, CRT = cardiac 
resynchronization therapy, 
1
 Secondary education or less (≤ 13 years of education) 
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Table 2. Predictors of anxiety at 12 months* 
Predictor variables OR 95% CI p 
    
Demographics    
   Male gender 0.93 0.42-2.09 .87 
   Age 1.03 0.99-1.06 .13 
   Single/no partner 1.16 0.44-3.10 .77 
   Lower education
1 
0.93 0.50-1.75 .82 
    
Clinical     
   Smoking 1.68 0.76-3.69 .20 
   Diabetes 4.57 1.65-12.66 .003 
   Secondary indication 1.33 0.69-2.60 .40 
   Ischemic etiology  0.81 0.38-1.72 .58 
   CRT 1.80 0.88-3.68 .11 
   Appropriate ICD therapy during follow-up 1.94 0.86-4.37 .11 
    
Psychological    
   Type D personality 2.81 1.48-5.36 .002 
* Multivariable logistic regression analysis, CRT = cardiac resynchronization therapy,      
1
 Secondary education or less (≤ 13 years of education) 
 
 
Prevalence of anxiety at 12 months stratified by diabetes and Type D personality   
Given that Type D personality and diabetes were the two most prominent predictors of 
anxiety at 12 months, we created 2 groups based on the presence of none versus one (i.e., 
either Type D or diabetes) of these risk factors. Anxiety at 12 months stratified by none 
versus one of these risk factors is presented in Figure 1. The prevalence of anxiety in the 
118 patients with no risk factors was 39.8%, whereas the prevalence was 65.4% in the 104 




Figure 1. Anxiety at 12 months stratified by risk factors (total numbers are listed on top of 


























In the current study, we found that 50% of ICD patients suffering from anxiety at baseline 
also experienced probable levels of clinical anxiety at 12 months post implantation, 
indicating a high level of chronicity. Diabetes and Type D personality were both 
independent predictors of chronic anxiety, with the presence of anxiety being significantly 
higher in patients with one of these risk factors compared to none. ICD therapy for 
ventricular arrhythmias was not significantly associated with chronic anxiety, although 
there was a trend.  
The study of anxiety in the context of ICD patients has received considerable 
attention
1-4, 13, 25, 26
, likely due to the unique feature of the device compared to any other 
intervention in clinical cardiology, namely its capacity to provide shocks to terminate life-
threatening ventricular arrhythmias. For this purpose, device-specific questionnaires have 
been developed, such as the Florida Patient Acceptance Survey
27
 and the ICD Concerns 
Questionnaire
28, 29
, to tap into the fears that patients have about the device providing a 
shock. However, generally studies have focused on prevalence rates or mean anxiety 








p < .001 
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patients who may experience chronic levels of distress
14
. Therefore, we selected patients 
who were anxious already at baseline in order to examine the level of chronicity at 12 
months and the profile of chronically anxious patients. To our knowledge, this is the first 
study to use such an approach to anxiety in ICD patients. We found that once anxiety was 
manifest at the time of implantation, 50% of patients had symptoms that did not remit 
spontaneously during the 12-month follow-up period. This level of chronicity is similar to 
that found in a recent study of patients treated with percutaneous coronary intervention 
(PCI), as part of the RESEARCH registry
30
.  
Diabetes and having a Type D personality typified patients experiencing chronic 
levels of anxiety in the current study. In PCI patients, Type D has also been associated 
with chronic anxiety adjusting for demographic and clinical risk factors, including stent 
type
30
. In previous studies of the MIDAS population, we also showed that Type D 
personality but not ICD indication was a predictor of poor quality of life at 3 months
15
, 
and that clustering of Type D with ICD concerns was associated with increased anxiety at 
6 months follow-up
13
. Type D has also been shown to independently predict self-reported 
as well as interviewer-rated levels of anxiety
26
. Diabetes has previously been associated 
with the onset of depressive symptoms in PCI patients
31
 and co-morbid diabetes and 
angina with anxiety in outpatients with chronic heart failure
32
. Increased anxiety in 
diabetic versus non-diabetic ICD patients found in the current study may reflect the toll of 
having to deal with multiple somatic diseases
33
, although we cannot rule out that the 
association may also represent a chance finding.  
The high level of chronicity of anxiety found in the current study may have clinical 
implications, as anxiety and general psychological distress have been associated with an 
increased risk of ventricular arrhythmias
9-12
. Anxiety may potentiate pathological 
processes that increase the risk of ventricular arrhythmias and sudden cardiac death 
through reduced heart rate variability
34
, which is an important risk factor for sudden 
cardiac death
35
. Distress may also be related to increases in T-wave alternans
36, 37
, which 
is an important predictor for ventricular arrhythmias and death
38
. Although anxiety levels 
in ICD patients generally have been shown to diminish and reach a plateau after 1 year
1
, 
this pattern may be different for shocked patients
39
 and patients whose ICD may be 
subject to malfunctioning and recall
40




anxious at the time of ICD implantation should be closely monitored and offered 
adjunctive psychosocial intervention if anxiety symptoms do not remit spontaneously. 
Screening for emotional distress in ICD patients at regular intervals has also been 
advocated by others to track changes in distress over time
41
. In terms of the clinical 
management of these patients, they should be offered adjunctive psychosocial 
intervention, using a multi-factorial approach incorporating an educational component on 
the ICD, cognitive behavioral therapy, problem-solving skills, and exercise
42
. Such an 
approach would also be cost-effective, as it would provide adjunctive intervention to those 
patients who need it the most and who are also likely to benefit the most. 
The results of this study should be interpreted with some caution. First of all, we 
had no information on participation in cardiac rehabilitation and the use of 
psychopharmaca, which may have influenced anxiety levels. Second, due to the small 
number of patients with the co-occurrence of diabetes and Type D personality (n = 9), we 
were not able to deduce whether these patients are particularly prone to experience 
chronic anxiety compared to patients with one or no risk factors. Third, the number of 
patients with anxiety at follow-up was insufficient to also adjust for medication use, which 
would lead to over fitting of the multivariable regression model. Nevertheless, in 
secondary analysis adjustment for medication did not change the overall results. Finally, 
we used a generic rather than a disease-specific measure to assess anxiety, with the 
likelihood that levels of anxiety would have been higher if assessed with a disease-
specific measure, as it taps into symptoms that are more pertinent to patients.  
In conclusion, more than 50% of ICD patients who were anxious at baseline still 
suffered from anxiety 12 months post implantation, indicating a high level of chronicity. 
Diabetes and Type D personality were independent predictors of chronic anxiety, as 
indicated by a 2- to 4-fold increased risk of experiencing anxiety both at baseline and at 
12-month follow-up. Patients who are anxious at the time of implantation should be 
closely monitored and offered adjunctive psychosocial intervention if symptoms do not 
remit spontaneously
42
. It may be important to prevent that anxiety becomes chronic, as 
these patients may be at increased risk of poor quality of life, life-threatening arrhythmias 
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Background A subgroup of patients experiences anxiety and depressive symptoms 
following implantable cardioverter defibrillator (ICD) implantation, but little is known 
about the course of these symptoms. Therefore, we examined 1) trajectories of anxiety 
and depressive symptoms in the first year post-implantation and 2) the predictors of these 
trajectories. 
Methods ICD patients (N = 312, 16.7% females, 62.8% ≥ 60 years) completed the STAI 
(state-version) and BDI at baseline, and at 2 and 12 months post-implantation. Anxiety 
sensitivity (Anxiety Sensitivity Index), Type D personality (Type D Scale), and self-
deception (Marlowe-Crowne scale) were also measured at baseline. SAS procedure TRAJ 
was used to examine trajectories over a 12-month period and multinomial logistic 
regression to examine predictors of these trajectories.  
Results Four distinct trajectories were found for both anxiety and depressive symptoms, 
that is, respectively very low (8.0%), low (53.2%), mildly (35.3%), and severely (3.5%) 
anxious groups and parallel groups for depression (respectively, 38.1%, 36.9%, 17.0%, 
and 8.0%). Trajectories were relatively stable, although particularly within depression 
classes some statistically significant change was observed. Multinomial regression 
analyses showed that anxiety sensitivity (ORmildly anxious = 3.76, p < .001) and Type D 
personality (ORmildly anxious = 2.09, p = .03; ORseverely anxious = 17.46, p = .001; ORseverely 
depressed = 4.11, p = .005) were the most prominent predictors of anxiety and depression 
groups.  
Conclusions Anxiety and, to a lesser extent, depression trajectories tend to be stable in the 
first year post-implantation, with anxiety sensitivity and Type D personality being the 
most prominent predictors of these trajectories. Psychological screening may be 
implemented in hospitals to identify patients at risk for chronic anxiety and depression. 
 




Ventricular arrhythmias are the most important cause of sudden cardiac death
1
. The main 
treatment to prevent sudden cardiac death in survivors of these arrhythmias, and also in 
patients at risk, is implantation with an implantable cardioverter defibrillator (ICD)
2
. ICDs 
can terminate ventricular arrhythmias by antitachycardia pacing (ATP) or high-voltage 
shocks
3
. Randomized trials have shown that the ICD is 20% to 60% more beneficial in 
reducing mortality rates as compared to antiarrhythmic drugs
2, 4
 in secondary as well as 
primary prevention patients
2
. However, a substantial subgroup of patients experiences 
psychological problems, including anxiety, depression, impaired quality of life, and 
avoidance behaviors
5-7
. Anxiety may be the most important emotion, but depression also 
is prevalent, with diagnosable levels being experienced by 13%-38% and 10%-15% of 
ICD patients, respectively
5




Little is known about the course of anxiety and depressive symptoms in ICD 





up, and in case of anxiety even to 30 months follow-up
16
. Other studies suggest that levels 
remain stable over various periods within 1 month and 5 years post-implantation
8, 9, 17, 18
, 
although one study found that anxiety levels increased from 6 to 12 months post-
implantation
14
. It is important to note that all these studies used mean scores in their 
analyses. This approach does not allow for the identification of subgroups with high levels 
of anxiety and depression. Identification and treatment of these patients is very important, 




The aims of the current study were to 1) determine whether different trajectories of 
anxiety and depressive symptoms exist in subgroups of ICD patients over the 12-month 
period following ICD implantation and 2) determine predictors of these trajectories, using 






Patients hospitalized between May 2003 and December 2006 for implantation with an 
ICD were included from two referral hospitals in the Netherlands (Catharina Hospital, 
Eindhoven; Amphia Hospital, Breda). Inclusion criteria were implantation with an ICD 
and age between 18 and 80 years. Exclusion criteria were significant cognitive 
impairments (e.g., dementia), life-threatening comorbidities (e.g., cancer), and insufficient 
knowledge of the Dutch language. 
The study was approved by the medical ethic committees of both participating 
hospitals. The study was conducted in accordance with the Helsinki Declaration, and all 
patients provided written informed consent. 
 
Procedure and psychological measures 
Patients completed self-report questionnaires on anxiety and depressive symptoms at 3 
time points, that is, between 0 and 3 weeks following ICD implantation and subsequently 
at 2 and 12 months following ICD implantation. Questionnaires on Type D personality, 
anxiety sensitivity, and self-deception were completed at the first time-point only. 
 
State-anxiety 
The State-Trait Anxiety Inventory (STAI) was used to assess general symptoms of 
anxiety
21
. The STAI is a self-report measure consisting of two 20-item scales developed to 
measure the level of general state and trait anxiety. In the current study, we only used the 
state measure. Each item is rated on a 4-point Likert scale from 1-not al all to 4-very much 
so. Ten items measure the presence of anxiety and 10 items the absence of anxiety. After 
recoding the anxiety absence items, scores range from 20, that is, low level of state-
anxiety to 80, that is, high level of state-anxiety, were scores above 40 indicate increased 
levels of anxiety
21
. The STAI has been demonstrated to have adequate validity and 








The Beck Depression Inventory (BDI) is a 21-item self-report measure developed to 
assess the presence and severity of depressive symptoms
22
. Each item is rated on a 
Guttmann scale from 0 to 3. The BDI is a reliable and valid measure of depressive 
symptomatology and the most frequently used self-report measure of depressive 




Type D personality 
The DS14 was used to assess Type D personality and contains the 7-item scales negative 
affectivity (e.g., “I often feel unhappy”) and social inhibition (e.g., “I am a closed kind of 
person”)
24
. Items are answered on a 5-point Likert scale, ranging from 0-false to 4-true, 
with total scores ranging from 0-28 for both subscales. Patients scoring ≥ 10 on both 
subscales are classified as Type D
24, 25
. The DS14 has good reliability, with Cronbach’s 
alpha being 0.88 and 0.86 and three-month test-retest reliability being 0.72 and 0.82, for 
negative affectivity and social inhibition, respectively. Recently, the DS14 was shown to 
be a stable measure of Type D personality over an 18-month period
26
, and scores were not 
affected by cardiac disease severity or symptoms of anxiety and depression
26, 27
. Type D 





Anxiety sensitivity was measured using the 16-item Anxiety Sensitivity Index (ASI), 
designed to assess sensitivity and fear of anxiety symptoms, e.g., “It scares me when I feel 
faint” and “When I am nervous, I worry that I might be mentally ill”
31
. Items are rated on 
a five-point Likert scale from 0-very little to 4-very much. Total scores are obtained by 
summing the scores on the 16 items, that is, total scores range from 0 to 64, with higher 
scores reflecting greater sensitivity and fear of anxiety symptoms. In our study, the 
reliability of the ASI was good, with Cronbach’s α = 0.89. Since there is no standardized 
cut-off for the ASI, we used a median split (i.e., ASI ≥ 12) to dichotomize ASI scores. 
Anxiety sensitivity is associated with an enhanced risk of clinically relevant levels of 
anxiety in ICD patients
12
. As a final point, it is important to distinguish anxiety sensitivity; 
Chapter 5 
78 
that is, the beliefs that anxiety symptoms have negative effects, from anxiety; that is, the 





The Marlowe-Crowne Social Desirability Scale is a valid and reliable measure of self-
deception
32, 33
. Originally, this scale consists of 33 items, but three items were omitted that 
were judged as being typical of an American population. We applied a previously reported 
cut-off score (≥ 22) to classify patients as high in self-deception
34
. Self-deception in 





Demographic and clinical variables 
Demographic and clinical variables were obtained from medical records. Demographic 
variables included gender, age (dichotomized using a median split, that is, ≥ 60 years), 
marital status (i.e., having a partner versus not having a partner), and education (low 
education, that is secondary school or less versus higher education). Clinical variables 
were obtained from medical records and included ICD indication (primary versus 
secondary prevention), etiology (ischemic versus non-ischemic), comorbidity (lung, renal, 
or rheumatic disease and/or diabetes versus none), and appropriate ICD therapies (i.e., 
ATP or shocks) for ventricular arrhythmias. 
 
Statistical Analyses 
Differences between patients who were excluded from analyses versus included in 
analyses were examined with a Chi-square test. 
SAS procedure TRAJ was used to examine trajectories of symptoms of anxiety and 
depression in ICD patients over a 12-month period
36
. TRAJ fits a finite mixture model (or 
latent class model) to identify classes of individuals following similar patterns of behavior 
over time. The model assumes unobserved latent variables to explain the associations 
among observed scores and can be seen as a categorical equivalent of factor analysis. To 
determine the optimal number of trajectories, the Bayesian Information Criterion (BIC) 
was used, with a higher BIC indicating a better fit. However, a difference of less than 3 
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will favor the least complex model. BIC is often used for comparing models, as it trades 
off model fit and model complexity.  
For comparison between classes we used the Chi-square test for discrete variables. 
Adjusted Standardized Residuals (ASRs) were used to identify groups responsible for 
significant differences. A residual greater than 2.0 was taken to indicate a significantly 
higher frequency, and a residual less than -2.0 was considered to indicate a significantly 
lower frequency, than expected if the independence hypothesis was true
37
. Cohen’s d was 
used as a measure of clinical significance. Cohen has defined effect sizes as small           
(d = 0.2), medium (d = 0.5), and large (d = 0.8). Multinomial logistic regression was used 
to assess whether demographic, medical, and personality variables were predictors of 
trajectories of symptoms of anxiety and depression. A similar approach has previously 
been used in myocardial infarction
38
, percutaneous coronary intervention
39







Of the 355 ICD patients who agreed to participate, 25 (7.0%) died within 12 months and 
18 (5.1%) had too many missing values on self-report or clinical data, resulting in a final 
sample of 312 patients (87.9%). The proportion of patients with a Type D personality was 
significantly higher among patients who were excluded from analyses as compared to 
included patients (39.0% versus 20.5%; χ
2
 = 7.09; df = 1, p = .008). There was also a trend 
for excluded patients to more often have no partner (20.9% versus 11.8%; χ
2
 = 2.79;        
df = 1, p = .095) and score low on self-deception (69.0% versus 53.4%; χ
2
 = 3.69; df = 1, 
p = .055). No other significant differences were found between excluded and included 





Table 1. Patient characteristics stratified by anxiety class 
 
 












(N = 312) 
 
% (n) 
(n = 25) 
 
% (n) 
(n = 166) 
 
% (n) 
(n = 110) 
 
% (n) 









      17 (52) 
 
   16 (4) 
 
    16 (26) 
 
    18 (20) 
 
    18 (2) 
 
 .96 
Age ≥ 60 yrs       63 (196)    64 (16)     59 (98)     70 (77)     46 (5)  .18 
Having no partner       12 (37)   8 (2)     12 (20)     12 (13)     18 (2)  .85 
Low educational level*       48 (151)    44 (11)     40 (66)     62 (68)     55 (6)  .003 
Secondary indication       48 (149)    60 (15)     45 (75)     47 (52)     64 (7)  .38 
Ischemic etiology       72 ( 226)    72 (18)     68 (113)     78 (86)     82 (9)  .27 
Comorbidity**       34 (107)    40 (10)     31 (51)     38 (42)     36 (4)  .50 
ATP/shocks       18 (57)    20 (5)     15 (25)     22 (24)     27 (3)  .38 
Anxiety sensitivity       53 (164)    4 (1)     42 (70)     76 (84)     82 (9)  <.001 
Type D personality       21 (64)    4 (1)     13 (22)     30 (33)     82 (9)  <.001 
Self-deception 
 
      47 (146)    68 (17)     52 (87)     36 (40)     18 (2)  .002 





Table 2. Patients characteristics stratified by depression class 












  (N = 312) 
 
     % (n) 
(n = 119) 
 
% (n) 
(n = 115) 
 
% (n) 
(n = 53) 
 
% (n) 









    17 (52) 
 
    13 (16) 
 
    17 (20) 
 
    23 (12) 
 
    16 (4) 
 
 .51 
Age≥60 yrs     63 (196)     61 (72)     67 (77)     60 (32)     60 (15)  .72 
Having no partner     12 (37)     11 (13)     10 (11)     19 (10)     12 (3)  .37 
Low educational level*     48 (151)     42 (50)     50 (57)     53 (28)     64 (16)  .20 
Secondary indication     48 (149)     56 (66)     44 (51)     36 (19)     52 (13)  .09 
Ischemic etiology     72 ( 226)     64 (76)     75 (86)     83 (44)     80 (20)  .04 
Comorbidity**     34 (107)     27 (32)     34 (39)     47 (25)     44 (11)  .04 
ATP/shocks     18 (57)     16 (19)     16 (18)     26 (14)     24 (6)  .24 
Anxiety sensitivity     53 (164)     32 (38)     61 (70)     66 (35)     84 (21)  <.001 
Type D personality     21 (64)     8 (10)     24 (27)     23 (12)     64 (16)  <.001 
Self-deception     47 (146)     59 (70)     47 (54)     34 (18)     16 (4)  <.001 
* Secondary school or less, ** Lung disease, renal failure, rheumatoid arthritis, diabetes 
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Class 1: Very low depressed group (38.1%)
Class 2: Low depressed group (36.9%)
Class 3: Mildly depressed group (17.0%)

















Class 1: Very low anxious group (8.0%)
Class 2: Low anxious group (53.2%)
Class 3: Mildly anxious group (35.3%)
Class 4: Severely anxious group (3.5%)
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Trajectories of anxiety and depression 
As displayed in figures 1 and 2, latent class analyses resulted in four distinct trajectories 
for both symptoms of anxiety (BIC = -3222) and depression (BIC = -2650). The first class 
was labeled as respectively the very low anxious group and the very low depressed group. 
Scores for anxiety and depression for the second class were slightly higher as compared to 
the first class but did not reach clinical significant levels; hence, they were classified as 
respectively low anxious and low depressed. The third class was described as mildly 
anxious and mildly depressed because scores within these trajectories were slightly higher 
as compared to cut-off scores to indicate clinically relevant levels. Finally, the fourth class 
was labeled as severely anxious and severely depressed because scores within these 
classes were far higher as compared to the cut-off scores for clinically relevant levels. 
Since the low anxious group (53.2% of the patients) and the low depressed group (36.9% 
of the patients) comprised a large percentage of patients and approximate total sample 
averages of anxiety and depression scores, these two groups were used as reference 
categories in the multinomial regression analyses.  
Trajectories for anxiety were relatively stable, although some within-class change 
was observed for two subgroups. A significant decrease was observed between baseline 
and 2-months follow-up for both the low anxiety class (Cohen’s d = -0.32) and the mild 
anxiety class (Cohen’s d = -0.51). Trajectories of depression were somewhat more 
variable. For the depression classes, a significant quadratic pattern was observed in the 
very low depressed class (Cohen’s dbaseline-2months = -0.50; Cohen’s d2months-12months = 0.20), 
the low depressed class (Cohen’s dbaseline-2months = -1.03; Cohen’s d2months-12months = 0.64), 
and the severely depressed class (Cohen’s dbaseline-2months = -0.80; Cohen’s d2months-12months = 
0.43). A significant linear increase was found in the mildly depressed class (Cohen’s 
dbaseline-12months = 0.84).  
The Spearman rank order correlation coefficient (rs) between the anxiety classes 
and depression classes equals 0.63 (p < .001) suggesting a considerable overlap between 
the trajectories of anxiety and depression. This association is visualized in Figure 3, which 



























Class 1: Very low depressed Class 2: Low depressed
Class 3: Mildly depressed Class 4: Severely depressed
 
Patient characteristics stratified by anxiety and depression class 
Demographic, clinical, and personality characteristics stratified by anxiety class are shown 
in Table 1 and by depression class in Table 2. Differences were found between anxiety 
groups on educational level (χ
2
 = 13.9; df = 3, p = .003), anxiety sensitivity (χ
2
 = 62.4; df 
= 3, p < .001), Type D personality (χ
2 
= 40.7; df = 3, p < .001), and self-deception (χ
2
 = 
15.0; df = 3, p = .002). Patients in the very low anxious and the low anxious groups were 
more likely to be self-deceptive (ASR = 2.2 resp. ASR = 2.1) but less likely to have high 
anxiety sensitivity (ASR = -5.1 resp. ASR = -4.0) or to have a Type D personality (ASR = 
-2.2 resp. ASR = -3.5) than would be expected from the independence hypothesis, 
whereas the opposite is true for patients in the mildly and severely anxious groups. 
Patients in the mildly anxious group were more likely to have a lower educational level 
(ASR = 3.6). 
Differences were found between depression groups on prevalence of ischemic 
etiology (χ
2
 = 8.4; df = 3, p = .04), comorbidity (χ
2
 = 8.1; df = 3, p = .04), anxiety 
sensitivity (χ
2
 = 38.8; df = 3, p < .001), Type D personality (χ
2
 = 39.9; df = 3, p < .001), 
and self-deception (χ
2
 = 19.9; df = 3, p < .001). Patients in the very low depressed group 
were more likely to be self-deceptive (ASR = 3.3) but less likely to have ischemic 
etiology (ASR = -2.7), comorbidities (ASR = -2.1), high anxiety sensitivity (ASR = -5.8) 
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or a Type D personality (ASR = -4.3) than would be expected from the independence 
hypothesis. Patients in the severely depressed group were more likely to have high anxiety 
sensitivity (ASR = 3.5) and a Type D personality (ASR = 5.5), but were less likely to be 
self-deceptive (ASR = -3.2). 
No association was found between classes of anxiety (χ
2
 = 3.1; df = 3, p = .38) or 
depression (χ
2
 = 4.2; df = 3, p = .24) and the occurrence of either ATP or shock between 
baseline and 12-months follow-up.  
 
Predictors of anxiety and depression trajectories 
Variables that were significantly associated with one of the anxiety or depression 
symptom trajectories were entered into a multivariable model. Multivariable predictors of 
anxiety and depression symptom trajectories are presented in Table 3. The estimates are 
reported in odds ratios (OR), using respectively the low anxious group, and the low 
depressed groups as the reference categories.  
Low anxiety sensitivity was a predictor of both the very low anxious class (OR = 
0.06; 95%CI 0.01-0.47, p < .001) and the very low depressed class (OR = 0.35; 95%CI 
0.20-0.61, p < .001) membership. In addition, Type D personality was associated with a 
low probability of being in the very low depressed class (OR = 0.33; 95%CI 0.14-0.76, p 
= .01). Anxiety sensitivity and Type D personality were the most prominent predictors of 
elevated symptoms of anxiety and depression over time, with odds ratios varying from 
2.09 to 17.46 (Table 3). Finally, low educational level was associated with being mildly 
anxious (OR = 2.44; 95%CI 1.42-4.20, p = .001). No significant associations were found 







Table 3. Multivariable associations of baseline covariates with trajectories of anxiety 
[A] and depression [B]. 
 
 






Covariate OR p-value OR p-value OR p-value 
 













Anxiety sensitivity 0.06 .007 3.76 <.001 ns ns 
Type D personality ns ns 2.09 .03 17.46 .001 
Self-deception 
 
ns ns ns ns ns ns 
 
 
   
[B]     Very low   
   depressed 
     Mildly  
  depressed 
   Severely     
   depressed 















Comorbidity** ns ns ns ns ns ns 
Anxiety sensitivity 0.35 <.001 ns ns ns ns 
Type D personality 0.33 .01 ns ns 4.11 .005 
Self-deception ns ns ns ns ns ns 
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DISCUSSION 
To our knowledge, this is the first study which examined trajectories of anxiety and 
depressive symptoms in ICD patients in the first year post-implantation. Our results 
suggest four distinct classes of both anxiety and depression symptoms, mainly based on 
absolute levels, ranging from low to severe levels, rather than differences regarding 
change over time. Anxiety symptoms, and to a lesser extent, depressive symptoms showed 
relatively stable trajectories, with depression scores showing some significant within-class  
changes. Anxiety and depression trajectories had considerable overlap. Importantly, ICD 
indication and ATPs or shocks were unrelated to anxiety and depressive symptoms 
trajectories. Type D personality and anxiety sensitivity were the most important predictors 
of trajectories. 
Results of the current study extend previous research, as we identified different 
trajectories of anxiety and depressive symptoms and found them to vary across subgroups 
of patients. Despite statistical significant within-class change, mainly due to small 
standard-deviations, we concluded that the four trajectories of anxiety and depressive 
symptoms were relatively stable over time, because the ranking of the trajectories did not 
change over time. The largest changes are consistent with previous studies which found a 
decrease of symptoms after implantation
14-16
, but our results are mainly in line with 
studies showing a stable course of anxiety and depression from 1 month to 5 years post-
implantation
8, 9, 17, 18
. However, these studies examined only overall mean scores. We also 
found that most subgroups of patients, defined by their symptom trajectories, show a 
relatively stable course of symptoms. The proportion of patients experiencing at least mild 
levels of anxiety symptoms (38.8%) was higher as compared to the proportion of patients 
experiencing at least mild levels of depressive symptoms (25.0%), which is in line with 
previous research in ICD patients
5, 8, 17
. The overlap between anxiety and depressive 
symptoms trajectories concur with results of previous studies
41
. Our results are rather 
salient, considering the chronicity of mild and severe levels of anxiety and depression in a 
substantial subgroup of patients.  
ICD indication was unrelated to anxiety and depression, although it seems likely 
that resuscitated patients and non-resuscitated patients with ventricular arrhythmias may 
experience higher levels of distress as compared to other patients. All other studies 
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regarding ICD indication and patient-centered outcomes also reported negative    
findings
8, 11-13, 42-44
. However, future research may investigate whether the effect of ICD 
indication on patient-centered outcomes may be influenced by other factors relating to 
these outcomes, including Type D personality and anxiety sensitivity. 
Occurrence of appropriate ICD therapies during the first year post-implantation 
was also included in the model, despite the fact that this variable is not a constant, as ICD 
therapies can occur after implantation at any time. Studies have shown that shocks may 
lead to increased anxiety and depression, although results are not conclusive
8-13
. Anxiety 
and depression may also precipitate ventricular arrhythmias
19, 20
. Therefore, if statistical 
differences had been found, causality could not be inferred. Our results seem to suggest 
that ATPs and shocks are not associated with increased distress; however these non-
significant results may be due to limited power to detect differences. 
Type D personality predicted persistent severe levels of anxiety and depressive 
symptoms. In addition, Type D personality, and also anxiety sensitivity and low 
educational level, predicted chronic mildly anxious symptoms. The predictive value of 
Type D personality for momentary anxiety and depressive symptoms in ICD patients has 
also been shown by others
43, 45
. Our results extend these findings by showing a predictive 
effect regarding trajectories over a 12-month period.  
The results of this study should be interpreted with caution. First, generalizability 
may be limited as 12.1% of initially participating patients had to be excluded due to death 
or missing values and these patients differed significantly or marginally from included 
patients with respect to Type D personality, marital status, and self-deception. Second, 
baseline questionnaires were completed between 0 and 3 weeks post-implantation, which 
means that baseline levels do not reflect pre-treatment levels. Third, the power to detect a 
differential effect of ATPs and shocks was limited.  
Identification of patients with mild and severe levels of anxiety and depressive 
symptoms is important, because our results demonstrate chronicity of these symptom 
levels from the time of implantation. Moreover, previous research in ICD patients 
suggests that anxiety is related to low treatment satisfaction
46





, pain intensity of ICD shocks
48
, and ventricular arrhythmias
20
. 
Considering the stability, anxiety and depression levels may already be measured at the 
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time of implantation. It is essential to support these patients, as anxiety and depression 
may precipitate ventricular arrhythmias
19, 20
. Treatment of anxiety may be best realized by 
cognitive behavioral therapy in combination with exercise training
49
. In addition, it may 
be timely to standardize screening for Type D personality in hospitals, as we and others 
have found that ICD patients with a Type D personality are at increased risk to experience 
high levels of anxiety
43, 45
, and previous research has also found that Type D patients are 
at increased risk for morbidity and mortality
28-30
. Screening may be realized during 
hospitalization for ICD implantation, by use of the Type D scale (DS14), which consists 
of 14 items only
24
.  
Several points may be addressed in future research. First, anxiety sensitivity is 
mostly neglected in ICD research, but our current and previous
12
 findings suggest an 
association with clinically relevant levels of anxiety. Therefore, to clarify the role of 
anxiety sensitivity, this personality disposition may be incorporated in future studies. 
Second, because this is the first study to examine trajectories of anxiety and depressive 
symptoms in ICD patients, future studies need to replicate our findings and it may also be 
important to look at the prognostic value of trajectories. Third, baseline levels of anxiety 
and depressive symptoms did not reflect pre-treatment levels as questionnaires were 
completed between 0 and 3 weeks post-implantation. Finally, randomized controlled trials 
are needed to examine adequate interventions for anxiety and depressive symptoms in 
ICD patients. Interventions aimed at patients with a Type D personality may be of 
particular interest. 
In conclusion, four trajectories of anxiety and depressive symptoms were identified 
and comprised very low, low, mild, and severe symptom levels. These trajectories tended 
to be relatively stable in the first year following ICD implantation. Anxiety sensitivity and 
Type D personality were the most prominent predictors of these trajectories, whereas 
ATPs and shocks were not associated with trajectories. Psychological screening may be 
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Implantation with an implantable cardioverter defibrillator (ICD) may cause 
psychological problems, including anxiety. The objective was to examine whether general 
anxiety and disease-specific anxiety differentially predict poor perceived health in ICD 
patients. Patient concerns about the ICD and feelings of disability were independently 
predicted by general as well as disease-specific anxiety. Clinical anxiety was predicted by 
general anxiety only, while cardiopulmonary symptomatology was predicted by disease-
specific anxiety. Identifying and supporting ICD patients with different anxiety symptoms 
is important. Future research should examine the differential predictive value of different 









The implantable cardioverter defibrillator (ICD) constitutes the main therapy in the 
treatment of life-threatening arrhythmias. The ICD is superior to antiarrhythmic drugs in 
reducing mortality rates
1, 2
. Furthermore, ICDs are proven to be efficacious in reducing the 
risk for sudden cardiac death in patients who receive the ICD for secondary as well as 
primary prevention
3, 4
. Despite these clear medical benefits, treatment with an ICD may be 
stressful in a subgroup of patients, most often due to concerns about a future ICD shock, 
although previous studies report inconsistent results regarding the impact of ICD shocks 
on psychological adaptation
5-8
. Conversely, some studies report that it is the survived 
cardiac arrest or the underlying arrhythmia disease that leads to psychological 
maladjustment rather than the treatment
5, 9, 10





 are frequently experienced by patients in the months or 
even years after ICD implantation. 
In cardiovascular research, the importance of such patient-centered outcomes is 
increasingly acknowledged. The working group of America’s National Heart, Lung, and 
Blood Institute reported in 2005 on the need for more patient-centered care, including the 
assessment of patient-centered health-status outcomes
13
. In addition, they recommended 
conducting studies aimed at identifying important determinants of patient-centered health 
status. 
Patient-centered research in ICD patients has frequently focused on anxiety, since 
the prevalence of clinically significant levels of anxiety vary from 13 to 46%
7, 8, 11, 12, 14, 15
. 
This shows that anxiety is a common negative emotion following ICD implantation. 
Moreover, emotions such as anxiety increase the risk for potential lethal arrhythmias and 
therefore ICD shocks
16-18
. Although this indicates the importance to study the concept of 
anxiety more deeply, most studies focused on general anxiety instead of specific disease-
related anxiety. Previous studies on disease-related anxiety in ICD patients concentrated 
on anxiety sensitivity (i.e., sensitivity to and fear of symptoms of autonomic arousal
11, 19
 
or patients’ anxiety or concerns about the ICD
6, 12, 20, 21
). Disease-related anxiety overlaps 
with general anxiety
6
 but both constructs are differentially associated with outcomes. For 
instance, anxiety sensitivity is more strongly related to quality of life than general 
anxiety
11
. In sum, these studies suggest that the distinction between general and disease-
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specific anxiety is important and should receive more attention in research on the 
prevalence and role of anxiety in ICD patients. 
The aim of the current study is to examine whether general anxiety and disease-
specific anxiety differentially predict poor perceived health outcomes. First, the 
differential assessment of anxiety by a general and a disease-specific measurement of 
anxiety was investigated. Next, the differential predictive power of disease-specific 
anxiety versus general anxiety regarding perceived health outcomes was determined. 
 
METHODS 
Patient population and design 
Patients hospitalized between May 2003 and July 2006 for implantation with an ICD were 
included from two teaching hospitals in the Netherlands (Catharina Hospital, Eindhoven; 
Amphia Hospital, Breda). Inclusion criteria were implantation with an ICD, technical ICD 
follow-up in the treatment center, and age between 18 and 80 years. Exclusion criteria 
were significant cognitive impairments (e.g., dementia), severe comorbidities (e.g., 
cancer), and inability to read and understand Dutch. Patients completed self-report 
measures on general and specific anxiety at baseline. Self-reports on feelings of disability, 
cardiopulmonary complaints, and ICD concerns were completed at 2 months follow-up. In 
addition, a diagnostic interview was administered to determine the severity of anxiety at 
this time. The two months follow-up period was adopted due to logistic reasons. Two 
months following ICD implantation, patients visited the outpatient clinic for a routine 
control. To minimize patient burden, we combined our study with these visits to the 
hospital. Of the original 212 patients who were included at baseline, 165 (78%) patients 
remained in the study at 2 months follow-up. The main reasons for exclusion were loss to 
follow-up and missing data on self-report measures (Figure 1). 
The study was approved by the medical ethic committees of the participating 
hospitals. The study was conducted in accordance with the Helsinki Declaration, and all 
patients provided written informed consent. 
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Figure 1. Flowchart of patient selection 
 
Number of patients at baseline 
 
Excluded due to missing data on 
baseline self-report measures 
 
Number of patients in baseline analyses 
 
Died between hospitalization 
and 2 months follow-up 
 
Refused to participate at  
2 months follow-up 
 
Lost to follow-up 
 
Excluded due to missing data on 
follow-up self-report measures 
 
Included patients at follow-up 
 
Demographic and clinical characteristics  
Demographic variables included sex, age, marital status, educational level, and working 
status. Clinical variables included ICD indication, shocks between implantation and 
follow-up, comorbidity (lung disease, renal disease, rheumatic disease, or diabetes 
mellitus), cardiac history (previous myocardial infarction (MI), percutaneous coronary 
intervention (PCI), or coronary artery bypass graft (CABG) surgery), smoking, 
psychotropic medication, and days between implantation and completion of the baseline 
questionnaire. Clinical variables were obtained from the medical records, except for 
smoking and psychotropic medication which were measured by self-report. 
n = 10 
n = 5 
n = 192 
N = 165 





n = 175 
n = 7 
n = 200 
N = 205 
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Symptoms of anxiety at baseline 
General anxiety 
The State-Trait Anxiety Inventory (STAI) was used to assess general symptoms of 
anxiety
22
. The STAI is a self-report measure consisting of two 20-item scales developed to 
measure the level of general state and trait anxiety. In the current study, we only used the 
state measure, because the purpose in this study was to assess the current presence of 
symptoms of anxiety at baseline and not anxiety as a stable trait. Each item is rated on a 4-
point Likert scale from 1-not at all to 4-very much so. Ten items measure the presence of 
anxiety and 10 items the absence of anxiety. After recoding the anxiety absence items, 
scores can range from 20, that is, low level of state-anxiety to 80, that is, high level of 
state-anxiety. The STAI has been demonstrated to have adequate validity and reliability, 





The 18-item Cardiac Anxiety Questionnaire (CAQ) was specifically designed to measure 
heart-focused anxiety, which refers to the fear of cardiac-related stimuli and sensations 
based upon their perceived negative consequences
23
. Answers are rated on a 5-point Likert 
scale, ranging from 0-never to 4-always. A total score is computed as the mean of the 
relative frequency ratings for each of the 18 items. Subscale scores are computed 
similarly. The CAQ comprises three subscales: Fear and worry about heart sensations (α 
= 0.83), Cardioprotective avoidance of activities that could bring on symptoms (α = 0.82), 
and Heart-focused attention and monitoring of cardiac–related stimuli (α = 0.69)
23
. Higher 
scores indicate higher cardiac anxiety. 
 
Poor perceived health outcomes at two months follow-up 
Feelings of disability and cardiopulmonary complaints 
The Health Complaints Scale (HCS) is a self-report measure on cognitive and somatic 
health complaints
24
. Of the cognitive health complaints scale, we included the subscale 
feelings of disability and of the somatic health complaints the subscale cardiopulmonary 
complaints, which are both answered on a 5-point Likert scale ranging from 0-not at all to 
4-extremely. The subscale feelings of disability contains 6 items, e.g., “able to take on 
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much more work formerly” and the subscale cardiopulmonary complaints contains 5 
items, e.g., “stabbing pain in heart or chest”. Both scales have good internal consistency 




Patient concerns about the ICD  
Patient concerns about the ICD were measured by the ICD-Concerns questionnaire 
(ICDC)
6
. Originally, the 20-item ICDC was developed in British ICD patients
25
. The 
ICDC was adapted to Dutch language and reduced to 8 items as a result of factor 
analyses
6
. All items were related to concerns about the ICD firing. Items are scored on a 
5-point Likert scale from 0-not at all to 4-very much so. Total scores range from 0-32. The 




Clinical anxiety at two months follow-up 
The Hamilton Rating Scale for anxiety (HAM-A) is a 14-item semi-structured interview 
and is a psychiatric standard for the assessment of current severity of anxiety symptoms
26
. 
The items comprise the symptoms of anxiety, including anxious mood, tension, insomnia, 
and several somatic symptoms. The interviewer has to rate the severity of the symptoms 
on a scale from 0-not present to 4-very severe/incapacitating. Scores range from 0 to 56, 
with a score above 17 indicating significant anxiety
26
. The validity and reliability are 
good, with α ranging from 0.82 to 0.92, and interrater reliability (i.e., intraclass 
coefficient) ranging from 0.74 to 0.98
26-28
. The HAM-A has been used as an outcome 





Since the STAI is considered a measure of general anxiety, whereas the CAQ is supposed 
to measure specific heart-focused anxiety, factor analyses were performed on STAI and 
CAQ items to verify this differential assessment of anxiety components. Bartlett’s test of 
sphericity and the Kaiser-Meyer-Olkin index were used to determine whether it was 
appropriate to perform factor analyses on these items. To determine the number of factors 
to retain, we used the criteria of Eigen values > 1 and scree plot analyses. Varimax 
rotation was applied to further examine the orthogonal dimensions of anxiety. The 
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resulting dimensions of the CAQ were subjected to reliability analyses in order to 
investigate the possibility to abbreviate this scale, because in clinical and epidemiological 
research, it is preferable to have a limited number of items. Item-total correlations and 
Cronbach’s α were calculated to identify redundant items in CAQ. Correlations between 
the STAI and the new CAQ scales, and the outcomes feelings of disability, 
cardiopulmonary complaints, patient concerns about the ICD, and clinical severity of 
anxiety were computed to investigate the degree to which these measures are related 
bivariately before entering them in multivariate analyses. 
A series of univariate linear regression analyses were performed to examine the 
predictive value of the following potential confounders: sex, age, marital status, 
education, work status, indication for ICD implantation, shocks, cardiac history, 
comorbidity, smoking (self-report), psychotropic medication (self-report), and days 
between implantation and completion of baseline questionnaire. Those potential 
confounders showing at least a marginal effect (p < .10) were subsequently entered in 
multivariable linear regression analyses, in which the independent predictive value of the 
anxiety dimensions was examined. 




Baseline demographic and clinical characteristics of the ICD patients as well as mean 
scores on the questionnaires and the interview are displayed in Table 1. The study 
population consisted of 26 women (12.7%) and 179 men (87.3%) with a mean age of 62.1 
(±10.6). An equal number of patients received their ICD for reasons of primary and 
secondary prevention. There were 144 (70.2%) patients with a history of ischemic heart 
disease and 73 (35.6%) patients had comorbid diseases, like lung disease, renal disease, 
rheumatic disease, or diabetes. 
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Table 1. Patient characteristics 
 N (%) Mean (SD) Range 
 
Demographics 
   
   Age  62.1 (10.6) 24-79 
   Female 26 (12.7)   
   No partner 24 (11.7)   
   Low education 45 (22.0)   
   No work 155 (75.6)   
    
Clinical variables    
   Primary indication 102 (49.8)   
   ≥1 shock since implantation
2 
7 (4.2)   
   History of ischemic heart disease
3 
144 (70.2)   
   Comorbidity
4 
73 (35.6)   
   Current smoking 39 (19.0)   
   Use of psychotropic medication 33 (16.1)   
   Days
5
  7.7 (6.8) 0-21 
    
Predictor variables    
   STAI absence of anxiety   26.8 (7.5) 11-40 
   STAI presence of anxiety   16.3 (5.8) 10-38 
   CAQ total score  1.1 (0.8) 0-4 
   CAQ Fear  1.2 (0.9) 0-4 
   CAQ Avoidance  1.4 (1.1) 0-4 
   CAQ Heart-focused attention  0.7 (0.8) 0-4 
    
Outcome variables2    
   Feelings of disability (HCS)  7.0 (6.4) 0-24 
   Cardiopulmonary complaints (HCS) 2.9 (3.5) 0-19 
   Patient concerns about the ICD (ICDC) 5.9 (6.6) 0-32 
   Clinical anxiety (HAM-A) 
 
 4.6 (5.3) 0-24 
1
 Data are presented as percentages, unless specified as mean (SD); 
2
 Based on patients at 
2-months follow-up (n = 165); 
3
 Previous MI, PCI, CABG; 
4
 Lung, renal, rheumatic 
disease, and/or diabetes; 
5
 Days between ICD implantation and completion of baseline 
questionnaire. 
STAI = State-Trait Anxiety Inventory; CAQ = Cardiac Anxiety Questionnaire; HCS = 
Health Complaints Scale; ICDC = ICD-Concerns questionnaire; HAM-A = Hamilton 
Rating Scale for Anxiety. 
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Dimensions of general versus disease-specific anxiety 
To explore whether the STAI and CAQ items assess different aspects of anxiety, we 
performed factor analyses on the total sample (N = 205). Bartlett’s test of sphericity        
(p < .0001) and the Kaiser-Meyer-Olkin index (0.885) indicated that it was appropriate to 
perform factor analyses on these items. Eight components had eigenvalues above 1.00 
(12.30, 4.93, 2.26, 2.05, 1.51, 1.16 1.10, and 1.01), but the scree plot showed a clear break 
between the fourth and fifth component. The resulting four factors were subjected to 
Varimax rotation. Table 2 displays the factor loadings.  
The first component covers the items of the STAI which measure absence of 
anxiety. The second component contains the 5 items of the CAQ subscale Heart-Focused 
Attention and 6 items of the CAQ subscale Fear. The third component covers the STAI 
items which measure presence of anxiety. Finally, the fourth component includes the 
items of the CAQ subscale Avoidance and also one item of the CAQ subscale Fear. CAQ 
item 13 had no loading on any of the four factors. The extraction of these four factors 
shows the differential measurement of general anxiety by the STAI and heart-specific 
anxiety by the CAQ. 
 
Avoidance and Fear measures of anxiety 
The above described factor analyses yielded two components of the CAQ. To identify 
redundant items in the CAQ, we calculated item-total correlations and Cronbach’s α. 
Since items 1, 14, 15, 16, and 17 of component 2 had the highest item-total correlations 
and the lowest α-values when the item was deleted, these items were selected for the new 
subscale labeled Fear. This scale consists of 1 item from the previous subscale Heart-
Focused Anxiety (item 1) and 4 items from the subscale Fear (items 14-17). Cronbach’s α 
of the new Fear subscale was 0.88. The item-total statistics of the other CAQ component 
showed clearly that CAQ item 18 had the lowest item-total correlations and the highest α-
values if this item was deleted from the scale. Omitting this item resulted in a new 5-item 
scale, which exactly comprised the initial CAQ subscale Avoidance. Hence, this name 
was retained. Results of the item-total correlations of the new subscales and α values are 
displayed in Table 3. 
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Table 2. Factor loadings of the STAI and CAQ items after varimax rotation (N = 205) 
SCALE “Item” (number)                  Components:  1 2 3 4 
STAI “Feel pleasant” (20) .83    
STAI “Feel self-confident” (11) .82    
STAI “Feel content” (16) .79    
STAI “Feel comfortable” (10) .78    
STAI “Feel at ease” (5) .77  -.31  
STAI “Feel satisfied” (8) .77    
STAI “Am relaxed” (15) .74  -.34  
STAI “Feel steady” (19) .74    
STAI “Feel calm” (1) .68    
STAI “Feel secure” (2) .64  -.31  
CAQ “Get frightened” (16)  .81   
CAQ “Might have heart attack” (14)  .81   
CAQ “Difficulty concentrating” (15)  .73  .35 
CAQ “Pay attention” (1)  .72   
CAQ “Feel heart in chest” (8)  .63   
CAQ “Check by doctor” (17)  .62   
CAQ “Check my pulse” (6)  .58   
CAQ “Awakening by chest pain” (4)  .56   
CAQ “Awakening by racing heart” (3)  .55   
CAQ “Normal test, still worry” (10)  .52   
CAQ “Safe around hospital” (11)  .51  .32 
CAQ “Do not believe symptoms” (13)*     
STAI “Am jittery” (13) -.33  .73  
STAI “Feel nervous” (12) -.37  .71  
STAI “Worry over misfortunes” (7)   .68  
STAI “Feel frightened” (9)   .66  
STAI “Feel strained” (4) -.41  .64  
STAI “Feel upset” (6)   .64  
STAI “Feel confused” (18)   .63  
STAI “Feel indecisive” (14)   .62  
STAI “Am worried” (17)  .31 .62  
STAI “Am tense” (3) -.40  .61  
CAQ “Avoid exercise” (7)    .84 
CAQ “Avoid physical exertion” (2)    .82 
CAQ “Take it easy” (5)    .74 
CAQ “Avoid activities: sweat” (12)    .73 
CAQ “Avoid activities: heart beat” (9)  .45  .67 
CAQ “Tell family” (18)    .34 
% of Variance 18.14 15.13 13.58 10.01 
Cronbach’s α 0.94 0.88 0.91 0.85 
* no factor loadings; STAI = State-Trait Anxiety Inventory; CAQ = Cardiac Anxiety Questionnaire
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Table 3. New subscales of the CAQ: item-rest correlations and factor loadings (N = 205) 
Item-total      Factor loadings 
                                                                                     correlations         1              2 
CAQ Fear    
When I have chest discomfort or when my heart is 
beating fast: 
   
... I get frightened (16) .81 .85  
... I worry that I might have a heart attack (14) .85 .88  
... I have difficulty concentrating on anything else (15) .79 .81  
... I like to be checked out by a doctor (17) .59 .66  
I pay attention to my heart beat (1) .56 .67  
Cronbach’s α .88   
    
CAQ Avoidance    
I avoid exercise or other physical work (7) .74  .84 
I avoid physical exertion (2) .76  .82 
I take it easy as much as possible (5) .66  .78 
I avoid activities that make me sweat (12) .69  .72 
I avoid activities that make my heart beat faster (9) .69  .70 
Cronbach’s α .88   
% of variance  12.39  11.82 
 
Univariate analyses 
After removing patients who did not meet inclusion criteria for follow-up measurements, 
165 patients remained in analyses (Figure 1). Included patients differed significantly from 
excluded patients regarding several baseline characteristics. Excluded patients were 
younger (58.3±13.9 versus 63.0±9.4, t(203) = -2.6, p = .011), had more days between 
implantation and completion of baseline questionnaire (10.7±8.0 versus 7.0±6.3 days, 
t(203) = 3.2, p = .002), and reported higher scores on STAI presence of anxiety (18.6±8.0 
versus 15.7±4.9, t(203) = 2.9, p = .005), CAQ Fear (1.5±1.1 versus 1.1±0.8, t(203) = 3.1, 
p = .003), and CAQ Avoidance (1.8±1.2 versus 1.3±1.0, t(203) = 2.5, p = .017). 
The obtained mean score of 5.9 (±5.3) on patient concerns about the ICD is lower 
compared to a previous study, which reported a mean score of 8.18
6
. The mean score on 
clinical anxiety was 4.6 and there were only 7 (4.2%) patients who experienced clinically 
significant levels of anxiety, that is, a score > 17 on the HAM-A
26
. 
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Correlations between STAI and the new CAQ scales with feelings of disability, 
cardiopulmonary complaints, patient concerns about the ICD, and clinical anxiety at two 
months following ICD implantation were all significant (Table 4).  
 
Table 4. Correlations between STAI and CAQ subscales and their correlations with 












STAI absence of anxiety          -.63
*** 
       -.22
** 
       -.30
*** 
STAI presence of anxiety            .32
*** 
        .34
*** 
CAQ Avoidance            .45
*** 
CAQ Fear     
     
Feelings of disability       -.42
*** 
        .48
*** 
        .45
*** 
        .35
*** 
Cardiopulmonary complaints             -.23
** 
        .29
*** 
        .31
*** 
        .22
** 
Patient concerns about the ICD       -.24
** 
        .35
*** 
        .18
* 
        .29
*** 
Clinical anxiety       -.30
*** 
        .45
*** 
        .24
** 
        .27
*** 
*
 p < .02 (2-tailed); 
**
 p < .005 (2-tailed); 
***
 p < .0001 (2-tailed). 
 
Univariate linear regression analyses showed that of the potential confounding 
variables low education (ß = .13, p = .088), shocks (ß = .16, p = .040), and comorbidity (ß 
= .23, p = .003) were (marginally) associated with feelings of disability. No work (ß = .17, 
p = .033), previous cardiac disease (ß = .13, p = .094), and comorbidity (ß = .24, p = .002) 
predicted cardiopulmonary complaints. Shocks (ß = .31, p < .0001) was the only variable 
that significantly predicted patient concerns about the ICD. Finally, smoking (ß = .17, p = 
.031) and use of psychotropic medication (ß = .20, p = .009) were significantly related to 
clinical anxiety. These variables were adjusted for in multivariable analyses. 
 
Multivariable regression model  
Multiple linear regression analyses were performed to determine the independent 
predictive value of STAI and CAQ scales. As shown in Table 4, the highest correlation 






The results of multiple linear regression analyses are shown in Table 5. Feelings of 
disability were significantly and independently predicted by STAI absence of anxiety      
(ß = -.22, p = .009), STAI presence of anxiety (ß = .22, p = .011), and CAQ Avoidance   
(ß = .28, p < .0001). The covariates shocks (ß = .15, p = .017) and comorbidity (ß = .20,   
p = .002) remained also independent predictors in the multivariable model. 
Cardiopulmonary complaints were predicted only by CAQ Avoidance (ß = .17, p = .049) 
and comorbidity (ß = .19, p = .014), not by the STAI. Patient concerns about the ICD 
were predicted by STAI presence of anxiety (ß = .25, p = .010), CAQ Fear (ß = .17,          
p = .043), and shocks (ß = .27, p < .0001). Finally, the only significant and independent 
predictor of clinical anxiety was STAI presence of anxiety (ß = .37, p < .0001). In other 
words: STAI absence of anxiety predicted feelings of disability; STAI presence of anxiety 
predicted feelings of disability as well, but also patient concerns about the ICD and 
clinical anxiety. CAQ Avoidance was significantly and independently associated with 
feelings of disability and cardiopulmonary complaints and CAQ Fear showed only an 
independent relation with patient concerns about the ICD.  
 
DISCUSSION 
This is the first study which examined the differential independent predictive value of 
general anxiety versus disease-related anxiety for poor perceived health outcomes. Our 
results confirm our hypothesis that different dimensions of general and specific anxiety 
predict different outcomes in ICD patients. We found that clinical anxiety was only 
predicted by a general measure of anxiety (from the STAI), while cardiopulmonary 
symptomatology was only predicted by a disease-specific measure of anxiety (from the 
CAQ). In turn, patient concerns about the ICD and feelings of disability were 
independently predicted by both general as well as disease-specific measures of anxiety. 
Moreover, three out of four anxiety dimensions predicted feelings of disability, indicating 
significant and independent predictive value of those dimensions. These results 
demonstrate the importance of differentiating between general and disease-specific 
anxiety.  
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Table 5. Multivariable predictors of feelings of disability, cardiopulmonary complaints, 
concerns about the ICD, and severity of anxiety (n = 165)
1 
 











Predictors      ß         p      ß         p      ß         p      ß         p 
STAI absence of 
anxiety  
  -.22      .009    -.08     .38    -.05      .57    -.01     .90 
STAI presence of 
anxiety  
   .22      .011     .15     .13     .25     .010     .37  <.0001 
CAQ Avoidance    .28   <.0001     .17     .049     .04      .61     .04     .61 
CAQ Fear    .08      .25     .05     .53     .17      .043     .11     .20 
     
Demographics     
   Low education    .08      .25     .03     .67     .01      .86    -.04     .60 
   Working   -.06      .40     .04     .65    -.14      .07    -.02     .84 
     
Clinical variables     
   Received ≥ 1 shock  
     since implantation 
   .15      .017   -.04      .63     .27  <.0001    -.01     .95 
   History of ischemic 
     heart disease
2 
   .02      .73    .08      .28     .07      .33     .04     .55 
   Comorbidity3    .20      .002    .19      .014     .06      .39     .07     .34 
   Current smoking   -.00      .96    .03      .67    -.01      .92     .03     .71 
   Using psychotropic      
     medication 
  -.08      .20   -.07      .35    -.06      .45     .12     .10 
1
 Linear regression analyses; 
2
 Previous MI, PCI, CABG; 
3
 Lung, renal, rheumatic disease, 
and/or diabetes.  
STAI = State-Trait Anxiety Inventory; CAQ = Cardiac Anxiety Questionnaire 
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Previous studies have also discriminated general from disease-specific anxiety, but 
simultaneous associations with outcome measures have not been examined, except for 
shocks. Our result that shocks are independently related to patient concerns about the ICD 
has been found in some
6, 20
 but not all
12, 21
 studies. It is important to note that one study 
found general anxiety to be predicted by previous shocks, whereas specific concerns 
following insertion of an ICD were not
21
. The discrepancies in the results of the different 
studies could in part be due to the use of different measures for assessing worries and 
concerns about the ICD. The questionnaire we used, that is, the ICDC, was previously 
used in the study of Pedersen et al
6
. They also reported that shocks received since 
implantation were related to specific patient concerns about the ICD. 
Correlations between general anxiety and disease-specific anxiety vary between 
0.42 and 0.61 in previous research
6, 21
. Since these correlations are moderate to high, they 
show that 18% to 37% of the variance is shared between both dimensions of anxiety, but 
that each construct has unique aspects.  
Disease-specific anxiety and avoidance of behaviors of which the patient believes it 
triggers shocks, can limit the frequency and intensity of activities of daily life
32
. Our 
results elaborate on this previously reported finding as disease-specific anxiety was most 
importantly related to feelings of disability and uniquely to cardiopulmonary complaints. 
Overall, these results suggest that physical complaints and functional impairment in ICD 
patients may be a result of disease-specific anxiety enhancing avoidance of physical 
activities. In line with this, previous studies have shown that patients with disease-specific 
anxiety may recover more slowly than patients without disease-specific anxiety
23, 33
. 
The CAQ has previously been described as an 18-item screening instrument for 
identifying patients with disease-specific anxiety
23
. However, in clinical and 
epidemiological research, questionnaires should contain a limited number of items. This 
study reported on two new 5-item CAQ subscales, which may be useful as a screening 
tool. However, before the two new subscales can be used in the clinical setting, the scales 
should be validated in future research. 
The present findings may have a number of clinical implications. First, identifying 
patients with general anxiety or disease-specific anxiety is important, since psychological 
distress, including anxiety, may precipitate ventricular arrhythmias and therefore ICD 





. Second, since feelings of disability were predicted by presence as well as 
absence of anxiety, it may be important to not only use total STAI-state scores, but also 
the sub scores. More specifically, clinicians may focus on positive answers regarding 
presence of anxiety, but also on low scores on the items reflecting absence of anxiety, e.g., 
‘feel calm’ and ‘feel at ease’. Next, two RCT trials using ICD patients have demonstrated 
the positive effect of comprehensive cardiac rehabilitation including an exercise 
programme on general anxiety
35-37
. Since patients with disease-specific anxiety may avoid 
physical exercise because of anxiety to elicit cardiac symptoms
33
, including arrhythmias 
and ICD shocks
32
, these patients may also benefit from rehabilitation in which physical 
exercise may be supplemented by a psychological intervention aimed at reducing this 
disease-specific anxiety. However, future research is warranted to examine appropriate 
interventions for both general as well as disease-specific anxiety. 
These results should be interpreted with some caution. Initially, 212 patients agreed 
to take part in the study, but follow-up analyses were based on 165 (78%) patients, mainly 
due to loss to follow-up and missing self-report data. The excluded patients were younger, 
had more days between implantation and completion of the questionnaire, and had higher 
scores on three of the anxiety indices. The loss of 47 subjects and the differences between 
excluded and included patients may have influenced the results and may have a negative 
impact on the generalizability. However, since excluded patients experienced more 
anxiety at baseline, the differential predictive value of general versus disease-specific 
anxiety found in this study is more likely to be an underestimation than an overestimation. 
Future research is warranted to replicate our findings. Nevertheless, this is the first study 
that explicitly determined the differential and independent predictive value of general 
anxiety versus disease-specific anxiety for poor perceived health outcomes. 
Future research should also examine the differential predictive value towards hard 
medical endpoints, such as mortality, morbidity, and ICD shocks. Research may focus on 
ICD patients or on the broader range of patients with cardiovascular disease. Following 
the distinction of both anxiety dimensions, future research should also focus on possible 
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Background Clinical factors increase the risk for ventricular arrhythmias, but little is 
known about the role of psychological factors. In this multicenter study, we examined 
whether increased levels of anxiety triggered ventricular arrhythmias in implantable 
cardioverter defibrillator (ICD) patients. 
Methods Patients (N = 565; 81% males; mean age = 60.4±11.4 years) completed the 
STAI (state-version) at the time of implantation. Ventricular arrhythmias were defined as 
appropriate ICD therapies (i.e., antitachycardia pacing or shocks for ventricular 
arrhythmias) during the 12-month follow-up period. Endpoints were ≥ 1 arrhythmia, ≥ 5 
arrhythmias, and ≥ 1 shock. 
Results 21.6% of patients experienced ≥ 1 arrhythmia, 8.0% ≥ 5 arrhythmias, and 11.2% 
≥ 1 shock. Patients with the ICD for secondary prevention were at a 2.2-fold risk (95% CI 
1.43-3.27; p < .0001) of experiencing ≥ 1 arrhythmia during follow-up, whereas no main 
effect was found for anxiety. However, increased anxiety was an independent predictor of 
patients who experienced ≥ 5 arrhythmias (OR = 2.3; 95% CI 1.21-4.48; p = .012); other 
independent predictors were secondary prevention (OR = 2.5; 95% CI 1.33-4.88; p = 
.005) and ischemic etiology (OR = 0.46; 95% CI 0.23-0.92; p = .028). Secondary 
prevention was also associated with a 2.8-fold risk (95% CI 1.58-4.78; p < .0001) for 
shocks. Analyses included anxiety, age, gender, indication, and ischemic etiology. 
Conclusions Secondary prevention was predictive for all three endpoints. Increased 
anxiety and ischemic etiology were related to ≥ 5 ventricular arrhythmias. It may be 
important to identify and treat patients at high risk for anxiety, as their increased risk of 
arrhythmias may lead to adverse health outcomes, including poor quality of life. 
 




Mortality from cardiovascular disease is caused by sudden cardiac death in about 50% of 
cases
1
, with 84% being attributable to ventricular arrhythmias
2
. Clinical factors, including 
low left ventricular ejection fraction (LVEF), QRS duration, and atrial fibrillation
3
, New 




, and vigorous exercise
1, 6
 have been 




The implantable cardioverter defibrillator (ICD) has become the therapy of choice 
for the treatment of life-threatening arrhythmias in patients who have experienced a 
previous arrest and in patients at risk due to reduced LVEF
8, 9
, with ICD implantation 
being associated with a 20-60% reduction in mortality as compared to antiarrhythmic 
drugs
9, 10
. The beneficial effects of the ICD have led to an expansion in the indications for 
ICD to include both primary and secondary prevention
8
. As a consequence, the number of 
implantations has increased substantially and this rise is projected to continue in the 
future
10
. Given this increase in the number of ICD patients, knowledge of precipitating 
factors of life-threatening arrhythmias is essential for the identification of high-risk 
patients in order to optimize the clinical management of these patients.  
Despite preliminary evidence that psychological factors may play a role in the 
onset of ventricular arrhythmias, there is a paucity of studies investigating the role of 
psychological factors as precipitants in ICD patients
11-14
. Anxiety may trigger ventricular 
arrhythmias in ICD patients, although this finding was not consistently found across 
studies
11, 12, 14
. Furthermore, patients with high levels of trait anxiety are at increased risk 
of experiencing anxiety-triggered arrhythmias
13
.  
The objective of this multicenter study was to determine whether increased levels 





Patients hospitalized between May 2003 and December 2006 for ICD implantation were 
included from three teaching hospitals in the Netherlands (Erasmus Medical Center, 
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Rotterdam; Catharina Hospital, Eindhoven; Amphia Hospital, Breda). Patients included in 
the Erasmus Medical Center were part of the ongoing study entitled “Mood and 
personality as precipitants of arrhythmia in patients with an Implantable cardioverter 
Defibrillator: A prospective Study (MIDAS)”. Exclusion criteria were significant 
cognitive impairments (e.g., dementia), life-threatening comorbidities (e.g., cancer), 
history of psychiatric illness other than affective/anxiety disorders, and insufficient 
knowledge of the Dutch language. Patients who died during the 12-month follow-up 
period were included in the analyses, since they could also have experienced ventricular 
arrhythmias during the follow-up period. 
The study was approved by the medical ethic committees of the participating 
hospitals. The study was conducted in accordance with the Helsinki Declaration, and all 
patients provided written informed consent. 
 
Measures 
Demographic and clinical variables 
Demographic variables included gender, age, marital status (single versus having a 
partner), low education (secondary education or less), and unemployment. Clinical 
variables included indication for ICD treatment (primary versus secondary prevention), 
underlying cardiac disease (ischemic versus non-ischemic etiology), pharmacological 
treatment, and cardiovascular risk factors including diabetes and smoking. These variables 
were obtained from the patients’ medical records, with the exception of smoking which 
was obtained from self-report.  
 
Anxiety 
The State-Trait Anxiety Inventory (STAI) was used to assess general symptoms of 
anxiety
15
. The STAI is a self-report measure consisting of two 20-item scales developed to 
measure the general level of state and trait anxiety. In the current study, we only used the 
state measure. Each item is rated on a 4-point Likert scale from 1-not al all to 4-very much 
so. Ten items measure the presence of anxiety and 10 items the absence of anxiety. After 
recoding the anxiety absence items, scores range from 20 (i.e., low level of state-anxiety) 
to 80 (i.e., high level of state-anxiety). The STAI has been demonstrated to have adequate 
Anxiety and Ventricular Arrhythmia 
125 
 
validity and reliability, with Cronbach’s α ranging from 0.87 to 0.92
15
. To indicate 
clinically elevated levels of general anxiety, a cut-off ≥ 40 was used. This cut-off was 
previously used in studies on ICD
16
 and patients with myocardial infarction.
17
 Patients 
completed the STAI in the period between 1 day prior to ICD implantation and 3 weeks 
following ICD implantation. 
 
Study endpoints 
Ventricular arrhythmias comprised the primary study endpoint, which was defined as 
appropriate ICD therapies, that is antitachycardia pacing episodes (ATP) or shocks, 
delivered for ventricular tachyarrhythmia or ventricular fibrillation during the 12-month 
follow-up period. Only the most aggressive treatment per episode was counted, such that 
if a patient experienced a ventricular arrhythmia for which first ATPs were delivered and 
then shocks, this episode was counted as a shock. The primary endpoint of ventricular 
arrhythmias was further subdivided using a cut-off ≥ 5 ventricular arrhythmias, analogous 
to the Canadian Implantable Defibrillator Study (CIDS)
18
 and other studies
19, 20
. These 
studies showed that a threshold number of shocks (i.e., ≥ 5 shocks) may be necessary in 
order for shocks to influence emotional functioning. Likewise, psychological distress may 
play a differential role in predicting patients who experience ≥ 1 versus ≥ 5 ventricular 
arrhythmias. The secondary endpoint was appropriate shocks (0 versus ≥ 1). Due to 
limited power, this outcome was not further subdivided. Information on the study 
endpoints was obtained from the patients' medical records. 
 
Statistical analyses 
Differences between patients who were included versus excluded in analyses were 
examined using the Chi-square test for dichotomous variables and Student's t-test for 
independent samples for continuous variables. The Kaplan-Meier method was used to 
graphically present the time to first ventricular arrhythmia for patients high versus low in 
anxiety. The log-rank test was applied to test for statistically significant differences 
between groups. To examine the influence of anxiety on the onset of ventricular 
arrhythmias, a series of univariable logistic regression analyses were performed, followed 
by multivariable logistic regression analysis. In the multivariable analyses, we decided a 
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, and ischemic etiology
23
 as covariates. 
All tests were two-tailed, and a p-value < .05 was used to indicate statistical significance. 




Initially, 587 ICD patients agreed to participate, but 22 (3.7%) were not included in the 
analyses due to missing data on self-report measures (n = 14) or clinical variables (n = 8). 
These excluded patients were compared with the remaining 565 patients on all 
demographic and clinical variables, but no statistically significant differences were found. 
Demographic and clinical baseline characteristics of the 565 ICD patients are presented in 
Table 1, as a function of the total sample and stratified by ≥ 1 arrhythmias and ≥ 5 
arrhythmias.  
 
Anxiety as a precipitant of ventricular arrhythmias (univariable analysis) 
Of the 565 patients included in the analyses, 122 (21.6%) had experienced at least 1 
episode and 45 (8.0%) at least 5 episodes with ATP or shocks for ventricular arrhythmias 
during the 12-month follow-up period; 63 (11.2%) patients had experienced at least 1 
shock and 36 (6.4%) had died. Mean anxiety levels in these patients were 41.18, 44.58, 
42.16, and 41.39, respectively, with the proportion of patients with increased anxiety 
being 52.5%, 66.7%, 56.3%, and 50%, respectively. 
The Kaplan-Meier curves for time to first ATP or shock, stratified by high versus 
low anxiety, are shown in Figures 1 and 2 for ≥ 1 episode and ≥ 5 episodes, respectively. 
The Log Rank test for ≥ 1 episode was not significant (χ
2 
= 1.10, df = 1, p = 0.29), 
indicating that the proportion of patients with ≥ 1 episode was equal among patients with 
high versus low levels of anxiety. In contrast, the Log rank test for ≥ 5 episodes was 
significant (χ
2
 = 6.48, df = 1, p = .011), with more high anxious patients experiencing ≥ 5 





Table 1. Demographic and clinical baseline characteristics (N = 565) 

















Demographic characteristics        
   Males 81.1% (458) 80.4% 83.6% ns 80.4% 88.9% ns 
   Age (Mean ±SD) 60.41 ±11.41 60.33 60.73 ns 60.50 59.38 ns 
   Single/No partner 9.7% (55) 8.8% 13.1% ns 9.4% 13.3% ns 
   Lower education* 54.4% (304) 54.8% 52.9% ns 55.0% 47.7% ns 
   Unemployed 71% (396) 70.2% 73.8% ns 71.0% 71.1% ns 
Clinical characteristics        
   Smoking 14.5% (82) 13.6% 18.0% ns 14.1% 20.0% ns 
   Diabetes 13.0% (71) 12.6% 14.4% ns 12.5% 18.6% ns 
   Secondary prevention 44.2% (250) 40.2% 59.0% <.0001 42.5% 64.4% .004 
   Ischemic etiology  66.2% (374) 67.0% 63.1% ns 67.1% 55.6% ns 
Medication        
   ACE-inhibitor 68.1% (376) 67.3% 71.1% ns 68.1% 68.2% ns 
   Amiodarone 23.5% (130) 24.5% 19.8% ns 23.0% 29.5% ns 
   Beta-blocker 80.8% (447) 81.5% 78.5% ns 80.9% 79.5% ns 
   Digoxin 13.6% (75) 12.8% 16.5% ns 13.6% 13.6% ns 
   Diuretic 63.8% (352) 64.5% 61.2% ns 64.2% 59.1% ns 
   Statin 62.6% (346) 63.2% 60.3% ns 63.1% 56.8% ns 
Anxiety        
   Anxiety scores (Mean±SD) 39.62 ±11.84       
   Probable clinical levels (STAI ≥ 40) 48.3% (273)       
*






















































Figure 1. Kaplan-Meier curve for ventricular arrhythmias for which appropriate ATPs or 


















Figure 2. Kaplan-Meier curve for more than 5 ventricular arrhythmias for which 















                  Number at risk 
 Low anxiety (dotted) 292           254                245                   240     233 
 High anxiety (solid)   273           240              227                   218     208 
                Number at risk 
Low anxiety (dotted) 292         279           276              276                  276 
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Secondary indication was the only significant predictor of ≥ 1 ventricular arrhythmias at 
follow-up (OR = 2.23; 95% CI 1.48-3.36; p < .0001). Anxiety was not significantly 
associated with ≥ 1 arrhythmia (OR = 1.19; 95% CI 0.80-1.78; p = .39). Secondary 
indication was also the only significant predictor of > 1 appropriate shocks (OR = 2.82; 
95% CI 1.62-4.90; p < .0001). In contrast, increased anxiety (OR = 2.28; 95% CI 1.20-
4.34; p = .012) and secondary indication (OR = 2.62; 95% CI 1.37-5.00; p = .004) were 
both associated with an increased risk of ≥ 5 ventricular arrhythmias; there was also a 
trend for ischemic etiology, with patients with ischemic heart disease having a lower risk 
of experiencing ≥ 5 arrhythmias (OR = 0.59; 95% CI 0.32-1.09; p = 0.094). 
 
Anxiety as a precipitant of ventricular arrhythmias (multivariable analysis) 
In multivariable analyses, we included increased anxiety, age, male, secondary indication, 
and ischemic etiology a priori as predictor variables. Using ≥ 1 ventricular arrhythmias as 
the endpoint (Table 2, left column), patients with a secondary indication were at a 2.2-fold 
risk of experiencing an arrhythmia during follow-up. In the second analysis, secondary 
indication was associated with a 2.8-fold risk (95% CI 1.58-4.78; p < .0001) for 
appropriate shocks; no other significant predictors were found (data not shown). In the 
third analysis, increased anxiety, secondary indication, and ischemic etiology were 
significant independent predictors of ≥ 5 ventricular arrhythmias (Table 2, right column). 
A trend was found for gender, with male patients having a 2.4-fold increased risk for 
experiencing ≥ 5 ventricular arrhythmias. In sum, secondary indication was predictive for 
all three endpoints. Patients with increased anxiety had an increased risk of experiencing  
≥ 5 ventricular arrhythmias, while patients with ischemic etiology had a decreased risk. 
 
Table 2. Multivariable model of predictors of ventricular arrhythmias 
 ≥ 1 ventricular arrhythmias ≥ 5 ventricular arrhythmias 
 OR 95% CI p OR 95% CI p 
       Increased anxiety 1.20 0.80-1.82 .37 2.33 1.21-4.48 .012 
Male 1.26 0.73-2.20 .41 2.35 0.88-6.32 .090 
Age 1.01 0.99-1.03 .47 1.00 0.97-1.03 .96 
Secondary prevention 2.16 1.43-3.27 <.0001 2.54 1.33-4.88 .005 




The objective of the current prospective multicenter study was to examine whether 
anxiety comprises a precipitant of arrhythmic events at 12 months follow-up in 
cardioverter defibrillator patients. Patients with probable clinical anxiety had a 2.3-fold 
increased risk of experiencing ≥ 5 ventricular arrhythmias within the first 12 months 
following ICD implantation, whereas anxiety was not a predictor of ≥ 1 events. Patients 
with a secondary indication were also at increased risk for experiencing ≥ 5 ventricular 
arrhythmias, with the risk being 2.5-fold, whereas patients with ischemic etiology had a 
decreased risk. In addition, secondary indication was an independent predictor for ≥ 1 
ventricular arrhythmias (2.2-fold risk) and ≥ 1 shock (2.8-fold risk).  
The results of the current study are in line with some previous studies in ICD 
patients. Dunbar and colleagues
11
 found that self-reported anxiety at 1 and 3 months was 
predictive for ventricular arrhythmias (i.e., appropriate ATPs and shocks) within 1-3 
months and 3-6 months follow-up, respectively. However, since the total mood 
disturbance score at baseline and 6 months follow-up did not predict arrhythmias in the 
consecutive 2 and 3 months, respectively, the authors did not specify total mood 
disturbance, despite the possibility that one of the separate mood disturbances could have 
been significant. Lampert and colleagues
12
 investigated predictors for appropriate shocks. 
In line with our results, they found that appropriate shocks were not predicted by anxiety, 
which was measured using a 5-point intensity scale. It may be important to note that the 
Dunbar et al.
11
 study included clinical risk factors in the multivariable models when 
predicting total mood disturbance (but not in the models on separate mood states), 
whereas the Lampert et al.
12
 study did not. Taken together, anxiety may be predictive for 
ventricular arrhythmias as defined by appropriate ATPs or shocks, but not for shocks 
alone. However, we have no explanation why anxiety in the current study was only a 
predictor of arrhythmic events when these were stratified by ≥ 5 and not a predictor of ≥ 1 
events. 
In the current study, secondary indication was related to all study endpoints, which 
is in line with other studies finding that secondary indication is associated with 
appropriate ICD discharges for ventricular arrhythmias
5, 21, 22
. We also found that patients 
with ischemic etiology had a lowered risk to experience ≥ 5 ventricular arrhythmias, but 
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not ≥ 1 event or shocks alone. We have no explanation for this finding, since an ischemic 
and infarcted myocardium provides an excellent substrate for developing arrhythmias
23
. 
To our knowledge, the predictive value of age and gender for ≥ 5 ventricular arrhythmias 
has not yet been examined. Comparable to our results, previous studies did not find a 
significant association between male gender and ≥ 1 ventricular arrhythmias
22
, although 
one study found an increased risk for older age and a trend for male gender
7
. 
Little is known about the pathways through which psychological factors in general 
and anxiety in particular may lead to the onset of ventricular arrhythmias. Disturbances in 
the autonomic nervous system may comprise one mechanism, as patients with anxiety or 
anxiety disorders
24
 exhibit reduced heart rate variability, which is an important risk factor 
for sudden cardiac death
24, 25
. As shown in experimental studies, general mental stress may 
lead to ventricular arrhythmias
26
, as mental stress may shorten the VT cycle length and 
may influence the termination of VTs, thereby creating a more dangerous arrhythmia
27
. 
Mental stress is also related to increases in T-wave alternans
28, 29
, which is an important 
predictor for ventricular arrhythmias and death
30
. 
In clinical practice, it may be timely to introduce a standard screening procedure in 
order to identify ICD patients at risk of clinical levels of anxiety and anxiety disorders, 
given that our findings and those of others
11
 show that anxiety may trigger arrhythmic 
events. In addition, anxiety is more pronounced than depression in ICD patients, with 
estimated levels ranging from 13% to 38%
31
. Furthermore, anxiety increases avoidance 
behaviors, in turn leading to a more sedentary lifestyle, which is counterproductive for 
cardiac patients
31-34
. Anxiety has also been associated with poor quality of life in patients 
with general cardiovascular disease
35
. A recent review of psychosocial intervention 
studies in ICD patients indicated that anxiety can be reduced in these patients and may 
best be realized using a multifactorial approach, including a cognitive behavioral 
component paired with exercise training
14
. 
The results of the current study should be interpreted with some caution due to the 
following limitations. First, anxiety was measured at baseline only. Alteration in anxiety 
levels during the follow-up period may have additional prognostic information to a single 
snapshot measure. Although this has not been examined in ICD patients to our 
knowledge, one study in myocardial infarction patients reported that a single measure of 
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depression was predictive for cardiovascular death
36
, whereas another study suggested that 
persistent depression may be more important than remittent depression for all-cause 
mortality
37
. Second, generalizability may be limited due to excluded patients who had 
missing data on self-report measures or clinical variables. However, these patients did not 
differ from included patients on all demographic and clinical variables. Third, VTs 
without therapy were not included. Fourth, the number of shocks was too few to subdivide 
this endpoint further into ≥ 5 shocks. Fifth, we did not have information on the cause of 
death for those patients who died during the 12-month follow-up period. Hence, we were 
not able to determine whether death may be attributed to a cardiac cause, including 
ventricular arrhythmia. Sixth, ≥ 5 ICD therapies may be associated with aggressive 
programming of the device, leading to unnecessary therapies for possibly non-sustained 
arrhythmias. However, we had no information about the device programming, but as there 
were no differences on baseline characteristics between patients who did and did not 
experience ≥ 5 ICD therapies, nor were there any differences in the prevalence of patients 
experiencing ≥ 5 ICD therapies between the three hospitals, it may be assumed that there 
was no aggressive programming. Finally, information on LVEF and NYHA class were not 
available for a substantial part of patients; hence, we could not adjust for these variables in 
multivariable analyses. 
Future research is warranted to further explore the role of psychological factors as 











 have also been related to the onset of ventricular 
arrhythmias. Personality may also be of importance, as Burg et al.
13
 showed that the state 
of anger and anxiety as triggers of arrhythmias were related to their corresponding trait 
measures. These studies should incorporate LVEF and NYHA class, as they may serve as 
confounders on the relationship between psychological factors and ventricular 
arrhythmias. Research should also be devoted to the study of the physiological 
mechanisms that may account for this relationship, including potential moderators. 
In conclusion, results of the current study suggest an important role for increased 
self-reported anxiety as a trigger of arrhythmic events the first 12 months following ICD 
implantation. Patients with secondary indication were also at increased risk, whereas 
patients with ischemic etiology were at decreased risk. These findings indicate that 
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patients with increased levels of anxiety should be identified in clinical practice, with the 
option of offering them adjunctive psychosocial intervention to reduce anxiety. Further 
research is warranted to increase our knowledge of the link between psychological factors 
and ventricular arrhythmias, as well as mechanisms and moderators of this relationship in 
order to optimize secondary prevention in ICD patients. 
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Background Little is known about the role of psychological factors in the occurrence of 
life-threatening arrhythmias. We examined anxiety, depression, and Type D personality 
(tendency to experience increased negative emotions paired with a tendency to inhibit the 
expression of these emotions) as predictors of ventricular arrhythmias in implantable 
cardioverter defibrillator (ICD) patients. 
Methods ICD patients (N = 324, 83% males, age = 62.0±10.5 years) completed 
questionnaires on anxiety (STAI), depressive symptoms (BDI), and Type D personality 
(DS14) at baseline (i.e., 0-3 weeks post-implantation). The endpoint was occurrence of 
ventricular arrhythmias, defined as appropriate ICD therapies, in the first year post-
implantation. 
Results Appropriate ICD therapies were experienced by 21% (n = 68) of patients. 
Increased anxiety (OR = 1.46; 95% CI 0.86-2.50; p = .17) and depression (OR = 1.13; 
95% CI 0.65-1.97; p = .67) did not predict arrhythmias, but there was a trend for Type D 
personality (OR = 1.71; 95% CI 0.94-3.11; p = .078). The combined presence of anxiety 
and Type D personality significantly predicted ventricular arrhythmias (OR = 2.39;     
95% CI 1.28-4.47; p = .006). Stepwise logistic regression analysis confirmed that this 
interaction was significant; depressive symptoms did not have an incremental prognostic 
value. Adjusting for gender, age, and ischemic etiology, the combined presence of anxiety 
and Type D personality was associated with a 2.3-fold risk (95% CI 1.20-4.35; p = .012) 
and secondary prevention with a 2.1-fold risk (95% CI 1.20-3.66; p = .009) to experience 
arrhythmias. 
Conclusions Anxious Type D patients and secondary prevention patients are at increased 
risk of experiencing ventricular arrhythmias in the first year post-ICD implantation. Type 
D patients with increased anxiety post-implantation may be identified and offered support. 
 




Implantable cardioverter defibrillator (ICD) treatment provides an opportunity to study 
factors associated with ventricular arrhythmias, which are the most common cause of 
sudden cardiac death
1
. Guidelines advocate ICD implantation in patients who have 
survived life-threatening arrhythmias and in patients with severe left ventricular 
dysfunction
2, 3
. The ICD does not prevent ventricular arrhythmias, but can terminate 
ventricular arrhythmias by antitachycardia pacing (ATP) or high-voltage shocks
4
. 
However, sudden cardiac death due to ventricular arrhythmias may still occur in a 
proportion of ICD patients
5
. Another important issue refers to possible increased 
emotional distress in shocked patients
6





, and impaired quality of life
12
 as compared to non-shocked patients, although 
some studies did not find this association
13-15
. For these reasons and also because patient 
selection for ICD implantation remains controversial, better knowledge of risk factors for 
ventricular arrhythmias is required
1, 16
. Possible clinical risk factors include ischemic heart 
disease
1






, low left 
ventricular ejection fraction, QRS duration, and atrial fibrillation
20
. Psychological factors 
may play a role, but little is known about their influence
21-24
. 
Few studies have evaluated the role of psychological factors as precipitants of 
ventricular arrhythmias in ICD patients
21-24
. Depression has been associated with an 
increased risk for appropriate shocks
21
, while others found that anxiety
22
 (but not 
depression and anger) or anger
23
 (but not sadness and anxiety) may trigger ventricular 
arrhythmias. Personality traits may also increase the risk of emotion-triggered appropriate 
shocks in ICD patients
24
. Taken together, anxiety, depression, and personality predicted 
ventricular arrhythmias in some studies, but evidence is not conclusive. 
Therefore, the objective of the current study was to examine the role of anxiety, 
depression, and personality traits as predictors of ventricular arrhythmias over the 12-







Patients who underwent ICD implantation between May 2003 and December 2006 were 
included from two referral hospitals in the Netherlands (Catharina Hospital, Eindhoven; 
Amphia Hospital, Breda). Inclusion criteria were implantation with an ICD and age 
between 18 and 80 years. Exclusion criteria were significant cognitive impairments (e.g., 
dementia), life-threatening comorbidities (e.g., cancer), and insufficient knowledge of the 
Dutch language. Patients who died during the 12-month follow-up period were not 
excluded from the analyses, since these patients could also have experienced ventricular 
arrhythmias during their follow-up period. The study was approved by the medical ethics 
committees of both participating hospitals. The study was conducted in accordance with 
the Helsinki Declaration, and all patients provided written informed consent. 
 
Psychological measures 
Patients completed questionnaires on anxiety, depressive symptoms, and personality in the 
period between 1 day prior to ICD implantation and 3 weeks following ICD implantation. 
 
Anxiety 
The State-Trait Anxiety Inventory (STAI) was used to assess general symptoms of 
anxiety
25
. In the current study, we only used the state measure, because the purpose in this 
study was to assess the current presence of symptoms of anxiety at baseline. The STAI 
state version consist of 20 items and each item is rated on a 4-point Likert scale from 1-
not al all to 4-very much so, with total scores ranging from 20-80, with higher scores 
indicating higher levels of state-anxiety. The STAI has adequate validity and reliability, 
with Cronbach’s α ranging from 0.87 to 0.92
25
. To indicate clinically elevated levels of 





The Beck Depression Inventory (BDI) is a 21-item self-report measure developed to 
assess the presence and severity of depressive symptoms
27
. Each item is rated on a 
Guttmann scale from 0 to 3. The BDI is a reliable and valid measure of depressive 
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symptomatology and the most frequently used self-report measure of depressive 





Type D personality 
The Type D scale (DS14) was used to assess Type D personality. Type D patients tend to 
experience increased negative emotions (e.g., worry and have a gloomy view of life) 
paired with emotional non-expression
29
. The DS14 contains two 7-item scales, negative 
affectivity (e.g., “I often feel unhappy”) and social inhibition (e.g., “I am a closed kind of 
person”)
29
. Items are answered on a 5-point Likert scale, ranging from 0-false to 4-true, 
with total scores ranging from 0-28 for both subscales. Patients scoring ≥ 10 on both 
subscales are classified as Type D
29, 30
. The DS14 has good reliability, with Cronbach’s 
alpha being 0.88 and 0.86 and three-month test-retest reliability being 0.72 and 0.82, for 
negative affectivity and social inhibition, respectively
29
. The DS14 is a stable personality 
measure over an 18-month period
31
 and scores are not confounded by cardiac disease 
severity or symptoms of anxiety and depression
31, 32
. Previous studies have shown an 
association between Type D personality and adverse clinical outcome, including mortality 
and morbidity
33-36
. Type D personality was included in this paper to examine its main 
effects and interaction effects with anxiety and depressive symptoms for arrhythmias. 
 
Demographic and clinical variables 
Demographic variables included gender and age. Clinical variables included ICD 
indication (primary versus secondary prevention) and etiology (ischemic versus non-
ischemic). These variables were obtained from medical records. 
 
Ventricular arrhythmias 
Ventricular arrhythmias were defined by appropriate ICD therapies, either ATPs or 
shocks, which were delivered for ventricular tachycardia or ventricular fibrillation, over a 
12-month period, beginning with ICD implantation. Only the most aggressive treatment 
per episode was counted, meaning that if a patient experienced a ventricular arrhythmia 
for which first ATPs were delivered and then shocks, this episode was only counted as 1 
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Differences between groups were examined with a Chi-square test (Likelihood ratio were 
appropriate) for dichotomous variables and a t-test for independent samples for 
continuous variables. To enhance clinical interpretability, anxiety and depression scores 
were dichotomized. A series of univariable logistic regression analyses were performed to 
determine whether anxiety, depressive symptoms, Type D personality, and the interaction 
effects anxiety by depressive symptoms, anxiety by Type D personality, and depressive 
symptoms by Type D personality predicted ventricular arrhythmias in the first year 
following ICD implantation. A subsequent stepwise regression (backward method) was 
applied to determine the most important psychological predictor of arrhythmias; because 
of suppressor effects, the backward method is preferable to the forward method
37
. The 
initial regression model contains all psychological variables; in each subsequent step a 
variable is deleted until the best model is reached. Next, a multivariable logistic regression 
analysis (enter method) was performed, including the psychological predictor(s), age, 
gender, ICD indication, and etiology. However, in order to determine whether ICD 
indication and etiology could be entered simultaneously, a Chi-square test was applied. 
The Kaplan-Meier method was applied to graphically present the time to first ventricular 
arrhythmia and the log-rank test was performed to test for significant differences between 
the groups. All data were analyzed using SPSS.14.0 for Windows and a p-value of .05 




Of the 345 patients who agreed to participate in the study, 324 (93.9%) patients were 
included in the analyses. Patients who were not included had missing data on self-report 
measures (n = 12) or clinical variables (n = 9). Table 1 shows demographic and clinical 
characteristics of the 324 patients included in the study. 
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Table 1. Baseline characteristics of 324 patients included in the analyses 
Characteristics % (n) 
  Demographic and Clinical  
   Males 82.7% (268) 
   Age; mean±SD 62.0±10.5 
   Secondary prevention 46.6% (151) 
   Ischemic etiology 72.2% (234) 
  
Psychological  
   Anxiety scores (STAI); mean±SD 39.2±8.8 
   Depressive symptoms (BDI); mean±SD 11.6±6.8 
   Increased anxiety (i.e., STAI ≥ 40) 46.9% (152) 
   Increased depressive symptoms (i.e., BDI ≥ 10) 34.6% (112) 
   Type D personality (DS14) 22.8% (74) 
  
SD = standard deviation, ATP = antitachycardia pacing, DS14 = Type D Scale, BDI = 
Beck Depression Inventory, STAI = State-Trait Anxiety Inventory 
 
Ventricular arrhythmias 
During the first year post-implantation, 68 patients (21%) experienced ventricular 
arrhythmias with appropriate therapies and 22 patients (6.8%) died. Of the 68 patients, 
51.5% of patients only had appropriate ATP episode(s), 25.0% only had shocks, and 
23.5% had both ATPs and shocks. The median number of appropriate ICD therapies was 
2, with a range from 1 to 1100 episodes. 
 
Anxiety, depressive symptoms, Type D personality, and ventricular arrhythmias 
Univariable logistic regression analyses showed that secondary prevention (p = .005) was 
a significant predictor of occurrence of ventricular arrhythmia, but not gender (p = .23), 
age (p = .65), or etiology (p = .34) (Table 2). Increased anxiety (p = .17) and depression  
(p = .67) did not predict arrhythmias, but there was a trend for Type D personality           
(p = .078). In addition, the combined presence of anxiety and Type D personality 
significantly predicted ventricular arrhythmias (p = .006). 
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Table 2. Univariable predictors of ventricular arrhythmias 
       Ventricular arrhythmias 
Variables OR 95% CI p* 
    
Demographic and Clinical    
   Male 0.99 0.96-1.01 .23 
   Age 0.85 0.43-1.70 .65 
   Secondary prevention 2.18 1.26-3.77 .005 
   Ischemic etiology 0.76 0.42-1.35 .34 
    
Psychological    
   Anxiety 1.46 0.86-2.50 .17 
   Depressive symptoms 1.13 0.65-1.97 .67 
   Type D personality 1.71 0.94-3.11 .078 
    
Psychological Interactions    
   Anxiety by Depression 1.19 0.65-2.17 .58 
   Anxiety by Type D personality 2.39 1.28-4.47 .006 
   Depression by Type D personality 1.69 0.85-3.37 .14 
    
*p ≤ .09 are presented in bold face 
 
Independent predictors of ventricular arrhythmias 
The predictive effect of the combined presence of increased anxiety and Type D 
personality was confirmed in a backward stepwise regression model (p = .006), including 
anxiety, depressive symptoms, Type D personality, and their interaction effects; all other 
variables did not add incremental prognostic value. 
ICD indication was not associated with etiology, as about 70% of patients in both 
indication groups had ischemic etiology (χ
2
 = 0.23, df = 1, p = .63). Hence, these variables 
could be entered at the same time. In the multivariable logistic regression analysis (enter 
model), adjusting for gender, age, secondary prevention, and ischemic etiology, the 
interaction between anxiety and Type D personality remained significant with a 2.3-fold 
risk. In addition, secondary prevention was associated with a 2.1-fold risk to experience 
ventricular arrhythmias (Table 3). 
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Table 3. Multivariable predictors of ventricular arrhythmias 
        Ventricular arrhythmias 
 OR 95% CI p 
    
   Male 1.06 0.51-2.22 .88 
   Age 0.99 0.96-1.102 .44 
   Secondary prevention 2.10 1.20-3.66 .009 
   Ischemic etiology 0.77 0.41-1.47 .43 
   Anxiety by Type D personality 2.29 1.20-4.35 .012 
      
Ventricular arrhythmias in anxious Type D patients  
Stratification by anxiety and Type D personality yielded 4 groups, that is a non-anxious 
non-Type D group (n = 156, 48.1%), an anxious non-Type D group (n = 94, 29%), a non-
anxious Type D group (n = 16, 4.9%), and an anxious Type D group (n = 58, 17.9%). 
Figure 1 shows that the incidence of ventricular arrhythmias significantly differed across 
these groups (Likelihood ratio = 9.13, df = 3, p = .028), with the anxious Type D group 
showing the highest incidence. The incidence of arrhythmia did not differ across the first 
three groups (Likelihood ratio = 2.06, df = 2, p = .36). Of note, the incidence was rather 
low in the small non-anxious Type D group. The three groups were merged and compared 
with the anxious Type D group, which yielded a significant difference (Likelihood ratio = 
7.07, df = 1, p = .008), with 34.5% of the anxious Type D group versus 18.0% of the 
reference group experiencing ventricular arrhythmias. Kaplan-Meier curves for the time to 
first ventricular arrhythmia for anxious Type D patients versus the other patients are 
shown in Figure 2. The log-rank test was significant (p = .004), with anxious Type D 
patients experiencing earlier and more often ventricular arrhythmia as compared to other 












































Figure 1. Proportion of patients who had experienced ventricular arrhythmia, stratified 




Figure 2. Kaplan-Meier curve for time to first ventricular arrhythmia in Type D patients 


























































p = .028 
p = .004 
                     Number at risk 
Other groups (dotted)     266     242     234                227       218 











In this prospective study, we examined whether ventricular arrhythmia in ICD patients 
was predicted by anxiety, depressive symptoms, Type D personality, or their interaction 
effects. Only the interaction between anxiety and Type D personality was significant, with 
anxious Type D patients having a 2.3-fold independent risk to experience ventricular 
arrhythmias in the first year following ICD implantation. This risk was comparable to the 
2.1-fold risk for patients with a secondary prevention. Gender, age, and etiology were not 
significantly related to ventricular arrhythmias. Stratifying patients according to anxiety 
and personality status showed a significant difference, with almost 35% of the anxious 
Type D patients experiencing ventricular arrhythmias as compared to 18% among other 
patients. 
Our results provide additional insight to prior research on predictors of ventricular 
arrhythmias. Incorporation of various psychological variables has been done by Lampert 
et al.
23
 and Dunbar et al.
22
, but they did not enter these variables simultaneously. Dunbar 
et al.
22
 reported that anxiety precipitated ventricular arrhythmias (including ATPs and 
shocks) but Lampert et al.
23
 reported no predictive role of anxiety for ventricular 
arrhythmias (only shocks). In line with the latter study, our results showed that anxiety 
alone did not predict arrhythmias (ATPs and shocks). Only in combination with the Type 
D personality, anxiety predicted the occurrence of arrhythmias, which was independent of 
age, gender, indication, and etiology. Moderate to high levels of depressive symptoms 
have been linked to appropriate shocks in the Whang et al. study
21
, however, Dunbar et 
al.
22
 did not find a precipitating role of mild depressive symptoms for appropriate ATPs 
and shocks, which is in line with our study. Burg et al.
24
 reported that anxiety-triggered 
ICD shocks were highly present in patients who scored high on trait-anxiety as a stable 
personality trait. The present findings confirm that personality may be important in 
moderating the effects of anxiety on the occurrence of ventricular arrhythmias. As this is 
the first study to show such effect for Type D personality, more research is needed to 
substantiate this finding.  
Type D personality has been studied extensively in cardiac patients and is 
associated with adverse clinical outcome, including mortality and morbidity
33-36
. Type D 
personality has also shown to be of value in arrhythmia research, being associated with 
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outcomes such as anxiety, depressive symptoms, and health-related quality of              
life
8, 9, 13, 38, 39
. Regarding ventricular arrhythmia, there was a trend for Type D personality 
alone, but the present findings clearly suggest a predictive effect of Type D personality in 
ICD patients with elevated anxiety following implantation. Therefore, a part of the 
relationship between Type D personality and morbidity and mortality might be due to an 
enlarged risk of ventricular arrhythmias in those Type D patients who experience elevated 
anxiety levels.  
The pathways or mechanisms linking emotions and personality traits in general, 
and anxiety and Type D personality in particular, to arrhythmias are not well-known and 
should be explored further in future research. Stress may be associated with increased 
sympathetic tone and its detrimental effects on arrhythmia
40, 41
. Experimental studies have 
shown that general mental stress may induce increased T-wave alternans
42
, which are 
associated with ventricular arrhythmias and death
43
. Mental stress may also shorten the 
cycle length of ventricular tachycardia and consequently result in more difficult 
termination of this arrhythmia
44
. 
Of the confounding variables, secondary prevention was significantly predictive for 
ventricular arrhythmias, whereas gender, age and ischemic etiology were not. The 
findings on indication, gender, and age are in line with results from previous        
research
18, 22, 45, 46
, although older and male patients may be at increased risk for 
ventricular arrhyhmias
47
. As ischemic etiology has been identified as a precipitant of 
ventricular arrhythmias
1
, it is difficult to explain the nonsignificant finding.  
Approximately half of the patients had increased anxiety, a third increased 
depression, and a quarter of patients was classified as Type D. In addition, about 80% of 
Type D patients also had increased levels of anxiety. These prevalences are in line with 
previous research in ICD patients
7, 8, 15
 and confirm that anxiety may be more prevalent in 
ICD patients as compared to depressive symptoms. 
Screening for anxious Type D patients may be standardized in clinical practice, as 
anxiety and Type D personality have been associated with adverse outcomes in ICD 
patients
10, 13, 15, 48, 49
. Anxiety has been related to occurrence of arrhythmias
22
 and this 
study more specifically showed that Type D patients with increased anxiety may have an 
enlarged risk for arrhythmias. The 20-item STAI and 14-item DS14 may be used as 
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screening tools for general anxiety and Type D personality, respectively, as these 
measures have good psychometric properties and standard cut-off scores
25, 29, 30
. Next, 
identified high-risk patients may be offered adequate behavioral support. A recent review 
indicates that cognitive-behavioral therapy paired with exercise training may be most 
useful to diminish anxiety symptoms in ICD patients
50
. Interventions for Type D 
personality have not yet been examined, but these may aim at changing coping styles for 
dealing with negative emotions. As only a few studies have focused on psychological 
intervention in ICD patients
50
 and no study has investigated interventions for Type D 
patients, more research is needed on this topic. 
This study has several limitations. First, it was not possible to control for clinical 
variables such as ejection fraction and NYHA class, because these data were not available 
for many patients. Second, ventricular arrhythmias without therapy were not included. 
Third, although the prevalence of arrhythmias in the non-anxious Type D group was 
rather low, this was probably related to the small number of patients in this group. Fourth, 
as cause of death is not known for most of the patients, it is unknown, though unlikely, 
whether death was attributable to ventricular arrhythmia. 
In conclusion, results of this prospective study suggest that Type D patients with 
increased levels of anxiety and patients with a secondary prevention are at increased risk 
to experience ventricular arrhythmias in the first year following ICD implantation. In 
clinical practice, patients with increased anxiety and Type D personality should be 
identified and offered adequate support. Future studies may focus on the mechanisms and 
pathways linking anxiety and personality traits to ventricular arrhythmias.  
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Background The medical benefits of the implantable cardioverter defibrillator (ICD) are 
unequivocal, but a subgroup of patients experiences emotional difficulties following 
implantation. For this subgroup, some form of psychological intervention may be 
warranted. This review provides an overview of current evidence on the efficacy of 
psychological intervention in ICD patients and recommendations for future research. 
Methods We searched the PubMed and PsycInfo databases in the period between January 
1980 and April 2007, using a set of a priori determined keywords. Based on the search 
and a hand search of the reference lists of the included articles, we identified nine studies 
that fulfilled the inclusion criteria.  
Results The majority of studies used a randomized controlled trial design, but studies 
varied considerably in sample size, response rate, attrition rate, and type of intervention. 
However, most interventions were multifactorial, using cognitive behavioral therapy as 
one of the mainstays of treatment. Overall, psychological interventions seem to have little 
impact on shocks and heart rate variability. Some studies found a decrease in depressive 
symptoms and gains in quality of life, but the most notable effects are seen in improved 
exercise capacity and reductions in anxiety. Effect sizes for changes in anxiety in the 
intervention group ranged from small to large compared to small in the usual care group, 
using Cohen’s effect size index. 
Conclusions Preliminary evidence from small-scale intervention trials suggests that 
psychological intervention is worthwhile in ICD patients. Nevertheless, large-scale, well-
designed trials are warranted to substantiate these findings. A multifactorial approach 








The superiority of the implantable cardioverter defibrillator (ICD) compared to anti-
arrhythmic drugs for the prevention of sudden cardiac death (SCD) both in primary
1,2
 and 
secondary prevention is well established
3,4
, with risk reductions ranging from 50%-63%
5
. 
Nevertheless, a subgroup of patients experiences emotional difficulties, with symptoms of 
anxiety and depression varying from 24%-87%
6
. Anxiety may exist on a continuum from 
normalized fear, generalized anxiety, and panic disorder to post-traumatic stress 
disorder
6,7
, with 13-38% of ICD patients experiencing clinical levels
8
. 
Generally, the manifestation of emotional distress in ICD patients has been 
attributed to shocks
6
. However, the Canadian Implantable Defibrillator Study (CIDS) 
indicated that a threshold ≥ 5 shocks is required
3
, whereas the Antiarrhythmics Versus 
Implantable Defibrillators (AVID) trial showed that one shock is sufficient to lead to 
decreased quality of life (QoL) and increased patient concerns
9
. Other studies show that 
catastrophic cognitions, such as attributing ICD shocks to the progression of disease and 
impending risk of SCD
10
, concerns about the ICD firing
10, 11
, and the distressed (Type D) 
personality (i.e., the tendency to experience increased negative emotions paired with the 




There is also preliminary evidence to suggest that distress may precipitate 
arrhythmic events
13,14
. For some patients, a vicious cycle may ensue, with ICD 
implantation leading to anxiety and depression in turn precipitating arrhythmic events and 
leading to more distress. ICD patients may be particularly prone to developing anxiety 
post implantation due to fears of the ICD firing and associated catastrophic cognitions, 
with some patients interpreting a shock as a sign of danger and progression of disease
6
. 
Being caught in this vicious cycle may lead to detrimental effects of a secondary nature, 
including avoidance behavior, not returning to work, reduced sexual activity, physical 
inactivity, and impaired QoL
6, 8
.  
Both anxiety and depression comprise risk factors for adverse prognosis in 
coronary artery disease
15,16
. More importantly, emotional distress in some ICD patients 
does not remit spontaneously but persists over time
17,18
. For these patients, psychological 
intervention on its own or combined with pharmacotherapy may be warranted in order to 
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reduce distress and adverse secondary outcomes. Given the exponential rise in ICD 
implantations and its projected increase in the future
19
, knowledge of psychological 
interventions and their efficacy is important for secondary prevention in this distinct 
patient group. 
The only review on psychological interventions in ICD patients was published in 
2003
20
. However, the search period extended only until 2002, with new studies having 
been published since then. The current review (i) provides an up-to-date overview of 
psychological intervention studies in ICD patients, (ii) evaluates their efficacy in terms of 
reducing distress and the occurrence of ventricular arrhythmias, and (iii) provides 
recommendations for future research. 
 
METHODS 
The databases PubMed and PsycInfo were searched in the period between January 1980 
and April 2007, using a combination of the following search terms: implantable 
defibrillator, psychological, psychosocial, intervention, rehabilitation, therapy, and 
treatment outcome. We included articles in the review irrespective of their design, as long 
as the study was empirical, included an intervention and a comparison group, the 
intervention had a psychological component, and the article was published in a peer-
reviewed English journal. Hence, studies that evaluated multifactorial interventions (e.g., 
comprising psychotherapy and/or exercise in addition to a psychological component) also 
qualified for inclusion. Reviews, case studies, and descriptive studies were excluded, as 
were studies based on mixed patient groups (i.e., if only part of the patients had received 
an ICD). In addition to the computer search, the reference list of the included articles was 
hand searched. The second author (KCB) conducted the computer search and eliminated 
double hits; subsequently, the first (SSP) and the second author (KCB) reviewed the 
abstracts and decided on whether an article qualified for inclusion based on the inclusion 
criteria. The hand search was conducted by the first (SSP) and the second author (KCB). 
No other hand searches were conducted.  
The search resulted in 232 hits. After removing double hits, the number of studies 
was reduced to 137. Weighing the remaining studies against the inclusion criteria reduced 
the number to 8. A hand search of the reference list of these studies identified one 
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additional study. See Figure 1 for an overview of the selection. Due to the limited number 
of studies, their heterogeneity, and the relatively small sample sizes, it was not possible to 
conduct a meta-analysis. However, we aimed to comply with the criteria for the reporting 
of Meta-analysis of Observational Studies in Epidemiology (MOOSE) to the extent that it 
was possible
21
. We chose to use the MOOSE criteria given that studies used a mix of 
designs (i.e., experimental or observational). 
 
Figure 1. Flowchart of the literature selection 
 
Identified titles and abstracts screened 
 
Excluded due to double hits 
 
 
Excluded based on exclusion criteria 
 
 
Included after hand search 
 




The current review is based on nine studies, with studies reporting on the same sample in 
different publications being listed under the first author and as one study. See Table 1 for 
an overview. In the following section, we provide a description of the included studies in 
relation to design, sample size, patient characteristics, and the intervention used. 
Subsequently, we evaluate the effect of the intervention on the primary outcome measures 
of the studies, divided into two main categories (i.e., cardiac and patient-centered). For the 
patient-centered outcomes, we focus on QoL, anxiety and depression, given that they were 
the outcome measures most frequently used across studies.  





N = 9 
n = 95 
n = 129 
n = 1 
 
 
Table 1. Overview of studies on psychosocial interventions in ICD patients 
Authorsreference Sample size 
  Nint        Ncon 
Study design Intervention Duration Comparison 
intervention 
Endpoint(s) therapy 
Badger et al. 
(1989)30 
6 6 Comparative 
study 
Support group 2 months Usual care 
 
QoL 
Carlsson et al. 
(2002)22 
10 10 RCT Education Not reported Usual care QoL 
Chevalier et al. 
(2006)23 
35 35 RCT CBT 3 months Usual care Shocks, HRV, QoL, anxiety, 
depression, defibrillator tolerance 
Dougherty et al. 
(2004, 2005)24, 32 
84 84 RCT Telephone 
support 
2 months Usual care Shocks, QoL, anxiety, depression, 
health care use, ICD-related 
knowledge 
Fitchet et al. 
(2003)25 
8 8 RCT CCR 3 months Usual care Ventricular arrhythmias and shocks, 
exercise test, anxiety, depression 
Frizelle et al. 
(2004)26 
12 10 RCT CCR 3 months Usual care Shocks, ATP episodes, QoL, 
exercise test, anxiety, depression, 
ICD-related concerns, perceived 
health status 
Kohn et al. 
(2000)27 
25 24 RCT CBT 5 months Usual care Shocks, anxiety, depression, 
psychosocial adjustment 
Molchany et al. 
(1994)31 
11 5 Comparative 
study 
Support group Not reported Usual care QoL, anxiety 
Sneed et al. 
(1997)28 




4 months Usual care Mood states, psychosocial 
adjustment 
CBT = cognitive behavioral therapy; CCR = comprehensive cardiac rehabilitation; HRV = heart rate variability; Ncon = number of patients in 
control group; Nint = number of patients in intervention group; RCT = randomized controlled trial; QoL = quality of life 
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Description of included studies 
Design  
The majority of studies (7/9) used a randomized controlled trial (RCT) design
22-28
, with 
two of these studies employing an RCT with a case-crossover design
25,26
. The RCT is 
considered the gold standard in medicine and the most powerful design in terms of 
providing the strongest evidence for the efficacy of a given intervention
29
. In two studies, 
an observational design was employed
30, 31
.  
In several studies, the participant rate was low, with 26% of eligible patients 
participating in the Frizelle et al. study
26
, 35% in the Chevalier et al. study
23
, and 47% in 
the Fitchet et al. study
25
, although in the latter study a random sample of 16 patients was 
drawn from those who agreed to participate (n = 34). Molchany and colleagues included a 
convenience sample of ICD patients and their significant other and did not report the 




, but not all 
studies
23
 with a low participant rate, responders and nonresponders were compared on 
baseline characteristics to rule out systematic differences. Such a comparison is important, 
in particular in studies with a low response rate, as systematic differences between 
responders and nonresponders jeopardize the external validity of the study. 
In four studies, patients were included during hospitalization for ICD implantation, 
with three studies including prior to implantation
22, 27, 28
 and one study at the time of 
discharge from hospital
24
. One study included patients who had their ICD implanted prior 
to or during the study
23
. The other four studies recruited patients who had their ICD 
implantation for some time. In these studies, the mean time since implantation was 8-12.5 
months
30
 and 20 months
25
. One study did not provide information on the time since 
implantation
26
 and one study only reported the range (i.e., 5-24 months)
31
. 
The follow-up periods for evaluating the endpoints varied widely between studies 
from 1
22







Sample sizes varied considerably across studies, ranging for the total sample from 12-168, 
and from 6-84 in the intervention group and 5-84 in the control group
22-28, 30, 31
. Generally, 
sample sizes were small, with ≤ 35 patients in the intervention and usual care groups, 





The majority of patients were men
22-25, 27, 30, 31
, with two studies not providing information 
on sex
26,28
. The mean age was between 57 and 66 years
22-28
, with a range of 28-83   
years
22, 25, 27, 30, 31
. When reported, mean left ventricular ejection fraction varied from      
30-44%
23-25, 29, 30
. Only four studies provided information on the reason for ICD 





The interventions employed across studies were heterogeneous, although the majority of 
studies used a multifactorial approach. Four studies included a cognitive behavioral 
component
23, 25-27
, with cognitive behavioral therapy (CBT) being the mainstay of 
treatment. Using a CBT framework, anxiety, apprehensions, avoidance behavior, fear of 
shocks, and distorted cognitions were targeted, with stress management and relaxation 
therapy often forming adjunctive therapies
23, 25, 26
. In two studies, patients also engaged in 
aerobic exercise, as part of a comprehensive cardiac rehabilitation program
25, 26
. 
Group or individual counseling comprised the key component in the other five 
studies
22, 24, 28, 30, 31
, with counseling most frequently being provided by a specialized 
nurse. The main objective of the counseling was to provide support to patients, educate 
patients about the ICD and their illness, and to enhance their coping styles.  
The duration of the intervention varied from 2 to 5 months across studies
23-28, 30, 32
, 
with the average length being 3 months. In two studies, the duration was not reported
22, 31
. 
Usual care comprised the control condition for all studies, although the exact constellation 
of, for example, visits to the cardiologist, ICD nurse, and general practitioner was often 
not reported. 
 
Review Psychological Interventions 
165 
 
Effect of intervention 
On cardiac outcomes 
Shocks. Shocks comprised one of the outcome measures in 5/9 studies
23-27
. In none of the 
studies did the intervention lead to a statistically significant reduction in the rate of shocks 
compared with usual care
23-27
, although reductions were found
23
. This null finding may in 
part be attributed to the relatively short follow-up periods, ranging from 1-12 months. In 
the study by Dougherty and colleagues, evaluating the effect of the intervention on shocks 
at several time points (i.e., 1, 3, 6, and 12 months post-implantation), there were no 
statistically significant differences between the intervention and usual care groups at any 
of the time points
24, 32
. Kohn and colleagues found similar results at 9-months follow-up, 
although when stratifying by number of shocks using a threshold of ≥ 1 shock, there was a 
trend for more shocks in the intervention versus usual care group (61% versus 33%,         
p = .07)
27
. A further subgroup analysis revealed, however, that of patients who received   
≥ 1 shock, usual care patients (n = 6) had significantly higher symptom levels of anxiety 
and depression compared with patients in the intervention group (n = 10). This suggests 
that the intervention per se had no direct effect on shocks but buffered the effect of shocks 
on distress
27
. In a subgroup analysis of patients without antiarrhythmic drugs, Chevalier 
and colleagues found a reduced risk of shocks in the CBT group (n = 19) versus usual care 
(n = 20) at 3 months but not at 12 months
23
. It is important to emphasize, however, that 
the subgroup analyses performed in the latter two studies were based on small numbers 
with only 16 and 39 patients, respectively. 
 
Heart rate variability and exercise capacity. Other physiological and cardiac outcome 
measures used were heart rate variability and exercise capacity. Chevalier and colleagues 
report an improved sympathovagal balance in patients treated with CBT, with daytime 
pNN 50 and nocturnal SDNN increasing significantly in the CBT group compared to 
usual care
23
. The two cardiac rehabilitation trials both found an improvement in exercise 
capacity in the intervention group. In the study by Fitchet and colleagues, mean exercise 
time increased with 16% (9m55sec versus 11m11sec, p = .001) in patients receiving the 
12-week rehabilitation program, whereas the mean exercise time did not differ 
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significantly in the usual care group pre- and post-test
25
. In the study by Frizelle and 
colleagues, significant increases were found in the level of difficulty (p = .05) and the 
total distance walked (p = .01) in the rehabilitation group compared to usual care
26
. No 
significant differences were found in heart rate change and patient-rated breathlessness. 
 
On patient-centered outcomes 
Quality of life. Of all studies, six studies focused on QoL as an endpoint
22-24, 26, 30, 31, 32
. 
Frizelle and colleagues found an improvement in emotional, physical, social, and global 
QoL in patients receiving rehabilitation compared with usual care
26
. Badger and 
colleagues found a trend toward improvement in role functioning and psychological 
adjustment in the treatment group, but differences in mean pre- and post-scores were not 
statistically significant
30
. Of note, there was a trend in the opposite direction for the usual 
care group, with these patients experiencing deterioration in adjustment over time. 
Carlsson and colleagues provided information on change scores within the intervention 
and usual care group, respectively, but did not compare the effect of the intervention on 
QoL relative to that in the usual care group
22
. None of the other studies found any effect 
of the intervention on QoL compared with usual care
23, 24, 31, 32
. 
 
Anxiety. Anxiety was employed as an outcome in the majority of studies (i.e., 7/9), with 
most
23, 27, 32
 but not all studies
28, 31
 finding that the intervention reduced levels of anxiety. 
In the study by Chevalier and colleagues, where CBT was the mainstay of treatment, the 
intervention group experienced significantly less anxiety than usual care at 3 (p = .04) and 
12 months (p = .03)
23
. Kohn and colleagues, also using CBT as the mainstay of treatment, 
reported equal levels of state as well as trait anxiety in the intervention and usual care 
group at baseline, but they found lower levels of trait anxiety in the intervention group 
compared with usual care (p = .013) at 9-months follow-up, but no difference on state-
anxiety
27
. However, this study only compared differences in anxiety between groups 
cross-sectionally, that is at baseline and at 9 months follow-up, but not the potential 
impact of the intervention on changes of anxiety over time
27
. In fact, when examining 
changes in anxiety over time both state and trait anxiety were reduced in the intervention 
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group between baseline and follow-up, whereas the usual care group experienced 
reductions in state anxiety only, but an increase in trait anxiety.  
Similarly, cardiac rehabilitation was found to reduce levels of anxiety. Fitchet and 
colleagues found a significant decrease in anxiety in the rehabilitation group (p < .001), 
whereas the usual care group experienced more feelings of anxiety after 12 weeks           
(p = .028)
25
. The second study on cardiac rehabilitation yielded similar results, with 
significant differences in change of anxiety scores between the rehabilitation and control 
group (p = .012)
26
. The results of Dougherty and colleagues were mixed, with a 
significant reduction in anxiety over a 12-month period in the intervention group 
compared with usual care
32
, although there were no significant differences between 
groups at 1 and 3 months
24
.  
Dougherty and colleagues also looked at the proportion of patients scoring in the 
range of severe anxiety, using a cut-off ≥ 40 on the State-Trait Anxiety Inventory
24, 32
. At 
baseline, 40% of the patients in the intervention group scored within this range, with it 
being reduced to 20%, 21%, and 18% at 3-, 6-, and 12-months follow-up. By contrast, 
fewer patients in the usual care group reported severe anxiety at baseline, namely 29%, 
with prevalence rates of 27%, 19%, and 23% at 3-, 6-, and 12-months follow-up. A post-
hoc analysis showed that the change in number of cases with severe anxiety in the 
intervention group was reduced by 55% compared with 21% in the control condition over 
the 12-month period. Fears and ICD-related concerns, which likely comprise the basis of 





Depression. Of studies on depression
23-28, 32
, 2/6 found a significant reduction in the 
burden of depression in the intervention group compared with usual care
25, 26
. The choice 
of intervention used in the two positive studies was comprehensive cardiac rehabilitation. 
In the study by Fitchet and colleagues, mean depression scores decreased from 9.9 pre-   
to 6.7 post-rehabilitation (p < .001), whereas mean scores in the control group rose     
from 7.6 to 9.5 (p = .074)
25
. In the study by Frizelle and colleagues, mean depression 
scores were also reduced between pre- and post-rehabilitation from 3.05 ±3.07                 
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to 1.73 ±1.90 (p = .003)
26
. Although Kohn and colleagues report a lower mean depression 
score in the CBT compared to the usual care group (6.9 ±5.9 versus 15.0 ±13.0, p = .037) 
at 9-months follow-up, this difference cannot necessarily be attributed to the intervention 
due to lack of baseline assessment of depression
27
. Dougherty and colleagues found no 
significant differences between groups on depressive symptoms
24, 32
. However, using a 
cut-off ≥ 16 on the Center for Epidemiologic Studies Depression Scale (CES-D), they 
found that 26% of patients in the intervention group compared with 19% in the usual care 
group experienced depressed mood at baseline; at 3 months, prevalences were similar, 
with 18% versus 19%. Nevertheless, a post-hoc comparison showed a reduction in the 
number of patients with depressive symptomatology in the intervention group by 31% 
versus 0% in the usual care group over the 3-month period. Unfortunately, in contrast to 
anxiety, the authors only reported depression prevalence rates for baseline and 3 months.  
 
Effect sizes for changes in anxiety 
Given that the majority of studies were based on relatively small sample sizes and hence 
at risk of being underpowered, which limits the chance of finding statistically significant 
differences if present, we evaluated the clinical significance of the intervention compared 
with usual care, using Cohen’s effect size index
33
. An effect size of 0.20 is considered 
small, 0.50 moderate, and ≥ 0.80 large. We chose to evaluate the effect of the intervention 
using anxiety as the outcome measure, since anxiety was the endpoint most frequently 
used across studies. In addition, in ICD patients symptoms of anxiety are more prevalent 
than depression
6, 12
, making it an important patient-centered outcome in this distinct 
patient group
34
. Effect sizes were calculated for the difference in anxiety between baseline 
and the last follow-up reported in the study. 
Effect sizes and the measures used to assess anxiety are shown in Table 2. For three 
studies, it was not possible to calculate effect sizes for the impact of the intervention on 
changes in anxiety either because anxiety was not assessed
22, 30
 or due to means and 
standard deviations not being reported for the groups at baseline
28
. In the two studies 
using an RCT with a case-crossover design, means and standard deviations were not 
reported separately for the groups but only for the total group (i.e., when all patients had 
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been subjected to the intervention)
25, 26
. Generally, the impact of the intervention on 
reductions in anxiety had a small
24, 26, 31, 32
 to large effect
23, 25, 27
, as indicated by Cohen’s 
effect size index, ranging from 0.14 to 1.79
31, 25
. In studies where it was possible to 
compare the effect size for the intervention versus usual care, the intervention was 
superior to usual care in terms of reducing anxiety at follow-up in 3 out of 4          
studies
23, 27, 32
. Of note, in the study by Chevalier and colleagues, the usual care group had 
















Badger et al. (1989)
30
 2 months - - - 
Carlsson et al. (2002)
22
 1 month - - - 
Chevalier et al. (2006)
23
 12 months 0.72 -0.84 HAM-A 
Dougherty et al. (2004,  
      2005)
24, 32
 
12 months 0.38 0.15 STAI-S 
Fitchet et al. (2003)
25
 ** 6 months 1.79 - HADS 
Frizelle et al. (2004)
26
 ** 3 months 0.34 - HADS 
Kohn et al. (2000)
27
 9 months 0.89 0.30 STAI-S 
Molchany et al. (1994)
31
 6 months 0.14 0.20 STAI-S 
Sneed et al. (1997)
28
 4 months - - POMS 
* Based on mean1 – mean2 / pooled standard deviation,  
** Pre- and post-treatment scores were not reported separately for the intervention and 
usual care groups, but only for the total group (i.e., when all patients including the 
waiting group had undergone the intervention) 
HADS = Hospital Anxiety and Depression Scale; HAM-A = Hamilton Anxiety Scale; 





Based on the current review, the evidence for a benefit of psychological intervention in 
ICD patients is most convincing for symptoms of anxiety and exercise capacity, with 
intervention leading to a significant reduction in anxiety and improvement in exercise 
capacity. By contrast, there is little evidence to suggest that the interventions studied to 
date have had a notable impact on depressive symptoms, QoL, heart rate variability, and 
shocks. These findings, however, should be viewed in the context of the small number of 
studies, the very small sample sizes, and the variability in their methodological quality. 
Generally, there is a paucity of large-scale, well-designed psychological 
intervention studies in ICD patients. Nevertheless, when calculating effect sizes to 
indicate the clinical impact of the intervention on reductions in anxiety, current evidence 
indicates that this pursuit is worthwhile and that patients may benefit substantially, with 
large effect sizes found in three trials
23, 25, 27
. In turn, a reduction in anxiety levels is likely 
to have beneficial effects on secondary outcomes, such as avoidance behavior, returning 
to work, sexual activity, physical activity, and QoL
6, 8
.   
In order to expand our knowledge of the most optimal intervention to offer ICD 
patients, it is paramount that future trials include sufficiently large samples to have 
adequate power to test the efficacy of a given intervention. This has also been suggested 
by others
6
. In addition, it is important to provide an intervention that appeals to patient 
needs and concerns and is logistically feasible for them to attend, as the response rate was 
low and the attrition rate high in a number of studies
23, 25, 26
. In this regard, a web-based 
intervention may be worth considering, as it is accessible and can reach large groups of 
patients as well as safeguard patients’ anonymity, in turn providing an interesting 
alternative to those patients who need help but are less inclined to see a psychologist
35
. 
On the basis of the current review, we would recommend that CBT and exercise 
training form the mainstays of treatment, as these components were included in those 
trials showing the largest effect
23, 25, 27
. Others have also advocated the inclusion of CBT
6
, 
primarily since CBT may be the most effective means by which to deal with ICD related 
concerns and fears that are highly prevalent in ICD patients
11, 26
, and which may 
eventually lead to manifest clinical anxiety, including panic disorder
7
. In this regard, 
education about the ICD in order to avoid misconceptions and minimize ICD related 
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concerns should form part of any intervention
11, 26, 36
, with adjunctive pharmacotherapy 
being necessary in subgroups of patients to curb emotional distress
7
. The available 
evidence also suggests that health policy makers are justified in supporting coverage for 
psychosocial and exercise interventions for ICD patients to reduce anxiety and improve 
functioning. However, future trials should evaluate the influence of the intervention on 
health-care utilization and the cost-effectiveness of the intervention in addition to the 
potential moderating influence of factors, such as ICD indication, cardiac 
resynchronization therapy, disease etiology and severity, on the effectiveness of the 
intervention. 
The preferred research design for future studies should be an RCT, which is the 
most powerful study design to test the efficacy of an intervention
29
. We also recommend 
the inclusion of multiple assessments of the outcome measures under study, spanning both 
psychological (e.g., anxiety) and physiological markers (e.g., cortisol) whenever possible, 
in order to evaluate changes over time and investigate whether the effect of a given 
intervention will remain stable and not just have short-term effects. The longest follow-up 
reported in studies included in the current review was 12 months
23, 24, 32
. Attention should 
also be given to the choice of instruments used to evaluate the effect of the intervention. 
Several instruments routinely used in psychosomatic research are not sensitive to tap 
treatment-related changes
37
. ICD disease-specific instruments have also been established, 
including measures of “ICD patient acceptance”, “shock anxiety”, “ICD worries”, and 
“ICD concerns” that allow for more precise interventional targets
11, 38-40
. Importantly, the 
instruments used to assess anxiety in the majority of studies in the current review have 
been shown to be sufficiently sensitive to measure an effect following intervention, if 
present. 
In future interventions, it may also be important to include personality traits, such 
as Type D personality, given its potential moderating effect on outcome. Type-D is an 
emerging risk factor in cardiovascular disease
41
 that has also been associated with 
increased anxiety and depressive symptoms in ICD patients, irrespective of shocks
12
. 
Positive affect comprises another important potentially moderating factor that has been 
associated with better mental health and social functioning in ICD patients
42
. Given that 
patients may not necessarily identify themselves by negative emotions alone, focus on 
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increasing positive emotions rather than only reducing negative emotions may also 
enhance the compliance and commitment of patients to the intervention. Finally, when 
reporting on future RCTs in the context of ICD patients, the CONSORT (Consolidated 
Standards of Reporting Trials) statement should be adhered to
43
. Briefly, the CONSORT 
statement includes a 22-item checklist and a flow diagram for reporting RCTs. There is 
preliminary evidence that the quality of the reporting of RCTs improves with compliance 
with these guidelines
44
. In addition, using this statement would enhance the interpretation 
of RCTs and facilitate the conductance of future meta-analyses.   
The results of this review should be interpreted with some caution, given that we 
only included studies published in English peer-reviewed journals. This could have led to 
a potential selection bias. In addition, the number of studies was limited, with the review 
based on only nine studies. The heterogeneity of studies, including the relative small 
sample sizes, made comparisons across studies difficult. Although we calculated and 
compared effect sizes for reductions in anxiety in the intervention and usual care group, 
respectively, with the aim of alleviating the problem of small sample sizes and reduced 
power, the use of small sample sizes increases the risk of having a selected group of 
patients.  
In conclusion, preliminary evidence from small-scale intervention trials suggests 
that psychological intervention is worthwhile in ICD patients, in particular with a view to 
reducing anxiety and concerns about the ICD. Nevertheless, large-scale, well-designed 
psychological intervention trials are warranted to substantiate these findings, with a 
multifactorial approach using a cognitive behavioral component and exercise training 
likely to be the most successful. These intervention trials are necessary in order to provide 
the most optimal care for the increasing number of patients who receive an ICD now and 
in the future
19 .  
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Objective The distressed (Type D) personality is an emerging risk factor in coronary 
artery disease that has been associated with adverse prognosis, impaired health status, and 
emotional distress. Little is known about factors that may influence the impact of Type D 
personality on health outcomes. Therefore, the aim of this study was to determine the 
combined effect of Type D and not having a partner on symptoms of anxiety and 
depression. 
Methods Patients (N = 554) hospitalized for acute myocardial infarction or implantable 
cardioverter defibrillator implantation completed the Type D Scale (DS14) during 
hospitalization and the State-Trait Anxiety Inventory and Beck Depression Inventory at 2 
months follow-up. 
Results Stratifying by personality and partner status showed that Type D patients without 
a partner had a higher risk of both anxiety (OR = 8.27; 95%CI 2.50-27.32) and depressive 
symptoms (OR = 6.74; 95%CI 2.19-20.76) followed by Type D patients with a partner 
(OR = 3.73; 95%CI 2.16-6.45 and OR = 3.81; 95%CI 2.08-6.99, respectively) and non- 
Type D patients without a partner (OR = 2.04; 95%CI 1.05-3.96 and OR = 3.03; 95%CI 
1.46-6.31, respectively) compared to non-Type D patients with a partner, adjusting for 
demographic and clinical baseline characteristics, indicating a dose-response relationship. 
Conclusion Lack of a partner further exacerbated the risk of symptoms of anxiety and 
depression in the already distressed Type D patients. In clinical practice, it is important to 
identify Type D patients without a partner and carefully monitor them, as they may be less 
likely to alter health-related behaviors due to their increased levels of distress.   
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INTRODUCTION 
There is increasing emphasis on patient-centered outcomes in cardiovascular disease 
(CVD), such as quality of life and emotional distress
1
. Knowledge of the determinants of 
these outcomes is also important in order to facilitate identification of high-risk patients in 
clinical practice
1
. The distressed (Type D) personality may be an important determinant of 
individual differences in outcomes, as this personality disposition has been associated 
with an increased risk of adverse prognosis
2-5










, and post-traumatic stress disorder
11
. Type D has been shown to 
be a risk factor for adverse health outcomes across different types of CVD, including 
peripheral arterial disease
6
, coronary artery disease
12







. The risk associated with Type D in relation to clinical 




Type D personality is characterized by the two stable personality traits negative 
affectivity (the tendency to experience negative emotions across time and situations)
16
 and 
social inhibition (the tendency to inhibit the expression of emotions and behaviors in 
social interactions to avoid disapproval by others)
17
. The prevalence of Type D ranges 




 to 33-53% in 
patients with hypertension
18
, peripheral arterial disease
6
, and chronic heart failure
10, 19
. 
Little is known about factors that may influence the impact of Type D personality 
on prognosis, quality of life, and emotional distress. Knowledge of these factors is 
important for optimizing risk stratification in clinical practice, and may also point to 
targets for intervention. There are several pathways that may link Type D to adverse 
health outcomes, including physiological and behavioral pathways. As for physiological 
pathways, they may comprise inflammation
19, 20
, blood pressure reactivity to stress
21
, and 
hyperactivity of the hypothalamic-pituitary-adrenal axis, including increased levels of 
cortisol
21, 22
. Potential behavioral pathways comprise health-related behaviors, including 
failure to change risk factors, such as smoking, and poor treatment adherence
3, 23
. In 
addition, because Type D patients inhibit behavior in social interactions, it is likely that 
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communication with doctors is impaired, which may also hinder effective treatment
24
. 
However, to date, these potential mechanisms have not been examined in Type D patients. 
A potentially important behavioral factor influencing the relationship between Type 
D and health outcomes is social support. Since social support has been shown to buffer the 
effects of stress on both well-being
25
 and cardiovascular function
26, 27
, lack of support may 
enhance the adverse effects of Type D personality on health outcomes, including 
emotional distress. By analogy, since Type D patients have been shown to have fewer 
social ties and to experience less social support than non-Type D patients
3
, Type D 
patients who have a fulfilling relationship with a partner may be at less risk for adverse 
health outcomes than patients without a partner. 
Therefore, the aim of this study was to determine the combined effect of Type D 
personality and not having a partner on symptoms of anxiety and depression across 
different CVD treatment groups, that is, in patients with acute myocardial infarction (MI) 
or patients who received an implantable cardioverter defibrillator (ICD). An additional 
advantage of pooling data was to enhance the statistical power of the study, which has 





Patient population and design 
Patients hospitalized for acute MI or ICD implantation between May 2003 and December 
2005 were included from five hospitals in the Netherlands (Catharina Hospital, 
Eindhoven; Amphia Hospital, Breda; St. Elisabeth Hospital, Tilburg; TweeSteden 
Hospital, Tilburg; and St. Anna Hospital, Geldrop). Inclusion criteria were hospitalization 
for acute MI (n = 452) or ICD implantation (n = 210). Exclusion criteria were significant 
cognitive impairments (e.g., dementia) and severe life-threatening comorbidities (e.g., 
cancer). Criteria for diagnosis of acute MI were troponin I levels that are more than twice 
the upper limit, typical ischemic symptoms (e.g., chest pain) lasting for more than 10 
minutes, and ECG evidence of ST segment elevation or new pathological Q waves. ICDs 
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Patients completed self-report measures on Type D personality at baseline as well 
as measures on anxiety and depressive symptoms at 2 months follow-up. The 2-month 
follow-up period was adopted due to logistic reasons. Two months after acute MI or ICD 
implantation, patients visited the outpatient clinic for a routine control. To minimize 
patient burden, we combined our study with these visits to the hospital. Demographic and 
clinical variables were obtained from the medical records. Of the original 662 patients, 
554 patients were included in the final analyses (i.e., 390 MI patients and 164 ICD 
patients; see Figure 1).  
 
Figure 1. Flowchart of patient selection 
Total number of patients  
 
Died between hospitalization  
and 2 months follow-up 
 
 
Refused to participate  
at 2 months follow-up 
 
 
Excluded due to cancer diagnosis 
 
 
Excluded due to missing data on  




The 108 patients who were excluded comprised 62 MI patients and 46 ICD 
patients. Excluded patients differed significantly from included patients regarding Type 
D/no partner (9.2% versus 3.6%, χ2(1) = 6.01, p = .014), female sex (28.0% versus 18.2%, 
n = 34 
n = 10 
n = 652 
n = 589 
n = 588 
N = 554 
N = 662 
n = 63 
n = 1 
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χ2(1) = 5.43, p = .020), history of ischemic heart disease (47.9% versus 34.1%,            
χ2(1) = 6.52, p = .011), treatment (ICD implantation) (43.0% versus 29.6%, χ2(1) = 7.42, 
p = .006), diabetes (23.2% versus 13.2%, χ2(1) = 6.35, p = .012), use of anticoagulants 
(62.8% versus 75.9%, χ2(1) = 7.14, p = .008), and use of psychotropics (25.2% versus 
13.6%, χ2(1) = 9.35, p = .002). 
The study was approved by the ethics committees of the participating hospitals. 
The study was conducted in accordance with the Helsinki Declaration, and all patients 
provided written informed consent. 
 
Measures 
Demographic and clinical characteristics  
Demographic variables included partner status (i.e., not having a partner), gender, age, 
and educational level. Clinical variables included comorbidity (arthritis, renal 
insufficiency or chronic obstructive pulmonary disease), history of ischemic heart disease 
(previous MI, percutaneous coronary intervention (PCI) or coronary artery bypass graft 
(CABG) surgery), multivessel disease and left ventricular ejection fraction (for MI 
patients), ICD indication and history of shocks (for ICD patients), diabetes mellitus, 
smoking (self-report), cardiac medication (β-blockers, anticoagulants, statins, and aspirin), 
and psychotropic medication (self-report).  
 
Personality 
The 14-item Type D Scale (DS14) was used to assess Type D personality
18
. Items are 
answered on a 5-point Likert scale from 0 to 4. The scale consists of two 7-item sub-
scales: negative affectivity (e.g., “I often feel unhappy”) and social inhibition (e.g., “I am 
a closed person”). Only patients scoring high on both subscales according to a 
standardized cut-off score ≥ 10 are categorized as Type D
18
. The DS14 is a valid and 
reliable scale with Cronbach’s α of 0.88 and 0.86 and a test-retest reliability over a 3-
month period with r = 0.72 and 0.82 for the two subscales, respectively
18
. It is important 
to note that in addition to negative affectivity, social inhibition is crucial in defining Type 
D personality, as it is the interaction of negative affectivity and social inhibition, and not 
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the single traits, that is related to cardiac prognosis, independent of concurrent symptoms 




Symptoms of anxiety and depression 
The State-Trait Anxiety Inventory (STAI) was used to assess symptoms of anxiety
31
. The 
STAI is a self-report measure consisting of two 20-item scales developed to measure the 
level of general state and trait anxiety
31
. In the current study, we only used the state 
measure, as the objective was to assess the current presence of anxiety symptoms at two 
months follow-up, rather than anxiety as a stable trait. Each item is rated on a 4-point 
Likert scale from 1 to 4. We used the cut-off ≥ 39, which represents clinical levels of 
anxiety
31
. The STAI has been demonstrated to have adequate validity and reliability, with 
a Cronbach’s α of 0.92
32
. Elevated scores on the STAI have been associated with poor 
prognosis in patients with CVD
33
.  
The Beck Depression Inventory (BDI) is a 21-item self-report measure developed 
to assess the presence and severity of depressive symptoms
34
. Each item is rated on a 
Guttmann scale from 0 to 3. The BDI is a reliable and validated measure of depressive 
symptomatology
35, 36
, with a Cronbach’s α of 0.81 in non-psychiatric samples
35
, and the 
most frequently used self-report measure of depressive symptomatology in cardiac 
patients. We used the standardized cut-off ≥ 10, indicative of at least mild to moderate 
symptoms of depression, which has also been associated with poor prognosis in patients 
with CVD
37-39
. In addition, this cut-off has good sensitivity and specificity to screen for 
major depression, that is, 81.8% and 78.7%, respectively
40
. 
Scores on anxiety and depression measures were dichotomized in order to enhance 





To examine differences in baseline characteristics stratified by personality type (Type D 
versus non-Type D) and partner status (partner versus single), we used the Chi-square test 
(Fisher’s Exact Test when appropriate) for nominal variables and analysis of variance 
(ANOVA) for continuous variables. In the ANOVA, we used Tukey’s test for post hoc 
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comparisons. The impact of Type D personality and partner status on symptoms of 
anxiety and depression was examined by means of logistic regression analysis with non- 
Type D/partner as the reference category. In multivariable analysis, we adjusted for sex, 
age, educational level, smoking status, cardiac history, treatment (MI versus ICD 
implantation), days between MI or ICD implantation and completion of baseline 
questionnaires, comorbidity, diabetes, dyslipidemia, hypertension, beta-blockers, aspirin, 
anticoagulants, statins, and psychotropic medication. A p-value < .05 was considered to be 
statistically significant. Odds ratios (OR) with 95% confidence intervals are reported. All 
statistical analyses were performed using SPSS 12.0.1 for Windows. 
 
RESULTS 
Patient characteristics  
No significant differences between ICD patients and MI patients were found for either 
Type D personality or partner status, although Type D personality was slightly more 
prevalent in ICD patients than in MI patients (27% versus 20%, χ2(3) = 3.40, p = .07). In 
the total patient group, 121 patients (22%) were classified as Type D and 89 patients 
(16%) had no partner. Partner status did not differ in Type D versus non-Type D patients 
(17% versus 16%, χ2(1) = 0.25, p = .88).  
Patient characteristics stratified by personality and partner status are presented in 
Table 1. The groups differed significantly with respect to female sex (14%, 28%, 19%, 
and 55%; χ2(3) = 25.97, p < .0001) and current use of psychotropic medication (9%, 13%, 
22%, and 35%; χ2(3) = 20.85, p < .0001). Type D patients without a partner were more 
likely to be female, to have had an invasive treatment for MI, and to use psychotropic 
medication compared with the other three groups. No other significant differences were 
found between groups on baseline characteristics.  
In the ICD group, 7 patients received a shock, but this number did not differ 
significantly between groups (Fisher’s Exact Test = 1.12, p = .76). Likewise, no 
significant differences were found for secondary indication for ICD implantation (χ2(3) = 
2.72, p = .44). In MI patients, multivessel disease (χ2(3) = 5.59, p = .13) and left 
ventricular ejection fraction (F (3,305) = 0.83, p = .48) did not differ significantly between 
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groups, whereas invasive treatment did (χ2(3) = 11.37, p = .01). However, because 
invasive treatment and the other four group-specific indices were not significantly related 
to anxiety and depression (all p-values > .10), they were omitted from further analyses. 
 





(n = 364) 
Non-Type 
D / no 
partner 













Demographics      
Female 14 28 19 55 <.0001 
Age, mean (SD)  61 (10) 61 (14) 60 (11) 60 (11) .91 
Low education
2 
43 50 53 70 .06 
      
Clinical variables      
History of ischemic   
     heart disease
3 
33 33 39 40 .65 
Treatment
4
  71 78 61 75 .10 
Days
5
, mean (SD) 7 (9) 9 (8) 8 (10) 10 (12) .44 
Comorbidity
6 
20 18 22 25 .86 
Diabetes 13 19 10 10 .46 
Dyslipidemia 39 40 39 25 .65 
Hypertension 39 43 33 35 .64 
Current smoking 29 40 36 45 .17 
Invasive treatment MI7 65 41 61 67 .01 
Multi-Vessel Disease
8 
42 32 26 47 .13 
LVEF
9
, mean (SD) 52 (13) 50 (13) 52 (13) 55 (12) .48 
Shocks
10
 5 7 3 0 .76 
Secondary indication  
   for ICD implantation
10 
65 53 54 40 .44 
      
Medication      
Beta-blockers 85 84 86 85 .99 
Aspirin 67 78 69 60 .32 
Anti-coagulants 78 68 72 75 .28 
Statins 85 81 88 75 .42 
Psychotropics 9 13 22 35 <.0001 
1
Data are presented as percentages (χ2 test), unless specified as mean (SD) (ANOVA); 
2
No education completed, first level (primary school), or secondary level (first phase); 
3
Previous MI, PCI, CABG; 
4
MI versus ICD implantation, MI = reference category; 
5
Days 
between MI or ICD implantation and completion of baseline questionnaire; 
6
Lung, renal, 
or rheumatic disease; 
7
MI patients (n = 389);
 8
MI patients (n = 318); 
9
LVEF = left 
ventricular ejection fraction (n = 309 MI patients); 
10
ICD patients (n = 164)   
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Group differences on anxiety and depressive symptoms  
Both Type D personality and partner status had main effects on anxiety (OR = 4.01; 
95%CI 2.63-6.11 and OR = 1.88; 95%CI 1.19-2.97, respectively) and depressive 
symptoms (OR = 3.91; 95%CI 2.53-6.05 and OR = 2.44; 95%CI 1.50-3.96, respectively) 
in unadjusted analyses. 
When stratifying by personality type and partner status, statistically significant 
differences were found between the four groups on anxiety (χ2(3) = 52.92, p < .0001) and 
depression scores (χ2(3) = 53.67, p < .0001) (Figure 2). Type D patients without a partner 
had the highest prevalence of symptoms of anxiety and depression compared to the other 
three groups. 
 
Figure 2. Prevalence of anxiety and depressive symptoms at 2 months stratified by Type 
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Univariable predictors of anxiety and depressive symptoms 
In univariable logistic regression analyses, non-Type D/no partner (OR = 1.76; 95%CI 
1.03-3.03), Type D/partner (OR = 3.78; 95%CI 2.39-5.97), and particularly Type D/no 
partner (OR = 11.66; 95%CI 3.80-35.75) had an increased risk of anxiety at 2 months 
follow-up compared with non-Type D/partner patients (Table 2, left). Other significant 
predictors were female gender, low education, comorbidity, and the use of psychotropic 
medication. 
Similarly, non-Type D/no partner (OR = 2.81; 95%CI 1.56-5.04), Type D/partner 
(OR = 4.27; 95%CI 2.61-6.99), and Type D/no partner patients (OR = 9.00; 95%CI 3.51-
23.08) had an increased risk of depressive symptoms compared to non-Type D/partner 
patients (Table 2, right). Female gender, current smoking, comorbidity, and psychotropic 
medication were also significantly related to an increased risk of depressive symptoms in 
univariable logistic regression analysis. For both anxiety and depressive symptoms, Type 
D/no partner patients had the highest risk followed by Type D/partner, and non-Type D/no 
partner patients. 
When analyzing the data separately for the two treatment groups, the results 
remained the same, with non-Type D/partner having the lowest risk and Type D/no 
partner having the highest risk. 
 
Multivariable predictors of anxiety and depressive symptoms 
In multivariable analysis, non-Type D/no partner (OR = 2.04; 95% CI 1.05-3.96), Type 
D/partner (OR = 3.73; 95%CI 2.16-6.45), and Type D/no partner (OR = 8.27; 95%CI 
2.50-27.32) remained significant predictors of anxiety symptoms, adjusting for all other 
variables (Table 3, left). Other independent variables related to anxiety symptoms were 
female gender, low education, and use of psychotropic medication. 
Similar results were found for depressive symptoms, where non-Type D/no partner 
(OR = 3.03; 95% CI 1.46-6.31), Type D/partner (OR = 3.81; 95%CI 2.08-6.99), and Type 
D/no partner (OR = 6.74; 95%CI 2.19-20.76) remained as significant predictors, adjusting 
for all other variables (Table 3, right). Other independent variables associated with 
depressive symptoms were female gender, treatment, comorbidity, use of aspirin, and 
psychotropic medication. For both anxiety and depressive symptoms, there was a dose-
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response relationship, with the presence of both risk factors (Type D and no partner) 
incurring the highest risk.  
 
Table 2. Univariable predictors of anxiety and depressive symptoms
1 
 
 Anxiety symptoms Depressive symptoms 
 OR 95% CI p OR 95% CI p 
 
Groups  
      
   Non TD/partner 1.00 - - 1.00 - - 
   Non TD/no partner 1.76 1.03-3.03 .04 2.81 1.56-5.04 .001 
   TD/partner 3.78 2.39-5.97 <.0001 4.27 2.61-6.99 <.0001 
   TD/no partner 11.66 3.80-35.75 <.0001 9.00 3.51-23.08 <.0001 
       
Demographics       
   Female  2.15 1.39-3.33 .001 2.30 1.44-3.66 <.0001 
   Age 1.00 0.98-1.02 .99 1.01 0.99-1.02 .59 
   Low education2 2.12 1.48-3.02 <.0001 1.36 0.92-2.03 .13 
       
Clinical variables       
   History of ischemic      
      heart disease
3 
1.24 0.85-1.80 .26 1.32 0.87-2.00 .19 
   Treatment
4
 0.76 0.52-1.11 .16 1.00 0.65-1.53 .98 
   Days
5 
1.01 1.00-1.03 .13 1.00 0.98-1.02 .88 
   Comorbidity6 1.72 1.11-2.66 .01 2.19 1.38-3.48 .001 
   Diabetes 1.46 0.87-2.43 .15 1.25 0.71-2.12 .44 
   Dyslipidemia 1.25 0.86-1.83 .25 1.52 1.00-2.31 .05 
   Hypertension 0.94 0.64-1.36 .74 1.05 0.69-1.60 .84 
   Current smoking 1.38 0.95-1.99 .09 1.61 1.07-2.42 .02 
       
Medication       
   Beta-blockers 1.18 0.71-1.96 .52 1.08 0.61-1.91 .79 
   Aspirin 0.89 0.61-1.30 .55 0.72 0.47-1.10 .13 
   Anticoagulants 0.88 0.88-1.33 .55 0.72 0.46-1.13 .15 
   Statins 1.26 0.76-2.10 .37 1.08 0.61-1.91 .79 
   Psychotropics 4.89 2.87-8.34 <.0001 5.40 3.21-9.10 <.0001 




No education completed, first level (primary school), or 
secondary school (first phase); 
3 
Previous MI, PCI, CABG;
 4 
MI versus ICD implantation, 
MI = reference category; 
5 
Days between MI or ICD implantation and completion of 
baseline questionnaire; 
6 
Lung, renal or rheumatic disease 
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Table 3. Multivariable predictors of anxiety and depressive symptoms
1 
 Anxiety symptoms Depressive symptoms 
 OR 95%CI p OR 95%CI p 
 
Groups 
      
   Non TD/partner 1.00 - - 1.00 - - 
   Non TD/no partner 2.04 1.05-3.96 .04 3.03 1.46-6.31 .003 
   TD/partner 3.73 2.16-6.45 <.0001 3.81 2.08-6.99 <.0001 
   TD/no partner 8.27 2.50-27.32 .001 6.74 2.19-20.76 .001 
       
Demographics       
   Female  1.79 1.01-3.17 .05 1.92 1.02-3.62 .05 
   Age 0.99 0.97-1.02 .61 1.00 0.97-1.02 .85 
   Low education2 1.79 1.14-2.81 .01 0.97 0.58-1.65 .92 
       
Clinical variables       
   History of ischemic  
      heart disease
3 
0.88 0.47-1.63 .68 1.75 0.87-3.53 .12 
   Treatment4 0.62 0.31-1.25 .18 2.50 1.13-5.53 .02 
   Days
5 
1.01 0.99-1.03 .26 0.99 0.97-1.02 .60 
   Comorbidity6 1.57 0.90-2.74 .12 1.96 1.06-3.60 .03 
   Diabetes 1.51 0.82-2.79 .19 1.34 0.65-2.73 .43 
   Dyslipidemia 1.21 0.75-1.95 .44 1.58 0.91-2.74 .10 
   Hypertension 0.91 0.57-1.47 .70 0.90 0.52-1.56 .70 
   Current smoking 1.57 0.95-2.60 .08 1.72 0.98-3.02 .06 
       
Medication       
   Beta-blockers 1.23 0.67-2.28 .51 1.13 0.56-2.28 .74 
   Aspirin 1.10 0.61-1.98 .76 0.46 0.23-0.90 .02 
   Anticoagulants 1.11 0.64-1.92 .72 0.61 0.33-1.15 .13 
   Statins 1.57 0.76-3.24 .22 1.30 0.56-3.01 .55 
   Psychotropics 3.06 1.64-5.70 <.0001 4.54 2.40-8.57 <.0001 




No education completed, first level (primary school), or 
secondary school (first phase); 
3 
Previous MI, PCI, CABG;
 4 
MI versus ICD implantation, 
MI = reference category; 
5 
Days between MI or ICD implantation and completion of 
baseline questionnaire; 
6 
Lung, renal or rheumatic disease 
 
DISCUSSION 
This is the first study to examine the combined effect of Type D personality and not 
having a partner on emotional distress in cardiac patients. Stratifying by personality and 
partner status showed that non-Type D patients without partner had a twofold increased 
risk of both anxiety and depressive symptoms followed by Type D patients with partner 
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with a threefold risk and, most importantly, Type D patients without partner having a six- 
to eightfold risk compared to non-Type D patients with partner, adjusting for demographic 
and clinical baseline characteristics. This shows that there was a dose-response 
relationship between the two risk factors (Type D personality and having no partner) and 
emotional distress, with Type D patients without a partner having the highest risk. It is 
important to note that the effect of the two risk factors on emotional distress was 
consistent across treatment group (i.e., MI versus ICD). 
Previous research has demonstrated that Type D personality is a cardiotoxic factor 
that is associated not only with adverse prognosis
2-5
 and impaired health status
6-8
 but also 
with increased levels of emotional distress
9-11
. It is important to include indices of 
emotional distress, such as symptoms of anxiety and depression, as outcome measures  
since these symptoms are associated with adverse prognosis
42
, impaired health-related 
quality of life
43





Traditionally, depression but not anxiety has been studied as an important 
psychosocial risk factor for adverse outcomes in CVD, despite the co-occurrence of 
anxiety and depression
42, 47, 48
. Recent studies have demonstrated the detrimental effect of 
anxiety for adverse outcomes in CVD over and above the effect of depression
42, 47, 48
. Our 
results also show that anxiety may be an important person-centered outcome; the dose-
response relationship of the combination of Type D personality and having no partner was 
found for both depressive and anxiety symptoms. In this context, it is important to note 
that Type D personality is not equivalent to anxiety or depressive symptoms. This was 
verified in a recent prospective study of patients treated with PCI who were all anxious at 
6 months
49
. Another study of PCI patients showed that Type D personality predicted 
adverse prognosis above and beyond symptoms of anxiety and depression, which was due 
to the combined effect of high negative affectivity and social inhibition and not to the 
main effects of anxiety and depressive symptoms
30
. 
As shown in the current study, not all Type D patients experience similar levels of 
risk, suggesting that within the group of Type D patients, there is some heterogeneity. 
This heterogeneity is also supported in a recent study of PCI patients, showing that Type 
D patients with diabetes were at increased risk of onset of depressive symptoms at 12 
months when compared to patients with a Type D personality or diabetes alone
50
.  
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 Although our findings indicate the importance of having a partner, the results also 
suggest that partner status does not completely buffer the effects of Type D on distress 
since Type D patients with a partner still had a significantly higher risk compared to non-
Type D patients with or without a partner. In a recent study of ICD patients, Type D 
personality was also shown to have a larger impact on distress than shocks
9
, emphasizing 
the importance of personality as an independent determinant of distress. In the present 
study, lack of a partner showed a further elevated risk of emotional distress in the already 
distressed Type D patients. 
It is important to note that in the current study, disease severity was not related to 
emotional distress at 2 months follow-up, indicating that emotional distress is not just a 
consequence of disease severity, which is in line with some
51, 52
 but not all
53
 studies. 
In view of our results, in clinical practice, it is important to screen for and identify 
patients with a Type D personality, particularly those Type D patients who do not have a 
partner. Type D personality has been associated with adverse prognosis
2-5
, and other 
studies have shown that patients without a partner are less compliant
54, 55
, less physically 
active
56
, and at increased risk of CVD mortality
57, 58
. Cardiologists and nurses should 
therefore carefully monitor Type D patients without a partner, as they may be less likely 
to adhere to medication, participate in cardiac rehabilitation, and attend regular check-ups. 
In this context, nurses could serve as an important source of support. In addition, these 
patients may benefit from psychosocial intervention in order to prevent the development 
of anxiety and depressive symptoms, as these symptoms are associated not only with 
reduced compliance
44, 45
 and impaired health-related quality of life
42




This study has some limitations. First, the number of patients in the Type D/no 
partner group was relatively small, which may have led to reduced power. Therefore, 
replication of these results is warranted in future studies. Nevertheless, we still found 
significant and consistent results across patient groups and psychological 
symptomatology. Second, the 2-month follow-up period was relatively short. Future 
studies need to replicate our findings using a longer follow-up period. Third, we had no 
information on the psychological and physical status of the partner or on marital quality or 
marital satisfaction. Marital status may have an impact on quality of life. Nevertheless, we 
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were able to show that not having a partner was associated with increased risk of anxiety 
and depressive symptoms in both non-Type D and Type D patients. Fourth, we had no 
information on behavioral risk factors and compliance with medical regiments, which may 
serve as confounders. Fifth, excluded patients differed from included patients with respect 
to several demographic and clinical indices, which may result in limited generalizability 
of the findings. However, since excluded patients appeared to be more ill, the adverse 
effect of Type D personality and having no partner found in this study is more likely to be 
an underestimation rather than an overestimation. Finally, the two pooled cardiac patient 
groups differed on indices of disease severity. However, disease severity was not 
associated with either the independent or outcome variables.  
Despite these limitations, this study also has several strengths. This is the first study 
to examine partner status as a potentially important factor in the link between Type D 
personality and anxiety and depressive symptoms. In addition, results are based on a 
heterogeneous patient group with acute MI or ICD implantation, showing that results are 
generalizable across CVD patient groups.  
In conclusion, these results show that there was a dose-response relationship 
between the two risk factors (Type D personality and having no partner) in relation to 
anxiety and depressive symptoms, with Type D patients without a partner having the 
highest risk 2 months after hospitalization for acute MI or ICD implantation. Given the 
fact that this is the first study to show that lack of a partner in patients with a Type D 
personality is associated with a particularly high risk of emotional distress, future studies 
that replicate these findings are warranted. In clinical practice, it is important to screen for 
Type D personality to monitor Type D patients without a partner particularly carefully. 
These patients may be less likely to comply with medication, take part in cardiac 
rehabilitation, and change health-related behaviors that are detrimental to their health due 
to their increased levels of emotional distress. 
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Background Little is known about the psychological consequences of implantable 
cardioverter defibrillator (ICD) implantation for partners of patients. The objective of this 
study was to examine anxiety in partners of ICD patients.  
Methods At baseline, partners (N = 182) completed measures on personality, that is, the 
Type D scale (DS14) and Anxiety Sensitivity Index (ASI). Two months following ICD 
implantation, general anxiety (STAI-state) and posttraumatic stress symptoms (PTSS) 
were assessed. The patient variables ICD indication and occurrence of shocks were 
deduced from medical records. 
Results Mean levels of general anxiety were equal (p = 0.42) among partners (37.6±11.4) 
and patients (36.7±10.9). Similarly, the proportion of partners (41%) and patients (40%) 
experiencing clinically relevant levels of general anxiety was also equal (p = 1.0). 
Multivariable linear regression analysis showed that Type D personality (β = .25, p = 
.001) and anxiety sensitivity (β = .35, p < .0001) were significant predictors of general 
anxiety in partners, independent of gender, age, shocks, and ICD indication. Regarding 
PTSS in partners, anxiety sensitivity (β = .48, p < .0001) and age (β = -.15, p = .041) were 
independent predictors, whereas Type D was not (β = .11, p = .12).  
Conclusion These findings emphasize the clinical significance of anxiety in partners of 
ICD patients. In clinical practice, following the implantation of an ICD in patients, it may 
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INTRODUCTION 
The implantable cardioverter defibrillator (ICD) is important in the treatment of life-
threatening arrhythmias, in patients who have already experienced a cardiac arrest (i.e., 
secondary prevention), and in patients with severe left ventricular dysfunction without 
documented cardiac arrest, ventricular fibrillation, or ventricular tachycardia (i.e., primary 
prevention)
1
. ICDs can terminate ventricular arrhythmias by antitachycardia pacing 
(overdrive pacing), or shocks, which constitute the most aggressive treatment
2
. 
A major issue has been the psychological adaptation after ICD implantation in 
patients. Psychological problems, such as anxiety
3-7





 are frequently experienced by patients in the months or even 
years after ICD implantation. ICD shocks may enhance these levels, although studies 
report inconsistent results
9-11
. In contrast, indication for ICD implantation may not 
influence anxiety
3, 12
 or health-related quality of life
12-14
 in the months post-implantation. 
Psychological distress may also be experienced by partners of ICD patients, but this 
issue has received little attention in the literature, even though some studies have reported 
that anxiety levels in partners are as high as levels in ICD patients
15, 26
 or even higher
10, 17
. 
To our knowledge, the prevalence of PTSS following ICD implantation has never been 




Personality may play an important role in the psychological adjustment after ICD 
implantation in both patients and partners. In their cross-sectional study, Pedersen et al.
10
 
found that Type D personality was independently related to anxiety in patients as well as 
partners. Type D personality refers to the combination of two personality traits, that is, 
negative affectivity (the tendency to experience negative emotions across time and 
situations) and social inhibition (the tendency to inhibit the expression of emotions due to 
fears of how others will react)
19
. Type D personality has been associated with an increased 
risk for morbidity and mortality
20
 as well as increased feelings of anxiety
10, 20
 in patients 
with coronary heart disease.  
Anxiety sensitivity may also play a role in the experience of anxiety. Anxiety 
sensitivity is a personality trait that refers to the fears of anxiety-related sensations based 
on beliefs that these sensations have harmful consequences
21
. For example, persons with 
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high anxiety sensitivity may believe that heart palpitations indicate a heart attack, whereas 
those with low anxiety sensitivity experience these sensations as unpleasant but non-
threatening. Such a misinterpretation of sensations in people high in anxiety sensitivity 
may lead to a vicious cycle, where higher levels of anxiety may cause further anxiety-
related sensations that may be misinterpreted again, et cetera.  
The aims of this study were 1) to determine the prevalence of general anxiety and 
posttraumatic symptoms in partners of ICD patients after ICD implantation and 2) to 
determine the influence of personality on general anxiety and posttraumatic symptoms in 
partners of ICD patients, taking into account the possible effects of gender, age, and ICD 
indication as well as shocks experienced by the patient. 
 
METHODS  
Study population and design 
Patients having had an ICD implanted in two large Dutch referral hospitals between 
September 2005 and July 2007 as well as their partners were asked to participate in an 
ongoing longitudinal study on psychological reaction to ICD implantation. Inclusion 
criteria for patients comprised implantation with an ICD and age between 18 and 80 years. 
Subjects were excluded in case of inability to read and understand Dutch. Partners could 
only participate when they were living together with the patient and the patient had 
already agreed to participate in the study. No further criteria were formulated for the 
partners. The study was approved by the Medical Ethic Committees of the participating 
hospitals. The study was conducted in accordance with the Helsinki Declaration, and all 
subjects provided written informed consent. 
 
Demographic and clinical variables 
Demographic variables included gender and age of the partner, since previous studies 
have shown that women
22
 and younger respondents
23, 24
 are more likely to experience 
anxiety, compared to men and older respondents, respectively. Age was dichotomized 
using the median score, which was 61. Clinical variables comprised ICD indication 
(primary versus secondary prevention) and shocks (0 versus ≥1 shocks). ICD indication 
was included, because the relationship between ICD indication and psychological 
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adaptation in partners has not been studied to our knowledge. Previous research regarding 






Measures of personality of the partner were completed at baseline, which was between 0 
and 3 weeks following ICD implantation. 
 
Anxiety sensitivity 
The 16 item Anxiety Sensitivity Index (ASI)
25
 was used to measure anxiety sensitivity, 
which refers to sensitivity and fear of anxiety symptoms
25
. Items are rated on a five-point 
Likert scale from 0-very little to 4-very much. Total scores are obtained by summing the 
scores on the 16 items, that is, total scores range from 0 to 64, with higher scores 
reflecting greater sensitivity and fear of anxiety symptoms. The reliability of the ASI 
among partners was good, with Cronbach’s α = 0.90. To determine effect sizes of anxiety 
sensitivity, the ASI was dichotomized. Since no standardized cut-offs have been described 
for the ASI, we used the upper quartile score (i.e., 14) to define patients with increased 
anxiety sensitivity. 
 
Type D personality 
Type D personality was measured using the 14-item Type D personality Scale (DS14)
19
. 
The DS14 consists of two 7-item subscales: negative affectivity (e.g., “I often feel 
unhappy”) and social inhibition (e.g., “I am a ‘closed’ person”). Items are answered on a 
five-point Likert scale ranging from 0-false to 4-true. Total scores on both subscales range 
from 0 to 28. Patients scoring high on both subscales, that is, equal to or above 10, are 
classified as Type D. Internal consistency is high, with Cronbach’s α values of 0.88 for 
negative affectivity and 0.86 for social inhibition
19
. A recent study has shown that Type D 













The 20-item state-version of the State-Trait Anxiety Inventory (STAI; form Dutch Y-1)
27
 
was used to assess the current presence of general symptoms of state anxiety. State 
anxiety refers to a transient emotional status, characterized by feelings of apprehension 
(i.e., worries and concerns) and tension as well as increased activity of the autonomic 
nervous system. Items are scored on a 4-point Likert scale from 1-not al all to 4-very 
much so. Scores range from 20, that is, low level of state-anxiety to 80, that is, high level 
of state-anxiety. The STAI has been demonstrated to have adequate validity and 
reliability, with Cronbach’s α ranging from 0.87 to 0.92
27
. To indicate clinically elevated 
levels of general anxiety, the cut-off ≥ 40 was used. In patients, this cut-off was 
previously used in studies involving the ICD
9





The Posttraumatic Stress Diagnostic Scale (PDS) was first described by Foa
29, 30
 and was 
translated into Dutch according to standard practice for the purpose of the current study. 
The PDS was designed to correspond to DSM-IV diagnostic criteria for PTSD. The Dutch 
PDS comprises 17 items that correspond to the 17 DSM-IV symptoms of PTSD, which 
can be clustered in the three symptom groups: reexperiencing (i.e., “Having bad dreams of 
nightmares about the ICD of your partner”, avoidance (i.e., “Trying to avoid activities, 
people, or places that remind you of the ICD of your partner”), and arousal (i.e., “Being 
jumpy or easily startled (for example, when someone walks up behind you”)). The 
frequency of each symptom in the past month is rated on a 4-point Likert scale, ranging 
from 0-not at all or only one time to 3-five or more times a week/almost always. The 
Dutch version of the PDS also contains questions on the level of impairment in 
functioning as well as on feeling helpless or terrified, but these questions were not used in 
this study. In our study, the ICD of the patient was referred to as the traumatic event, since 
the ICD is implanted to prevent sudden cardiac death. Foa
29
 reported good internal 
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consistency, with Cronbach’s α = 0.92 for the 17 symptom items. Our study confirmed 






The Chi-square test (Fisher’s Exact Test when appropriate) was used to compare discrete 
variables, Student’s t-test for independent samples to compare groups on continuous 
variables, and the paired-samples t-test to compare means of continuous variables. The 
nonparametric McNemar test was used to compare two percentages. A correlation 
coefficient was used to determine the association between levels of anxiety of partners 
and patients. Cross tabulation was applied to determine if the proportion of patients with 
increased levels of anxiety was different between partners with increased levels of anxiety 
and partners without increased levels. A biseral correlation coefficient was computed to 
determine the association between a discrete variable and a continuous variable. A series 
of univariate and multivariable linear regression analyses were performed to examine 
determinants of general anxiety and PTSS. A priori, we decided to include anxiety 
sensitivity, Type D personality, gender, age, secondary prevention, and the experience of 
shocks in multivariable analyses. To test the mediational effect of anxiety sensitivity, we 
performed a Sobel test, which directly tests the significance of a mediated effect, in 
contrast with causal step methods (e.g., the Baron and Kenny approach). However, a 
major drawback of the Sobel test is its assumption that the distribution of the mediational 
effects is normal
31
. Therefore, we additionally used a bootstrapping approach, by taking 
5,000 samples from the data. This approach makes no assumptions about the shape of the 
distributions of the variables or the sampling distribution of the statistic
31
. The point 
estimate of the indirect effect is the mean computed over the 5,000 samples. The 95% 
confidence interval is computed and when this interval does not include zero, the indirect 
effect is significantly different from zero. Sobel tests and bootstrapping were performed 
with an SPSS macro by Preacher and Hayes
31
 (http://www.comm.ohio-
state.edu/ahayes/sobel.htm). All other statistical analyses were performed using SPSS 





Of the 268 patients who agreed to participate, 225 (84%) had a partner, of whom 
199 (88%) agreed to participate in the study. At two months follow-up, 1 (0.5%) patient 
had died, 10 (4%) patients and partners refused to complete the follow-up questionnaires, 
and 6 (3%) partners had missing data on questionnaires, resulting in a final sample of 182 
(81%) partners. Included partners did not differ significantly from excluded partners on 
any of the baseline characteristics.  
Demographic, clinical, and personality characteristics of the 182 included partners 
are shown in Table 1, as well as the mean scores and prevalences of general anxiety and 
PTSS. In our study, data on general anxiety in patients two months following ICD 
implantation were available. Partners (37.6±11.4) and patients (36.7±10.9) reported 
similar levels of general anxiety (t = 0.80, p = .42) and the proportion of partners (41%) 
and patients (40%) experiencing increased levels of general anxiety was also similar (p = 
1.0), indicating that anxiety is not only important in ICD patients, but also in their 
partners. The correlation coefficient between anxiety levels of the partners and patients 
was 0.26 (p < .0001), indicating that higher anxiety levels in the partner may be associated 
with higher anxiety levels in the patient. In contrast, the proportion of patients with 
increased levels of general anxiety was not significantly different in partners with 
increased levels of anxiety (47%) versus partners without increased anxiety scores (35%; 
p = .11).  
Type D personality was significantly related to anxiety sensitivity, with Type D 
partners scoring higher on anxiety sensitivity than non Type D partners (17.0±12.6 versus 
9.0±7.6, t = -4.19 p < .0001). Similarly, significantly more Type D partners reported 
increased feelings of anxiety sensitivity compared to non Type Ds (42% versus 21%, p = 
.005). However, the biseral correlation coefficient between Type D personality and 
anxiety sensitivity was 0.49, indicating no multicollinearity and permitting these variables 
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Table 1. Partner characteristics (N = 182)
 
 % (N) Mean (SD) Range 
Demographics    
   Female 82 (150)   
   Age  60.2 (9.3) 28-80 
    
Clinical variables patient    
   Secondary prevention 29 (53)   
   ≥ 1 shock since implantation 5 (9)   
    
Personality    
   Type D personality 28 (50)   
   Anxiety sensitivity score  11.2 (9.9) 0-54 




27 (49)   
    
Anxiety     
   General anxiety   37.6 (11.4) 20-74 
   Increased general anxiety
2 
41 (75)   
   Posttraumatic symptoms 
 
 5.4 (7.5) 0-36 
1
 Anxiety Sensitivity Index ≥ 14, 
2
 State-Trait Anxiety Inventory ≥ 40 
 
 
General anxiety and PTSS 
T-tests for independent samples revealed that partners with a Type D personality, elevated 
levels of anxiety sensitivity, or younger age experienced significantly more general 
symptoms of anxiety and posttraumatic stress, compared to partners without these 
characteristics (Figure 1). Univariable linear regression analyses yielded the same results. 
Effect sizes, computed by Cohen’s d, were large for Type D personality and anxiety 
sensitivity, and small to moderate for shocks regarding general anxiety as well as PTSS 
(Figure 2). Age had a small effect on general anxiety and a moderate effect on PTSS. 








Figure 1. Mean scores on general anxiety and PTSS among partners of ICD patients at 



































PDS = Posttraumatic Stress Diagnostic Scale  
p = .001 p < .0001 p = .007 





















s p =. 27 p < .0001 
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Figure 2. Effect size estimates indicating the magnitude of the effect of ICD indication, 
shocks, age, Type D personality, and increased anxiety sensitivity 
 
 














































Results of multivariable linear regression analyses are shown in Table 2. Anxiety 
sensitivity and Type D personality remained the only significant and independent 
predictors of general symptoms of anxiety. Regarding PTSS, anxiety sensitivity as well as 
age were significant and independent predictors, with younger partners experiencing more 
PTSS. 
Simultaneous entering of anxiety sensitivity and Type D personality in the 
multivariable analysis resulted in a nonsignificant contribution of Type D personality to 
PTSS. Therefore, anxiety sensitivity may have mediated this relationship. Both Sobel tests 
(z = 4.28, p < .0001) and the bootstrapping method (95% confidence interval 1.24-5.20) 
confirmed this hypothesis, indicating that anxiety sensitivity may act as a mediator in the 
relationship between Type D personality and PTSS. 
 
Table 2. Multivariate predictors of general anxiety and posttraumatic stress symptoms in 






  ß                p 
Posttraumatic stress 
symptoms 
 ß                 p 
   Anxiety sensitivity  .35 <.0001   .48 <.0001 
   Type D personality  .25 .001  .11 .12 
     
   Female gender  .06 .38  .08 .22 
   Age -.01 .92 -.13 .041 
     
   Secondary prevention
1 
 .02 .77  .09 .14 
   Shocks
1 
 
 .09 .20  .09 .17 
1 
Patients’ medical characteristics 
 
DISCUSSION 
This study suggests that anxiety levels are equally high in ICD patients and their partners, 
indicating that anxiety is a major issue not only in ICD patients, but also in their partners. 
Partners with increased anxiety sensitivity and Type D personality were at increased risk 
for experiencing general anxiety two months following ICD implantation. Posttraumatic 
stress in partners was predicted by anxiety sensitivity and younger age. Type D 
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personality was not directly related to PTSS, but evidence was found for an indirect 
association, in which anxiety sensitivity mediated the relation between Type D personality 
and PTSS.  
Our finding that partners may experience similar levels of anxiety as compared to 
patients corroborates results of previous research
10, 15-17
. However, previous studies 
included small samples
16-18 
or applied a cross-sectional design with a wide interval range 
between ICD implantation and completion of questionnaires
10, 15
. In the present study, 182 
partners completed measurements on anxiety at two months following ICD implantation. 
One third of the partners experienced clinically elevated levels of general anxiety two 
months following ICD implantation, indicating that anxiety is an important issue in 
partners of ICD patients. Therefore, research and clinical practice should not only focus 
on psychological distress in ICD patients, but also in their partners. 
To our knowledge, no previous studies have investigated PTSS in partners of ICD 
patients. Even studies on PTSS in patients are scarce and comprise merely case-studies
8
. 
The paucity of studies may be due to a lack of adequate measurements to assess PTSS 
specifically after ICD implantation in both patients and their partners. The PDS was used 
in this study and showed good reliability. Therefore, future research may incorporate this 
questionnaire. 
Only a few studies have focused on the identification of partners at high risk for 
anxiety, let alone PTSS. Pedersen and collegues
10
 reported that Type D personality was 
associated with an eightfold increased risk of anxiety in partners, which is in line with our 
results. Partners of patients who had experienced a shock did not experience more general 
anxiety or PTSS as compared to partners of patients who did not experience a shock. 
Therefore, we may conclude that the experience of a shock is not a risk marker for anxiety 
in partners. However, this result should be interpreted with caution, since only 9 patients 
experienced a shock. Moreover, a number of studies have found that shocks were 
associated with increased levels of anxiety and other forms of psychological distress in 
family members, including partners
17, 18
. Only De Groot et al.
15
 reported no association 
between shocks and mood. However, as mentioned earlier, these studies differ in their 
methods and suffer from serious flaws. Overall, future studies are warranted on risk 
markers for anxiety in partners of ICD patients.  
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The major limitations of our study comprise the short-term follow-up period of 
only two months and concomitant low number of shocks experienced by patients. 
Therefore, the power to detect effects of shocks for anxiety was rather low. Furthermore, 
personality and anxiety outcomes were measured with self-report questionnaires only. 
Another limitation concerns the generalizability of the results, since 7% of the patients 
had missing data or refused to complete the questionnaires and were subsequently omitted 
from analyses. However, these patients did not differ from patients included in the 
analyses. Nevertheless, the results clearly showed that anxiety is an important issue in 
partners of ICD patients and also that partners with Type D personality and anxiety 
sensitivity are at increased risk. 
In clinical practice, it is important to identify high risk patients, but also high risk 
partners. In particular, attention should be focused on partners who are high in anxiety 
sensitivity and have a Type D personality. This may be realized by the use of the easy to 
administer 16-item ASI and DS14. The DS14 has well-established cut-off scores, but 
further research is required on the critical cut-off point to determine enhanced anxiety 
sensitivity. Next, these high-risk partners should receive adequate psychological support, 
but no randomized controlled trials have focused on the treatment of Type D personality 
or anxiety sensitivity, to our knowledge. Hence, future research should focus on the 
treatment options for these personality traits. Interventions for Type D persons may aim at 
coping differently with negative emotions, whereas for persons with enhanced anxiety 
sensitivity it may be important to focus on the meaning of anxiety-related sensations. 
In sum, anxiety is a major issue not only in ICD patients, but also in their partners. 
Partners with a Type D personality or enhanced anxiety sensitivity are at increased risk to 
experience anxiety and posttraumatic stress symptoms. In clinical practice, these partners 
at risk should be identified and receive adequate support.  
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Background We examined whether partner research may affect participation rates of 
implantable cardioverter defibrillator (ICD) patients with a Type D personality (joint 
presence of negative affectivity and social inhibition). 
Methods 507 patients (80.5% men, mean age = 62.7±10.1 years) who underwent ICD 
implantation between May 2003 and November 2007 were included. In September 2005, 
a substudy on partners of ICD patients was added (N = 276 patients). The DS14 was used 
to assess Type D personality. 
Results The proportion Type D patients after the start of the partner substudy was 
significantly lower as compared to the proportion before the start of this substudy (18.8% 
versus 29.1%; p = .007). Multivariable regression analysis showed that patients who 
participated after the start of the partner substudy were less likely to have a Type D 
personality (OR = 0.48; 95%CI 0.30-0.78; p = .003) and biventricular ICD (p =. 003), and 
more likely to have primary prevention (p = .0001) and comorbidities (p = .023), adjusting 
for age, gender, education, and etiology. In the partner substudy, nonparticipation was 
more prevalent among partners of Type D patients as compared to partners of non-Type D 
patients (20.4% versus 10.1%; p = .044). Multivariable regression analysis showed that 
partner nonparticipation was associated with female gender of patients (OR = 2.92; 
95%CI 1.30-3.45; p = .010) and marginally significant with Type D personality of the 
patient (OR = 2.13; 95%CI 0.91-4.99; p = .083), but not with age and education. 
Conclusion The addition of a partner substudy was related to a decreased proportion of 
participants with a Type D personality. Nonparticipation was more prevalent among 
partners of Type D patients. These issues should be taken into account when planning 







The psychological impact of cardiac disease and treatment on patients has been studied 
widely, but relatively little attention has been paid to the psychological effects of disease 
and treatment on the partners of cardiac patients
1-3
. More specifically, research on partners 
of implantable cardioverter defibrillator (ICD) patients is lacking
1
. However, the number 
of studies on partners of cardiac patients is increasing, and in this regard, it is important to 
examine the influence of conducting a partner study on participation rates.  
In general, study participants may systematically differ from nonparticipants. This 
threat to the generalizability of study results is called ‘selection bias’ and constitutes a 
major issue in research using volunteers as study participants
4
. Nonparticipation or 
nonresponse exists in different forms and each form may be related to different 
characteristics
5-6
. For instance, potential participants who immediately refuse participation 
may differ from participants who refuse continuation of the study
5
. These groups may also 
be different from participants who omit items during the survey
6
. Another form of 
selection bias may result from the addition of a substudy (for instance, on partners of 
patients), but to our knowledge, this has not been examined to date. 
There are no established risk factors for nonparticipation
7
. Some medical studies 




, or less 
healthy
11, 12
, while other studies found nonparticipants to be younger
10, 12
. Personality 
characteristics may also play an important role in the distinction between participants and 
nonparticipants. A recent study has shown that participants were significantly lower in 
neuroticism and higher in conscientiousness, extraversion, and agreeableness as compared 
to nonparticipants
5
. In line with the findings regarding neuroticism and extraversion, Type 
D personality may also be related to nonparticipation. Type D personality comprises two 
stable personality traits, that is negative affectivity (i.e., the tendency to experience 
negative emotions across time and situations) and social inhibition (i.e., the tendency to 
inhibit self-expression in order to avoid negative reactions from others)
13
. Type Ds are 
rather reserved in nature, which may augment the probability of refusal to participate 




The construct of Type D personality has been developed in the cardiovascular field. 
Previous studies in different cardiac populations have shown that Type D patients are at 
increased risk for morbidity and mortality
14
. A potential association between Type D 
personality and nonparticipation may have important consequences for the outcomes of 
such studies, because research has shown that nonparticipants may be less healthy than 
participants
5, 11, 12
. For these reasons, it is important to examine the impact of having Type 
D personality on participation rates. 
The aim of this study was twofold. First, to examine whether the addition of a 
partner substudy was associated with participation rates of ICD patients with a Type D 
personality. Second, to examine whether Type D personality of patients was associated 




Patients, aged 18-80 years, who underwent ICD implantation in the Catharina Hospital, 
Eindhoven, The Netherlands and the Amphia Hospital, Breda, The Netherlands between 
May 2003 and November 2007, were included in a study on personality, anxiety, and 
person-centered and medical outcomes in ICD patients. Patients were excluded in case of 
significant cognitive impairments (e.g., dementia), severe life-threatening comorbidities 
(e.g., cancer), or inability to read and understand Dutch.  
  
Partner substudy 
In September 2005, a substudy on psychological effects of ICD implantation for partners 
of ICD patients was added. Partners were asked to participate when they were living 
together with the patient and when the patient had already agreed to participate in the 
study. No further criteria were formulated for the partners. When the patient agreed to 
participate in the study, he/she was asked whether he/she had a partner. Next, the partner 
substudy was explained to the patient, and he/she was asked to hand over the study 
material to the partner, including a form which outlined the study, the informed consent 
form, and the questionnaire.  
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The later addition of the partner substudy provided us with the opportunity to test 
differences between patients who were included before the start of the substudy and 
patients who were included after the start of the substudy. In addition, differences could 
be examined between patients whose partner participated in the substudy and patients 
whose partner refused to participate. 
Both the main study and the partner substudy were approved by the Medical Ethics 
Committees of the participating hospitals, and were conducted in accordance with the 
Helsinki Declaration. All patients and partners provided written informed consent. 
 
Demographic variables 
The demographic patient variables age, gender, and education were included, with low 
education referring to less than 7 years of education. In addition, clinical patient variables 
were incorporated, including type of ICD (1 or 2 chamber ICD versus biventricular ICD), 
ICD indication (primary versus secondary prevention), etiology (ischemic 
cardiomyopathy versus nonischemic cardiomyopathy), and comorbidity (rheumatic, lung, 
or kidney disease, or diabetes). 
 
Personality 
Between 0 and 3 weeks following ICD implantation, patients completed the 14-item Type 
D Scale (DS14) to measure Type D personality
13
. The DS14 consists of the 7-item 
subscales negative affectivity (e.g., “I often feel unhappy”) and social inhibition (e.g., “I 
am a ‘closed’ person”). Items are answered on a five-point Likert scale ranging from 0-
false to 4-true. Total scores on both subscales range from 0 to 28. Patients scoring high on 
both subscales; i.e., equal to or above the standardized cut off score 10, are classified as 
Type D
13
. These cut-off points have shown to be reliable in discriminating Type Ds from 
non Type Ds
15
. Internal consistency is high with Cronbach’s α values of 0.88 for negative 
affectivity and 0.86 for social inhibition
13
. The temporal stability of Type D personality 









First, differences in clinical and personality characteristics between patients included after 
the start of the partner substudy and those included before the start of this substudy were 
examined by means of Chi-square tests and independent t-tests. Next, another series of 
Chi-square tests and independent t-tests were performed to investigate differences 
between patients whose partner agreed to participate and patients whose partner declined 
participation. Subsequently, logistic regression analysis was performed to determine 
independent associations of Type D personality and demographic and clinical variables 
with the cohort of patients who were included after the start of the partner substudy. A 
logistic regression analysis was also applied to determine independent associations 
between Type D personality and demographic variables and the cohort of patients whose 
partner did not participate. Clinical variables were not included in these additional 
analyses. All statistical analyses were performed using SPSS 14.0 for Windows. A p-
value < .05 was considered to be statistically significant. 
 
RESULTS 
Patient and partner characteristics 
Of the 513 patients who agreed to participate in the study, 6 patients had to be excluded 
due to missing data on Type D personality (n = 4) or smoking (n = 2), resulting in a final 
sample of 507 ICD patients. Of these patients, 22.5% was classified as Type D (n = 114), 
80.5% was male (n = 408), 23.3% had less than 7 years of education (n = 118), 60.0% had 
a primary indication (n = 304), 72.4% had ischemic cardiomyopathy (n = 367), 32.1% had 
a biventricular ICD (n =163), and 36.7% was suffering from comorbidities (n = 186). The 
mean age of these patients was 62.7 years (SD = 10.1, range 24-79).  
Of these 507 patients, 325 patients (64.1%) were included after the start of the 
partner substudy. About 15% of these patients did not have a partner (n = 49), resulting in 
a potential sample of 276 partners, of whom 243 (88.0%) participated and 33 (12.0%) did 
not participate. The mean age in this sample of 243 partners was 60.3 years (SD = 9.4) 





Patient participation following start partner substudy 
First, differences between patients included before (n = 182) and after (n = 325) the 
partner substudy were investigated. The proportion of Type D patients included after the 
start of the partner substudy was significantly lower compared to the proportion before the 
start of this substudy (18.8% versus 29.1%, p = .007), suggesting a decreased participation 
rate of Type D patients following the addition of the partner substudy (Figure 1). 
Furthermore, patients included after addition of the partner substudy were slightly older (p 
= .047) and more often had primary prevention (p < .0001) and comorbidities (p = .024) 
as compared to patients included before the start of the substudy (Table 1).  
 
Figure 1. Percentage of patients with a Type D personality before and after the start of 
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Multivariable logistic regression analysis showed that patients who were included during 
the partner substudy were less likely to have a Type D personality (OR = 0.48) as 
compared to the proportion of Type Ds before the start of the substudy, when controlling 
for other variables (Table 2). This indicates that the reduction in the proportion of Type D 
patients after the start of the partner substudy was not a function of other patient 
characteristics. Patient participation after the start of the partner substudy was also 
independently associated with primary prevention (OR = 6.13) and comorbidities (OR = 
1.66), and inversely with having a biventricular ICD (OR = 0.47). Age, gender, education, 
and etiology were not significant in this model. 
% p = .007 
   Patients with a 
Type D personality 
(n = 182) 




Table 1. Characteristics of patients included before and after the start of the partner 






(n = 182) 
After start 
substudy 
(n = 325) 
 
Patient variables % (n) % (n) p* 
    
Demographic variables 







   Female gender 16.5% (30) 21.2% (69) .20 
   Low education 23.1% (42) 23.4% (76) .94 
    
Clinical variables 







   Ischemic cardiomyopathy 75.3% (137) 70.8% (230) .28 
   Biventricular ICD 








* Univariate analysis (Chi-square tests and independent t-tests) 
 
Table 2. Characteristics of patients included after the start of the partner substudy          
(N = 507) 
 
 Multivariable logistic regression 
analysis* 
Patient variables    OR 95% CI p 
 
Personality 










    
Demographic variables 







   Female gender 1.43 0.83-2.45 .20 
   Low education 1.04 0.64-1.70 .88 
    
Clinical variables 







   Ischemic cardiomyopathy 0.63 0.38-1.02 .060 
   Biventricular ICD 






















Partner nonparticipation in the substudy 
Selection bias was also investigated in partners who participated in the study (n = 243) 
versus partners who did not participate in the study (n = 33). Chi-square analysis showed 
that nonparticipation was more prevalent among partners of Type D patients as compared 
to partners of non-Type D patients (20.4% versus 10.1%; p = .044) (Figure 2). In addition, 
9.4% of the partners did not participate when the patient was male versus 22.6% when the 
patient was female (p = .008).  
 













Multivariable logistic regression analysis (Table 3) showed that female gender of 
the patient was the only variable which was independently associated with a 2.9 fold risk 
of nonparticipation of partners. In addition, there was a trend for Type D personality of 
the patient (OR = 2.13) to be associated with nonparticipation of the partner. Age and 
education of the patient were not significantly related to partner nonparticipation. 
 




(n = 227) 
(n = 49) 
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Table 3. Participating versus nonparticipating partners as a function of patient 







(n = 243) 
Nonparticipating 
partners  
(n = 33) 
Multivariable logistic 
regression analysis*  
 
Patient variables % (n) % (n) OR 95% CI p 
 
Personality patient 
















      
Demographic variables 











   Female gender 16.9% (41) 36.4% (12) 2.92 1.29-6.61 .010 
   Low education 21.4% (52) 24.2% (8) 0.89 0.36-2.21 .81 
      
* Nonparticipation of partner coded as 1.  
 
DISCUSSION 
This study investigated the associations of Type D personality and demographic and 
clinical variables of ICD patients (i) with their participation rate in research either 
involving or not involving additional participation of their partners, and (ii) associations 
of Type D personality and demographic variables of the patient with nonparticipation 
rates of their partners. We found that patients who participated following the start of the 
partner substudy were significantly less likely to have a Type D personality and 
biventricular ICD, and significantly more likely to have primary prevention and 
comorbidities. Partner nonparticipation was more prevalent among partners of female 
patients and tended to be more prevalent in partners of Type D patients. Hence, the 
addition of a substudy on partners of ICD patients has caused selection bias related to the 
personality of the patients in two different ways.  
We can only speculate why the prevalence of Type D personality significantly 
decreased after the addition of a substudy on partners. Type D patients are closed persons 
and want to keep people at a distance, in combination with a tendency to experience high 
negative affect
13
. It may be speculated that because of this combination, they are more 
reluctant to cooperate in a study which may trigger their partner to encourage the patient 
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to disclose their negative feelings. Since the patients’ cooperation was also needed in 
asking the partner to participate, this also may have influenced participation rates of their 
partners.  
In this study, the Type D personality played an important role in selection bias. 
Participants and nonparticipants may also differ on a number of characteristics related to 
personality traits, including their psychological and physical health; that is, participants 
may be more psychologically adapted (e.g., lower in neuroticism and higher in 
conscientiousness) and may therefore be healthier than nonparticipants
5
. In patients with 
coronary heart disease, Type D personality has been associated with clinical outcomes, 
such as an increased risk for morbidity and mortality
14
. As a consequence, selection bias 
may result in an underrepresentation of Type D patients and therefore an 
overrepresentation of healthy participants. The power to detect differences between Type 
D patients and non Type D patients will also be decreased. These effects imply potentially 
important consequences for study results. 
ICD indication is being incorporated in most studies on ICD patients. In recent 
years, guidelines for ICD implantation have been expanded, particularly regarding 
primary prevention
17
. Therefore, the significant effect of primary prevention for patients 
included after the partner substudy was expected. We had no specific prospects regarding 
etiology, having a biventricular ICD, or comorbidities, but these characteristics were all 
(marginally) significantly related to inclusion after the start of the partner substudy.  
Some of the demographic covariables were also significantly associated with study 
participation. Differences were found regarding age, with patients included after the 
substudy being slightly older. However, this small difference (mean age 63.4 versus 61.5) 
may not have clinical relevance. In addition, male partners more often did not participate 
as compared to female partners, which contradicts results of previous studies
8-10
, but is 
important to take into account when performing substudies involving partners of (ICD) 
patients.  
The results of this study should be interpreted with caution. No data were available 
on patients who were invited to participate but declined. This group may contain a high 
percentage of Type D patients, but this prevalence is hard to determine, since Medical 
Ethics Committees will not easily approve a proposition to provide patients, who declined 
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participation immediately, with a questionnaire. Nevertheless, the present study reveals 
important information on the association of Type D personality with participation rates, 
when adding a partner substudy to the main study. Given that a better comprehension of 
the interpersonal context of Type D patients is important
18
, the results of the current study 
should be taken into account in future studies. 
In conclusion, in the ICD population, the addition of a partner substudy was related 
to a decreased proportion of participating patients with a Type D personality. Also, 
nonparticipation of partners was more prevalent among partners of Type D patients as 
compared to partners of non Type D patients. These effects should be considered when 
planning a partner substudy. In general, it is important for researchers to consider possible 
bias by introducing new elements to the main study that may affect participation rates. 
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The present thesis describes ongoing prospective research in patients with an implantable 
cardioverter defibrillator (ICD) and their partners. ICD implantation constitutes the main 
treatment of choice in patients with life-threatening arrhythmias as well as in patients at 
increased risk for these arrhythmias
1
. Although ICDs do not prevent ventricular 
arrhythmias, their aim is to prevent sudden cardiac death due to ventricular arrhythmia. 
Most patients adapt well to the ICD, but a subgroup experiences psychological problems, 
including anxiety
2
. Identification of patients with anxiety is important as this adverse 
emotional state may be related to unfavorable outcomes
3
, including ventricular 
arrhythmias, although results are inconclusive
4-6
. Furthermore, anxiety levels in partners 
may be as high as in ICD patients themselves, although only a few studies have 
investigated this issue.  
The objectives of this thesis were to examine vulnerability factors for anxiety in 
ICD patients and to examine the role of anxiety for patient-centered and clinical 
outcomes. In addition, anxiety in partners of ICD patients was investigated. ICD patients 
and their partners completed questionnaires on psychological variables at the time of 
implantation, and 2, 12, and 18 months post-implantation. In this chapter, the main 
findings of this thesis are summarized and discussed. Limitations and strengths of the 
research as well as implications for clinical practice and research are also discussed. 
 
VULNERABILITY FACTORS FOR ANXIETY IN ICD TREATMENT 
The first part of this thesis presented studies on vulnerability factors for anxiety in ICD 
patients. Findings on both short-term (including 2 months post-implantation) and longer-
term (12 months post-implantation) follow-up are discussed. 
Chapter 2 showed that clinically relevant levels of self-reported anxiety were 
present in 46% of patients at baseline and in 36% of patients at 2 months post-
implantation, although mean levels of self-reported anxiety were equal at both time points. 
These prevalences are in the range of prevalences reported in previous research
2, 7
. Despite 
similar levels at baseline, shocked patients exhibited higher levels of self-reported anxiety 
at follow-up as compared to non-shocked patients. Type D personality and anxiety 
sensitivity were the only vulnerability factors for self-reported anxiety and interviewer-
rated anxiety, adjusting for shocks, gender, age, marital status, education, ICD indication, 
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etiology, and comorbidity. Regarding Type D personality, the present findings are in line 
with those from previous research, as one cross-sectional study found an association 
between Type D and anxiety
8
 and another study reported a large effect size of Type D 
personality for anxiety
9
. Regarding anxiety sensitivity, two previous studies did not find a 
clear relationship with anxiety in ICD patients
10, 11
. Although Lemon et al.
11
 reported a 
significant relationship at the time of implantation, anxiety sensitivity was not related to 
changes of anxiety. This may be due to a power problem as only 21 patients completed 
the follow-up assessments. The nonsignificant results in the study by Hegel et al.
10
 may 
either also be due to limited power (range of N 21-38), or to the use of the trait-version of 
the STAI instead of state version or the longer time since ICD implantation (mean of 4.2 
years). Thus, our study is the first to report an independent predictive effect of both Type 
D personality and anxiety sensitivity for anxiety in ICD patients. The nonsignificant effect 
of shocks for anxiety may be due to limited power but may also reflect the actual 
relationship, since other studies also demonstrated that shocks were unrelated to anxiety
12, 
13
. However, as there are also prospective studies which reported an effect of shocks on 
anxiety
9, 14, 15
 and an adverse effect of ≥ 5 shocks, but not of < 5 shocks, on emotional 
states
16
, future studies on this relationship are warranted
17
. Our study shows that ICD 
indication was unrelated to anxiety, which is in line with previous studies
9, 18, 19
. 
Chapter 3 focused on ICD recall because of potential malfunctioning of particular 
ICDs as a determinant of anxiety. Although mean levels of anxiety did not differ between 
baseline and extra device evaluation, a significantly higher proportion of patients 
experienced highly increased levels of anxiety after additional device evaluation (24.2%) 
as compared to the time of ICD implantation (6.1%). Hence, ICD recall may also be a 
vulnerability factor for anxiety. This is in line with an older study which demonstrated 
that ICD recall negatively affected confidence in the ICD
20
. In addition, a vignette study 
showed that patients would be concerned about ICD recall, regardless of the brand that 
was recalled
21
. In contrast, Cuculi et al.
22
 reported that distress levels in patients with ICD 
recall were not increased, as mean distress levels of these patients were within the normal 
range and a control group of ICD patients with unaffected devices reported similar levels. 




Chapter 4 presented a large prospective study on chronic anxiety, which showed 
that over 50% of patients who experienced increased anxiety levels at the time of 
implantation were still anxious after 12 months of follow-up. Type D personality and 
diabetes were identified as vulnerability factors, as Type D personality was associated 
with a 2.8-fold risk to experience chronic anxiety and diabetes with a 4.6-fold risk, 
independent of various demographic and clinical variables. Although prior research in 
ICD patients showed that diabetes was unrelated to anxiety
9
, a study in heart failure 
patients showed that comorbid diabetes and angina were related to anxiety
23
. Diabetes 




; we have no explanation 
for the inconsistent results. The finding of Type D personality corroborates the results of 
the short-term study reported in Chapter 2. Similarly, shocks and ICD indication were not 
related to chronic anxiety, which also expands the findings of Chapter 2. Anxiety 
sensitivity could not be included in this study as this construct was not assessed in the 
MIDAS study
26
, which was part of this particular investigation. 
While previous studies examined changes in mean distress scores, Chapter 5 
focused on trajectories of anxiety and depressive symptoms in the first year following 
ICD implantation. Four trajectories were found for both anxiety and depressive 
symptoms, with very low (8%), low (53%), mildly (35%), and severely (4%) anxious 
groups and correspondingly labeled depressive groups (respectively, 38%, 37%, 17%, and 
8%). Trajectories were relatively stable, although particularly depressive trajectories 
showed some initial within-class change. A decline of symptom levels after ICD 
implantation is in line with other studies
27, 28
, but our results also support previous studies 
showing a stable course of symptoms from one month to five years post-       
implantation
7, 13, 18
. This study also demonstrated that anxiety is more prevalent in ICD 
patients as compared to depression, which was also reported in the review by Sears et al.
2
 
Finally, comparable to previous chapters, Type D personality and anxiety sensitivity were 
the most prominent predictors of trajectories, while ICD indication and appropriate ICD 
therapies were unrelated to trajectories.  
 Overall, the findings of the first part of this thesis are graphically shown in    
Figure 1, with significant associations being presented in bold face. This part emphasizes 
the prevalence and chronicity of anxiety in ICD patients. ICD indication, etiology, and 
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ICD shocks were all unrelated to anxiety, but patients with ICD recall and diabetes were 
at increased risk to experience anxiety. In terms of psychological risk factors, both Type D 
personality and anxiety sensitivity were independently associated with increased anxiety 
in ICD patients. 
 






















THE ROLE OF ANXIETY IN THE OUTCOME OF ICD TREATMENT  
Considering the high prevalence of anxiety, it is essential to evaluate the influence of 
anxiety on patient-centered and clinical outcomes in ICD patients. Previous studies found 
that anxiety in ICD patients is related to low treatment satisfaction
29
, impaired quality of 
life
30, 31
, and higher pain intensity of ICD shocks
32
. Moreover, anxious patients may also 
be at increased risk to experience ventricular arrhythmias, although these findings are 
inconclusive
5, 6
. Therefore, part II of this thesis focused on empirical studies examining 
the role of anxiety for outcomes in ICD patients. In addition, treatment of anxiety is also 
important. Hence, we conducted a systematic review of studies investigating interventions 
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Chapter 6 examined the role of general anxiety versus disease-specific anxiety for 
patient-centered outcomes. The shared variance between these anxiety dimensions ranged 
from 5% tot 12%, suggesting uniqueness of dimensions. Anxiety dimensions were 
differentially associated with outcomes: patient concerns about the ICD and feelings of 
disability were associated with general as well as disease-specific anxiety. However, 
clinical anxiety was predicted by general anxiety only and cardiopulmonary 
symptomatology by disease-specific anxiety only. These results demonstrate a differential 
but also independent predictive value of general and disease-specific anxiety, which has 
not been investigated before. In addition, shocks and comorbidity were related to feelings 
of disability, and shocks were also associated with patient concerns about the ICD, while 
comorbidity was also related to cardiopulmonary symptomatology. Shocks have been 
related to patient concerns about the ICD in some
14, 33
 but not all
34, 35
 studies. Results may 
depend on the instrument used for measuring ICD concerns. Education, working status, 
smoking, etiology, and use of psychotropic medication were unrelated to the outcomes.  
The following two chapters center on psychological predictors of ventricular 
arrhythmias for which appropriate ICD therapies (ATPs or shocks) were delivered. 
Chapter 7 reported three endpoints, including occurrence of ≥ 1 ventricular arrhythmia(s) 
with appropriate therapies, ≥ 5 ventricular arrhythmias with appropriate therapies, and ≥1 
shocks. While ICD indication (secondary prevention) was associated with a 2.5-fold risk 
of arrhythmia for all three endpoints, increased anxiety (2.3-fold risk) and ischemic 
etiology predicted the occurrence of ≥ 5 ventricular arrhythmias. Previous research also 
reported a relationship between anxiety and appropriate ICD therapies
6
. However, this 
particular study reported a relationship between anxiety and ≥ 1 appropriate therapies 
whereas in our study anxiety was only related to ≥ 5 appropriate therapies but not to ≥ 1 
appropriate therapies. Another study also found that anxiety was not related to ≥ 1 
shocks
5
, which was supported by our results. In sum, anxiety may be related to life-
threatening arrhythmias, but future research is warranted to clarify inconsistent findings. 
Chapter 8 compared the importance of anxiety, depressive symptoms, Type D 
personality, and their interaction effects for ventricular arrhythmias with appropriate ICD 
therapies. This is the first study that examined the independent predictive value of several 
psychological variables at the same time. Only the combined presence of increased 
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anxiety and Type D personality was significantly related to appropriate ICD therapies. 
Anxiety by Type D personality was associated with a 2.3-fold independent risk for 
arrhythmias and secondary prevention with a 2.1-fold risk, adjusting for gender, age, and 
etiology. Given the inconsistent results of previous studies regarding anxiety and 
ventricular arrhythmias
5, 6
, these results are very important, as they suggest that the 
combined presence of anxiety and Type D personality may be detrimental rather than the 
presence of anxiety alone. In addition, these results may give more insight into the 
relationship between Type D personality and morbidity and mortality
36
, at least for a 
subgroup of Type D patients. 
Given the high prevalence of anxiety and other psychological problems in ICD 
patients, studies have examined psychological interventions in ICD patients. Chapter 9 
provides a systematic review of these studies. Most studies were small-scale randomized 
controlled intervention trials. Evidence from these trials suggests anxiety may best be 
treated by a multi-factorial approach using a cognitive behavioral component together 
with exercise training. In contrast, the results were inconclusive to present 
recommendations for interventions regarding depressive symptoms and quality of life. 
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Figure 2 schematically shows the results of the second part of this thesis. Anxiety 
alone and in combination with a Type D personality was associated with appropriate ICD 
therapies, independent of ICD indication. In addition, general anxiety and disease-specific 
anxiety were differentially related to patient-centered outcomes and interviewer-rated 
anxiety. Shocks and comorbidity were also associated with some of these outcomes. Our 
review of psychological intervention studies suggests that patients with anxiety may be 
well treated with a combination of cognitive-behavioral therapy and exercise training. 
 
THE ROLE OF PARTNERS IN ICD TREATMENT 
Previous parts of this thesis focused on anxiety in ICD patients, but attention should also 
be given to anxiety in partners, because partners may be at least as anxious as ICD 
patients themselves
8, 28, 37, 38
. In addition, as lack of social support may be related to 
increased emotional distress
39
, not having a partner may also be associated with distress, 
especially in Type D patients who have fewer social ties and experience less social 
support as compared to non-Type Ds
40, 41
. Moreover, Type D personality is associated 
with adverse outcomes
36
, but not all Type D patients are at increased risk. 
Chapter 10 examined the role of partner status and Type D personality for 
psychological distress in a pooled sample of ICD patients and myocardial infarction 
patients. This short-term follow-up study showed that Type D patients without a partner 
had a 6- to 8-fold risk to experience increased levels of anxiety and depressive symptoms 
as compared to non-Type D patients with a partner, followed by a 3-fold risk for Type D 
patients with a partner and a 2- to 3-fold risk for non-Type D patients without a partner. 
Since this pattern of results was obtained in both patient groups, we concluded that not 
having a partner may negatively affect emotional distress levels in ICD patients with a 
Type D personality. 
Chapter 11 showed that ICD patients and partners reported equal levels of anxiety 
symptoms and also that the proportion of patients and partners experiencing increased 
levels of anxiety was similar, which confirms findings of previous small-scale or cross-
sectional studies
8, 28, 37, 38
. Comparable with the patient studies presented in this thesis, 
Type D personality and anxiety sensitivity of the partner were vulnerability factors of 
anxiety and posttraumatic stress symptoms (PTSS) in partners, and ICD indication and 
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shocks experienced by the patient were not. In addition, anxiety sensitivity acted as a 
mediator in the relationship between Type D personality and PTSS in partners.  
Chapter 12 reported that the proportion of Type D patients was significantly lower 
after the start of the partner substudy as compared to before the start of the substudy. In 
addition, during the partner substudy, nonparticipation of partners was more prevalent 
among partners of Type D patients as compared to partners of non-Type D patients. 
Hence, the addition of a partner substudy may affect participations rates of both patients 
with a Type D personality and their partners, which in turn may influence generalizability 
of results. We speculated that the partner substudy may trigger partners to encourage the 
patient to disclose their negative feelings, which may be unpleasant for the Type D patient 
and may result in nonparticipation. 
The results regarding research involving partners is schematically presented in 
Figure 3. Distress levels of patients were influenced by partner status, with Type D 
patients without a partner having the highest risk to experience emotional distress. In 
addition, partners of ICD patients experience as least as much anxiety as ICD patients 
themselves. Anxiety levels in partners were not related to ICD indication and shocks. 
However, partners with a Type D personality or anxiety sensitivity were at increased risk 
to experience anxiety. Importantly, starting a substudy in partners of ICD patients may 
lead to nonparticipation of Type D patients and their partners, which may influence 
generalizability of results.  
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LIMITATIONS AND STRENGTHS OF THE PRESENT THESIS 
The present research has a number of limitations. First, no information was available on 
nonresponse rate, i.e., the proportion of patients who were invited to participate but 
declined. However, attrition rate was consequently reported as were differences between 
patients in- versus excluded from analyses. Although some studies reported no differences 
(Chapter 4 and 7), other studies reported that excluded patients more often had a Type D 
personality, no partner, and increased anxiety as compared to included patients (Chapter 
2, 5, 6, 8, and 10), which may have limited the generalizability of results. Second, baseline 
questionnaires were completed between 0 and 3 weeks post-implantation, which means 
that baseline levels of distress do not reflect pre-implantation levels. However, personality 
assessment may not be influenced by the time of completion of questionnaires. Third, the 
power to find an association between shocks and outcomes may have been limited 
because of a low incidence of shocks, especially in the short-term follow-up studies. 
Fourth, the study in Chapter 3 involved a small sample. Fifth, we had no information on 
participation in cardiac rehabilitation and use of psychopharmaca. These factors may have 
influenced anxiety levels. Sixth, addition of the partner substudy may have influenced 
patient participation which in turn may have affected results and generalizability. Finally, 
it was not possible to investigate clinical factors including ejection fraction and functional 
class because these data were missing for many patients. 
Nevertheless, this thesis reports the results of a large prospective long-term multi-
center study focusing on anxiety in ICD patients and their partners. Both self-reported 
anxiety and interviewer-rated anxiety were investigated. These prospective studies are the 
first to show that Type D personality and anxiety sensitivity independently predict 
anxiety. In addition, several psychological factors were simultaneously investigated in 
relation to ventricular arrhythmias. Finally, this is one of the few prospective studies on 
distress in partners of ICD patients. 
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IMPLICATIONS FOR CLINICAL PRACTICE AND FUTURE RESEARCH  
The studies presented in this thesis generate a number of implications for clinical practice 
as well as recommendations for future research.  
Chronic anxiety in the first year post-implantation may be present in a quarter of 
patients (Chapter 4). Similarly, after a small initial decline, levels of anxiety and 
depression tended to be relatively stable within the first year post-implantation     
(Chapter 5). Future studies need to a) replicate these findings, with inclusion of more time 
points as well as pre-implantation levels of anxiety, and b) investigate the prognostic 
value of trajectories. Given the probable triggering effect of anxiety and depression on 
ventricular arrhythmias
4, 6
, early identification of ICD patients at risk for emotional 
distress is important. Identification of anxiety and depression may already be realized at 
the time of implantation, as these levels seem to represent the level of anxiety during the 
first year post-implantation. The state version of the STAI may be used as a screening tool 
for anxiety, because the STAI is an adequate measure of general anxiety and is easy to 
administer. To screen for depression, we used the Beck Depression Inventory, which is 
also an easy to administer questionnaire although it comprises 21 items. 
General anxiety and disease-specific anxiety were differentially predictive for 
patient-centered outcomes in ICD patients (Chapter 6). Future research may examine the 
possible differential effect towards clinical endpoints, including ventricular arrhythmias 
and mortality. To measure disease-specific anxiety, we recommend the use of two short  
5-item scales deduced from the Cardiac Anxiety Questionnaire, measuring fear and worry 
about heart sensations and cardioprotective avoidance of activities that could bring on 
symptoms (Chapter 6). However, these scales need to be validated first and cut-off values 
indicating increased levels of disease-specific anxiety need to be determined. 
The results of the present thesis indicate that some (ICD recall, shocks and 
diabetes) but not all (ICD indication and etiology) clinical factors may be related to 
anxiety in ICD patients. As ICD recall may lead to increased anxiety (Chapter 2), 
psychological support for patients with ICD recall is warranted. Next, shocks were related 
to self-reported anxiety (Chapter 2), feelings of disability, and patient concerns about the 
ICD (Chapter 6), but not to interviewer-rated anxiety (Chapter 2 and 6), chronic anxiety 
(Chapter 4), trajectories of anxiety (Chapter 5), and anxiety or PTSS in partners of 
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patients (Chapter 11). Importantly, limited power was a problem in some of these studies. 
However, prior research also contains inconsistencies regarding the role of shocks for 




 but not all
12, 13
 studies 
demonstrating a relationship between shocks and anxiety. A final point regarding shocks 
refers to the number of shocks. The CIDS trail reported that having had ≥ 5 shocks was 
associated with a poorer quality of life, but ≥ 1 shocks was not
16
. Our study did not have 
sufficient power to study the effect of having had ≥ 5 shocks on patient-centered 
outcomes, but future research may investigate this issue.  
Regarding diabetes, we found a relationship with chronic anxiety in ICD patients 
(Chapter 4). Diabetes has also been linked to depression and anxiety in other cardiac 
populations
23, 42
, but other studies found no relationship between diabetes and distress
9
. 
Therefore, more research is needed on the role of diabetes for emotional distress in ICD 
patients. Regarding ICD indication, our results indicated no relationship with anxiety in 
patients and partners (Chapter 2, 4, 5, and 11), which is in line with all previous studies 
on this topic
9, 18, 19
. However, comparable to the point mentioned for shocks, the 
relationship between ICD indication and distress may be influenced by other factors that 
have been related to distress, including personality factors. Future research is needed to 
explore this issue. 
A non-cardiac factor that may play an important role in the relationship between 
shocks and patient-centered outcomes is personality. Future research needs to examine 
further whether Type D personality and anxiety sensitivity influence the effect of shocks 
on emotional distress. Regarding vulnerability factors for anxiety, future research should 
not only investigate clinical factors but also personality dispositions, as our studies 
showed that Type D personality and anxiety sensitivity may predispose patients for 
increased levels of anxiety (Chapter 2, 4, and 5). As these personality traits were often 
independently associated with anxiety, they may have a differential influence on anxiety. 
In addition, the combined presence of Type D personality and increased anxiety predicted 
life-threatening arrhythmias (Chapter 8). In clinical practice, it may be timely to 
standardize screening for Type D personality, and possibly also for anxiety sensitivity. 
Especially Type D patients without a partner should be closely monitored. In addition, 
partners may also be screened for Type D personality and anxiety sensitivity, as these 
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were predictors of anxiety in partners (Chapter 11). In clinical practice, screening may be 
performed by ICD nurses or other health-care professionals. The 14-item Type D Scale 
and 16-item Anxiety Sensitivity Index reflect short, adequate, and easy to administer 
questionnaires to screen for Type D personality and anxiety sensitivity. The DS14 also has 
established cut-off values to classify a person as Type D
43
, but the ASI needs further 
evaluation regarding cut-off values to indicate clinically relevant levels. In addition, some 
physical symptoms in ICD patients may reflect an actual threat for survival and several 
items of the ASI may therefore measure realistic concerns
11
. 
The role of psychological factors as precipitants of life-threatening arrhythmias 
should be further explored. These studies may incorporate various emotions besides 
anxiety, as depression, anger, fatigue, vigor, and confusion have also been linked to 
ventricular arrhythmias
4-6
. In addition, the predictive value of personality characteristics 
such as Type D personality, but also anxiety sensitivity, may be further investigated. 
Importantly, ejection fraction and functional class should be included in this research, as 
these factors are associated with arrhythmias
44-46
. Due to missing values, these factors 
could not be included in our research. A final recommendation for future research in this 
regard concerns the investigation of physiological mechanisms that may account for the 
relationship between psychological factors and life-threatening arrhythmias. 
As partner levels of anxiety were as high as levels in patients (Chapter 11), future 
research should also focus on anxiety in partners of ICD patients. PTSS should also be 
included in partner research; our study was the first to investigate these symptoms in 
partners. However, even in patients, only a few studies have focused on PTSS, and these 
were mostly case-studies
47
. Our results suggest that ICD indication and shocks are not 
related to distress in partners, but future studies are warranted. Another essential topic of 
future research is the influence of partner characteristics and distress on patient well-
being. However, research involving both ICD patients and their partners should take into 
account the possible negative effect of the partner study on participation rates, especially 
among Type D patients and their partners.  
Finally, the research presented in this thesis necessitates psychological intervention 
in ICD patients, as anxiety and depression levels may remain high in a subgroup of ICD 
patients. In addition, anxiety, Type Personality, and anxiety sensitivity were associated 
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with adverse outcomes. According to the review presented in Chapter 9, treatment of 
anxiety may comprise cognitive behavioral therapy combined with exercise training. 
Cognitive behavioral therapy may address anxiety, apprehensions, avoidance behavior, 
fear of shocks, and distorted cognitions. Stress management training and relaxation 
therapy may also be applied, as most of the cognitive behavioral interventions studies 
included these trainings as adjunct therapies. In addition, as patients with disease-specific 
anxiety want to avoid physical exercise
48
, these patients may also benefit from exercise 
training. Management of depressive patients may be realized by comprehensive cardiac 
rehabilitation, because our review of psychological interventions demonstrated this to be 
effective. 
Interventions for patients with a Type D personality or anxiety sensitivity have not 
been systematically investigated in trials. Sher
49
 has proposed a number of interventions 
which may reduce distress in Type D patients and improve the ability to socialize. 
Suggested interventions included cognitive behavioral therapy, social skills training, 
interpersonal psychotherapy, and progressive muscle relaxation. The following 
considerations may also be implemented in intervention. Although changing personality 
itself may be very difficult, behaviors arising from the personality trait may be targeted. 
For instance, Type D patients perform fewer health-related behaviors
41
 and inadequate 
consultation behavior
50
 as compared to non-Type D patients. Therefore, interventions may 
address self-management and self-care abilities of the Type D patient. In addition, the 
socially inhibited Type D patients may benefit from a supportive and stimulating social 
network. Hence, interventions should focus on consolidation of the social network. 
Furthermore, since Type D patients experience a number of negative emotions, another 
target of intervention may comprise coping abilities for these emotions. 
Interventions for anxiety sensitivity may also embrace cognitive behavioral 
therapy, including education and arousal reduction, cognitive-restructuring techniques, 
and exposure to the somatic sensations which are feared by the patients
51
. Interoceptive 
exposure may be accomplished by means of exercise. A recent study showed that both 
high-intensity exercise and low-intensity exercise were successful in reducing anxiety 
sensitivity levels, although high-intensity exercise was associated with more rapid 
reductions in anxiety sensitivity levels
52
. 
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CONCLUDING REMARKS 
Anxiety represents a major issue in ICD patients, as anxiety levels in a quarter of patients 
tended to be chronic. ICD indication, etiology, and shocks appear less important for 
anxiety, although results regarding shocks were inconsistent. Personality factors, 
including Type D personality and anxiety sensitivity, were related to anxiety and should 
be incorporated in future studies on vulnerability factors for anxiety. Future research may 
also investigate whether inter-individual differences exist regarding the impact of clinical 
factors on patient-centered outcomes, as this impact may be influenced by personality 
traits or other psychological factors. Anxiety alone and in combination with a Type D 
personality was associated with the occurrence of ventricular arrhythmias in ICD patients. 
However, these findings should be replicated in future studies, and importantly, 
mechanisms of this relationship should be studied. Our review on psychological 
interventions indicated that anxiety in ICD patients may be treated with cognitive-
behavioral therapy and exercise training, although larger studies are needed. 
Anxiety levels in partners of ICD patients were as high as in patients themselves, 
but were not influenced by disease etiology or ICD indication. However, partners with a 
Type D personality or anxiety sensitivity were at increased risk to experience anxiety 
levels. Although this calls for more research in partners of patients, our results also 
showed that a substudy in partners may be associated with nonparticipation rates of Type 
D patients and their partners. Future research has to take this issue into account. 
 Overall, the results of this thesis suggest that psychological factors are important in 
ICD treatment. A subgroup of patients as well as partners experiences increased levels of 
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EEN IMPLANTEERBARE DEFIBRILLATOR 
Ongeveer 50% van de overlijdens door een cardiovasculaire ziekte wordt veroorzaakt 
door een plotse hartdood
1
. Plotse hartdood is in de meeste gevallen (85%) het gevolg van 
ventriculaire hartritmestoornissen
2
. Patiënten die dergelijke levensbedreigende 
ritmestoornissen hebben ervaren (secundaire preventie) of die een verhoogd risico hebben 
op deze ritmestoornissen (primaire preventie) worden behandeld met een implanteerbare 
cardioverter defibrillator (ICD)
3
. De ICD kan de ritmestoornissen niet voorkomen, maar 
wel beëindigen door middel van een schok, cardioversie, of antitachycardia pacing 
(ATP)
4
. Tijdens ATP geeft de ICD korte elektrische impulsen aan het hart die 10-20% 
sneller gaan dan de ritmestoornis. Door de complexe technologie van de ICD wordt de 
betrouwbaarheid soms betwijfeld, waardoor patiënten met deze ICDs opgeroepen moeten 
worden voor extra controle (ICD-recall). 
 
PSYCHOLOGISCHE GEVOLGEN VAN ICD IMPLANTATIE 
Veel patiënten ervaren geen psychologische problemen na ICD-implantatie. Er is echter 
een subgroep patiënten die wel psychologische problemen vertonen na de ICD-
implantatie. Deze patiënten ervaren angst, depressie en een verminderde kwaliteit van 
leven en ze vertonen vaak vermijdingsgedragingen
5-7
. Vooral angst is een belangrijk 
probleem binnen de ICD-populatie. Studie schatten de prevalentie van klinische angst op 
13% tot 38% bij ICD-patiënten en van klinische depressie op 10% tot 15%
7
.  
Aanpassingsproblemen kunnen voortkomen uit verschillende bronnen, zoals de 
reanimatie, de diagnose van een levensbedreigende ziekte, en de onvoorspelbaarheid van 
de ritmestoornissen, maar ook de ICD-implantatie zelf kan een rol spelen
8
. Uit eerdere 
onderzoeken is gebleken dat de reden voor het krijgen van de ICD (primaire versus 
secundaire preventie) geen invloed heeft op angstniveaus
9, 10
. Bevindingen over de relatie 
tussen schokken en angst zijn daarentegen tegenstrijdig
9, 11, 12
. Aanpassingsproblemen 




Angst bij ICD-patiënten kan ook veroorzaakt worden door kwetsbaarheidfactoren 
die niet direct gerelateerd zijn aan de ICD zelf, zoals bijvoorbeeld leeftijd (≤ 50 jaar), 
geslacht (vrouw) en psychologische problemen in het verleden
9, 14
. Er zijn echter weinig 
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, op angst hebben onderzocht.  
 
PSYCHOLOGISCHE FACTOREN EN RISICO OP VENTRICULAIRE 
RITMESTOORNISSEN BIJ ICD-PATIËNTEN 
Het is belangrijk om risicofactoren voor ventriculaire ritmestoornissen te onderzoeken, 
omdat a) ICDs de ritmestoornissen niet kunnen voorkomen, b) de laatste jaren steeds meer 
ICDs worden geïmplanteerd vanwege uitbreiding van de preventie redenen, c) ICD- 
schokken kunnen leiden tot psychologische problemen en d) ICDs niet 100% effectief zijn 
in het beëindigen van ventriculaire ritmestoornissen. Onderzoeken hebben aangetoond dat 
klinische factoren, zoals een verlaagde pompfunctie
18
 en functionele klasse
19
, 
risicofactoren zijn voor ventriculaire ritmestoornissen, maar er is nog weinig bekend over 
de rol van psychologische factoren. Eerdere studies hebben een samenhang gevonden 
tussen depressie
20
, angst (maar niet depressie en woede)
21
 en woede (maar niet angst en 
depressie)
22
 en ventriculaire ritmestoornissen. Een andere studie heeft aangetoond dat 
ICD-patiënten met angst en woede als persoonlijkheidskenmerken een hogere kans 




DE ROL VAN DE PARTNER BIJ BEHANDELING MET EEN ICD 
Patiënten die geen partner hebben zijn mogelijk meer kwetsbaar voor angst in vergelijking 
met patiënten die wel een partner hebben. Vooral bij Type D patiënten, die toch al minder 
sociale steun ervaren
14, 24
, kan het al dan niet hebben van een partner een rol spelen ten 
aanzien van negatieve emoties. Daarnaast kunnen partners van ICD-patiënten ook angst 
ervaren. De reanimatie van de patiënt en de kans op nieuwe levensbedreigende 
hartritmestoornissen kunnen leiden tot negatieve emoties bij partners. Ondanks studies die 
aangetoond hebben dat angstniveaus bij partners en patiënten mogelijk even hoog zijn
7
, 
hebben nog weinig onderzoeken zich gericht op partners van ICD-patiënten. 
 
DOEL VAN DIT PROEFSCHRIFT 
Dit proefschrift richt zich voornamelijk op angst bij ICD-patiënten, omdat a) angst meer 
voorkomt bij ICD-patiënten in vergelijking met depressie
25
, b) angst veroorzaakt kan 
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worden door factoren rondom de behandeling met een ICD, zoals reanimatie en de 
onvoorspelbaarheid van ritmestoornissen, en c) angst gerelateerd lijkt te zijn aan 
verschillende negatieve uitkomsten. In dit proefschrift verwijst angst voornamelijk naar 
algemene symptomen van toestandsangst. Dit is een voorbijgaande emotionele toestand, 
die gekenmerkt wordt door bezorgdheid en spanning, maar ook door fysiologische 
arousal. Naast algemene angst wordt ook aandacht besteed aan ziektespecifieke angst en 
klinische angst gemeten met een interview. 
Dit proefschrift rapporteert de bevindingen van een voortdurend onderzoek bij 
ICD-patiënten, waarbij we het volgende wilden onderzoeken 1) kwetsbaarheidfactoren 
voor angst bij ICD-patiënten, 2) de rol van angst voor uitkomsten inclusief 
ritmestoornissen en 3) angst bij partners van ICD-patiënten. De patiënten en hun partners 
werden geworven in het Catharina Ziekenhuis (Eindhoven) en het Amphia Ziekenhuis 
(Breda). 
 
SAMENVATTING VAN DE BELANGRIJKSTE RESULTATEN VAN DIT 
PROEFSCHRIFT 
 
Deel I Kwetsbaarheidfactoren voor angst bij ICD-patiënten  
In het eerste deel van dit proefschrift is gerapporteerd dat tijdens de implantatieperiode 
ongeveer 50% van de ICD-patiënten verhoogde angstniveaus ervaart (Hoofdstuk 2 en 4). 
Bij de helft van deze patiënten is het verhoogde angstniveau 1 jaar na de implantatie nog 
steeds aanwezig, wat betekent dat bij een kwart van de ICD-patiënten verhoogde 
angstniveaus chronisch aanwezig zijn (Hoofdstuk 4). Ook in een andere studie werd 
gevonden dat angstniveaus, na een initiële daling, relatief stabiel bleven (Hoofdstuk 5). 
ICD-indicatie, schokken en vaatlijden waren niet gerelateerd aan de angstniveaus 
(Hoofdstuk 2, 4 en 5). Daarentegen hadden patiënten met een ICD-recall of diabetes wel 
een verhoogde kans op angst (Hoofdstuk 3 en 4). Voor wat betreft psychologische 
factoren hadden de patiënten met een Type D persoonlijkheid of angstgevoeligheid een 
significant verhoogde kans om angst te ervaren (Hoofdstuk 2, 3 en 5).  
De gevonden prevalentie van angst komt overeen met eerdere onderzoeken
7, 26
. 
Toekomstig onderzoek moet de stabiliteit van angst bevestigen, maar kan zich ook richten 
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op de prognostische waarde van deze stabiele angstniveaus. Desalniettemin lijkt het 
belangrijk om patiënten met angst tijdig te identificeren. 
Onze bevindingen omtrent ICD-indicatie komen overeen met resultaten van eerdere 
onderzoeken
5, 9, 10, 27, 28
, namelijk dat ICD-indicatie geen invloed heeft op angst, depressie 
en kwaliteit van leven. Dat schokken niet onafhankelijk gerelateerd waren aan 
angstniveaus zou de werkelijke relatie kunnen weergeven omdat sommige eerdere 
onderzoeken ook geen relatie gevonden hadden
11, 29
. Niettemin zijn er ook onderzoeken 
die wel een verband hadden aangetoond
30, 31
 of die vonden dat met name het ervaren van  
≥ 5 schokken een negatieve invloed heeft
32
. Toekomstig onderzoek is daarom nodig, 




Vergelijkbaar met onze studies, hadden eerdere onderzoeken binnen de ICD-
populatie ook een verband aangetoond tussen Type D persoonlijkheid en angst
9, 14
. 
Daarentegen hadden onderzoeken gericht op angstgevoeligheid bij ICD-patiënten geen 





Deel II De rol van angst voor uitkomsten 
Het tweede deel van dit proefschrift beschrijft dat angst, zowel op zichzelf (Hoofdstuk 7) 
als in combinatie met Type D persoonlijkheid (Hoofdstuk 8), gerelateerd is aan het 
optreden van levensbedreigende ritmestoornissen. Verder werd aangetoond dat algemene 
en ziektespecifieke angst op een verschillende manier gerelateerd waren aan uitkomsten, 
zoals invaliditeitsbeleving en zorgen van de patiënt omtrent de ICD (Hoofdstuk 6). 
Schokken en co-morbiditeit waren ook aan bepaalde uitkomsten gerelateerd. Tenslotte 
werd uit het review geconcludeerd dat behandeling van angst het beste verwezenlijkt kan 
worden met cognitieve-gedragstherapie in combinatie met beweging (Hoofdstuk 9). 
Resultaten uit eerdere onderzoeken naar het verband tussen angst en 
levensbedreigende hartritmestoornissen waren inconsistent
20, 21
. Volgens onze resultaten 
zou juist de gecombineerde aanwezigheid van angst en Type D persoonlijkheid ook 
belangrijk kunnen zijn. Meer onderzoek is nodig om de relatie tussen angst en 
ritmestoornissen te verhelderen. 
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Algemene en ziektespecifieke angst waren verschillend voorspellend voor bepaalde 
uitkomsten. Toekomstige studies zouden kunnen onderzoeken of dit ook geldt ten aanzien 
van klinische uitkomsten zoals ritmestoornissen en overlijden. 
 
Deel III De rol van partners bij behandeling met een ICD 
Het derde deel van dit proefschrift beschrijft onderzoeken met betrekking tot partners van 
ICD-patiënten. Met name bij Type D patiënten is partnerstatus belangrijk omdat Type Ds 
zonder partner de grootste kans hadden op verhoogde angst- en depressieniveaus in 
vergelijking met de andere patiënten (Hoofdstuk 10). Verder werd aangetoond dat angst 
bij partners even hoog is als bij patiënten (Hoofdstuk 11). Net als bij patiënten, werden de 
angstniveaus van de partner niet beïnvloed door ICD-indicatie of -schokken. Partners met 
een Type D persoonlijkheid of angstgevoeligheid hadden wel een verhoogde kans om 
angst te ervaren. Tenslotte werd duidelijk dat het uitvoeren van een substudie bij partners 
van ICD-patiënten een negatieve invloed heeft op deelname aan de studie (Hoofdstuk 12). 
Na het opstarten van de partner substudie bleek het deel patiënten met een Type D 
persoonlijkheid namelijk veel lager te zijn in vergelijking met het deel Type D patiënten 
vóór de start van de substudie. Ook werd gevonden dat deelname van partners van Type D 
patiënten veel lager was in vergelijking met de deelname van partners van niet Type D 
patiënten. 
Uit het eerste deel van dit proefschrift bleek dat patiënten met een Type D 
persoonlijkheid een verhoogde kans hebben op angst en uit dit derde deel blijkt dat met 
name de Type D patiënten zonder partner een verhoogde kans hebben op angst. Omdat het 
tweede deel ook had aangetoond dat angstige Type D personen een verhoogde kans 
hebben op ritmestoornissen, lijkt het erg belangrijk om in de klinische praktijk te screenen 










1. Zipes DP, Wellens HJ. Sudden cardiac death. Circulation 1998;98:2334-51. 
2. Bayes de Luna A, Coumel P, Leclercq JF. Ambulatory sudden cardiac death: 
mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. 
Am Heart J 1989;117:151-9. 
3. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for 
management of patients with ventricular arrhythmias and the prevention of sudden 
cardiac death: a report of the American College of Cardiology/American Heart 
Association Task Force and the European Society of Cardiology Committee for 
Practice Guidelines (Writing Committee to Develop Guidelines for Management of 
Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac 
Death). J Am Coll Cardiol 2006;48:e247-e346. 
4. Glikson M, Friedman PA. The implantable cardioverter defibrillator. Lancet 
2001;357:1107-17. 
5. Pedersen SS, Theuns DA, Muskens-Heemskerk A, et al. Type D personality but not 
implantable cardioverter-defibrillator indication is associated with impaired health-
related quality of life 3 months post-implantation. Europace 2007;9:675-80. 
6. Lemon J, Edelman S, Kirkness A. Avoidance behaviors in patients with 
implantable cardioverter defibrillators. Heart Lung 2004;33:176-82. 
7. Sears SF, Todaro JF, Lewis TS, et al. Examining the psychosocial impact of 
implantable cardioverter defibrillators: a literature review. Clin Cardiol 
1999;22:481-9. 
8. Pauli P, Wiedemann G, Dengler W, et al. Anxiety in patients with an automatic 
implantable cardioverter defibrillator: what differentiates them from panic patients? 
Psychosom Med 1999;61:69-76. 
9. Pedersen SS, Theuns DA, Erdman RA, et al. Clustering of device-related concerns 
and Type D personality predicts increased distress in ICD patients independent of 
shocks. Pacing Clin Electrophysiol 2008;31:20-7. 
10. Groeneveld PW, Matta MA, Suh JJ, et al. Quality of life among implantable 
cardioverter-defibrillator recipients in the primary prevention therapeutic era. 
Pacing Clin Electrophysiol 2007;30:463-71. 
Chapter 14 
262 
11. Crossmann A, Pauli P, Dengler W, et al. Stability and cause of anxiety in patients 
with an implantable cardioverter-defibrillator: a longitudinal two-year follow-up. 
Heart Lung 2007;38:87-95. 
12. Pedersen SS, Van den Broek KC. ICD shocks and their adverse impact on patient-
centered outcomes: Fact or Fiction? J Am Coll Cardiol, in press. 
13. Sears SF, Conti JB. Psychological aspects of cardiac devices and recalls in patients 
with implantable cardioverter defibrillators. Am J Cardiol 2006;98:565-67. 
14. Pedersen SS, Van Domburg RT, Theuns DA, et al. Type D personality is associated 
with increased anxiety and depressive symptoms in patients with an implantable 
cardioverter defibrillator and their partners. Psychosom Med 2004;66:714-9. 
15. Hegel MT, Griegel LE, Black C, et al. Anxiety and depression in patients receiving 
implanted cardioverter-defibrillators: a longitudinal investigation. Int J Psychiatry 
Med 1997;27:57-69. 
16. Lemon J, Edelman S. Psychological adaptation to ICDs and the influence of 
anxiety sensitivity. Psychol Health Med 2007;12:163-71. 
17. Denollet J. DS14: standard assessment of negative affectivity, social inhibition, and 
Type D personality. Psychosom Med 2005;67:89-97. 
18. Desai AD, Burke MC, Hong TE, et al. Predictors of appropriate defibrillator 
therapy among patients with an implantable defibrillator that delivers cardiac 
resynchronization therapy. J Cardiovasc Electrophysiol 2006;17:486-90. 
19. Whang W, Albert CM, Sears SF, et al. Depression as a predictor for appropriate 
shocks among patients with implantable cardioverter-defibrillators: results from the 
Triggers of Ventricular Arrhythmias (TOVA) study. J Am Coll Cardiol 
2005;45:1090-5. 
20. Dunbar SB, Kimble LP, Jenkins LS, et al. Association of mood disturbance and 
arrhythmia events in patients after cardioverter defibrillator implantation. Depress 
Anxiety 1999;9:163-8. 
21. Lampert R, Joska T, Burg MM, et al. Emotional and physical precipitants of 
ventricular arrhythmia. Circulation 2002;106:1800-5. 
22. Burg MM, Lampert R, Joska T, et al. Psychological traits and emotion-triggering of 
ICD shock-terminated arrhythmias. Psychosom Med 2004;66:898-902. 
Nederlandse Samenvatting 
263 
23. Williams L, O'Connor RC, Howard S, et al. Type D personality mechanisms of 
effect: the role of health-related behaviour and social support. J Psychosom Res 
2008;64:63-9. 
24. De Groot NMS, Bootsma M, Van der Wall EE, et al. The impact of an implantable 
cardioverter defibrillator: the Leiden follow-up study of ICD patients and their 
partners. Netherlands Heart Journal 2003;11:154-8. 
25. Van der Ploeg HM, Defares PB, Spielberger CD. Manual for the ZBV. A Dutch-
language adaptation of the Spielberger State-Trait Anxiety Inventory. Lisse: Swets 
& Zeitlinger B.V.; The Netherlands; 1980. 
26. Kamphuis HC, De Leeuw JR, Derksen R, et al. A 12-month quality of life 
assessment of cardiac arrest survivors treated with or without an implantable 
cardioverter defibrillator. Europace 2002;4:417-25. 
27. Bilge AK, Ozben B, Demircan S, et al. Depression and anxiety status of patients 
with implantable cardioverter defibrillator and precipitating factors. Pacing Clin 
Electrophysiol 2006;29:619-26. 
28. Sweeney MO, Wathen MS, Volosin K, et al. Appropriate and inappropriate 
ventricular therapies, quality of life, and mortality among primary and secondary 
prevention implantable cardioverter defibrillator patients: results from the Pacing 
Fast VT REduces Shock ThErapies (PainFREE Rx II) trial. Circulation 2005; 
111:2898-905. 
29. Burke JL, Hallas CN, Clark-Carter D. The psychosocial impact of the implantable 
cardioverter defibrillator: a meta-analytic review. Br J Health Psychol 2003;8:165-
78. 
30. Kamphuis HC, De Leeuw JR, Derksen R, et al. Implantable cardioverter 
defibrillator recipients: quality of life in recipients with and without ICD shock 
delivery: a prospective study. Europace 2003;5:381-9. 
31. Carroll DL, Hamilton GA. Quality of life in implanted cardioverter defibrillator 
recipients: the impact of a device shock. Heart Lung 2005;34:169-78. 
32. Irvine J, Dorian P, Baker B, et al. Quality of life in the Canadian Implantable 






Dit proefschrift is tot stand gekomen dankzij de ideeën, het werk, de hulp en de steun van 
een heleboel mensen, die ik graag wil bedanken in dit woord (in een redelijk willekeurige 
volgorde). 
Mijn enthousiasme voor onderzoek is ontstaan tijdens mijn afstudeeronderzoek in 
Antwerpen onder supervisie van Johan Denollet, mijn promotor. Johan, hiervoor wil ik je 
bedanken, maar nog meer voor jouw vertrouwen in mij en dat je mij hebt aangenomen op 
het ICD-project, ondanks mijn uitstapje van drie jaar zonder enige wetenschappelijke 
activiteit. Jouw goede begeleiding met een verantwoorde (?) dosis humor tijdens de 
gesprekken werkt erg stimulerend, ondanks de (niet altijd even hartelijk ontvangen) 
suggesties om op een andere manier naar de data te kijken. Ik ben vereerd dat ik de 
komende jaren deel mag blijven uitmaken van jouw onderzoeksgroep. 
Ivan Nyklíček, co-promotor, jou wil ik natuurlijk ook bedanken voor de goede 
begeleiding, de opbouwende kritiek en de tijd die je te pas en onpas voor me hebt 
vrijgemaakt (als dagelijkse begeleider van dit promotie-onderzoek heb ik volgens mij 
goed gebruik gemaakt van jouw openstaande deur). Van jou heb ik geleerd om te 
relativeren en stil te staan bij het ‘waarom’ (waarom zou dit een voorspeller zou van dat, 
etc). 
Albert Meijer, co-promotor, voor jouw inhoudelijke uitleg over cardiologische 
onderwerpen, kritische opmerkingen, suggesties voor verder onderzoek en voor alle 
andere hulp ben ik je dankbaar. Hopelijk wordt de samenwerking in de toekomst 
voortgezet. 
Mijn collega’s van de UvT wil ik graag bedanken voor de aangename 
werkomgeving, prettige sfeer en gezellige lunches (Floor bedankt voor je stiptheid, ga zo 
door). In het bijzonder wil ik een aantal (ex)collega’s bedanken: Ilona, voor het uitwerken 
en opzetten van de studie; Liesje en Viola, voor onderzoeksadviezen en gezelligheid in 
kamer P612; Susanne, Liesje, Robert, en Alien, voor hulp en gezelligheid op congressen; 
Nina, voor je uitleg, onder andere het over gebruik van computerprogramma’s; Robert, 
voor uitleg over statistische toetsen; Kim, voor de vlotte samenwerking bij de parenting 
Dankwoord (Aknowledgements) 
266 
papers; Angelique, voor jouw adviezen als recent gepromoveerde collega; Mariette, voor 
paraatheid en assistentie; en Susanne, voor deelname in de commissie, maar zeker ook 
voor de prettige samenwerking (ik hoop op een vruchtbare ICD toekomst). Ook Ton 
Heinen en Hans Dieteren wil ik graag bedanken voor hun behulpzaamheid. 
Medewerking van de ziekenhuizen is erg belangrijk, daarom wil ik graag de 
mensen bedanken van het Catharina Ziekenhuis en het Amphia Ziekenhuis die bij dit 
project betrokken waren, en in het bijzonder de volgende personen. (Catharina 
Ziekenhuis:) Pepijn, bedankt voor je enthousiaste en nauwe betrokkenheid bij dit project 
en voor alles wat je me geleerd hebt en nog steeds leert over ICDs en wat daar mee te 
maken heeft. Collega’s van de afdeling Cardiologie R&D van het Catharina Ziekenhuis, 
in het bijzonder Antoinette, bedankt voor jullie hulp en hartelijkheid. Het medisch archief, 
in het bijzonder Lizet, bedankt voor de bereidwilligheid om statussen keer op keer klaar te 
leggen. (Amphia Ziekenhuis:) John Bartels, bedankt voor je interesse in het onderzoek en 
de introductie van het onderzoek in het Amphia Ziekenhuis. Speciale dank aan het ICD-
team van het Amphia ziekenhuis, in het bijzonder Marco, bedankt voor jouw 
belangstelling voor dit onderzoek, hulp bij het opzetten, uitleg over cardiologische 
onderwerpen en kritische opmerkingen; en Eefje en Hidde, bedankt voor jullie inzet bij de 
inclusie van patienten. 
Onmisbaar voor dit type onderzoek is de medewerking van patiënten. Daarom wil 
ik hen hartelijk bedanken voor hun tijd waarin ze vier keer binnen anderhalf jaar een 
omvangrijk vragenlijstenboekje hebben ingevuld en ook (in de eerste jaren van de studie) 
bereid waren om twee keer een interview te ondergaan. 
De dataverzameling van dit project was omvangrijk, daarom dank aan de studenten die in 
de afgelopen jaren voor hun masterthesis (Jolien Diekhorst, Mike de Vet), 
onderzoeksstage (Esther Muskens) of vrijwillig (Martha van den Berg, Vivianne Sterk, 
Marjan Traa, Marie-Anne Mittelhaeuser) hebben bijgedragen aan de datamanagement. 
I would like to thank all members of the defense committee for their valuable time 
to read and judge this thesis and discuss the results next September: Dr. A.M.W. Alings, 
Dr. M.M. Burg, Prof.dr. G.L.M. van Heck, Prof.dr. K.H. Ladwig, Dr. S.S. Pedersen, and 
Dr. D.A.M.J. Theuns. 
Dankwoord (Acknowledgements) 
267 
Nanda, Judith en Miriam, met jullie als paranimfen moet ik de weken tot 19 
september en De dag goed door kunnen komen. Bedankt voor jullie vriendschap en voor 
jullie hulp en steun bij alle voorbereidingen en op De dag. 
Naast de paranimfen wil ik natuurlijk ook andere vrienden bedanken, voor 
(vrouwen) film- en TVserie-avondjes, tennispartijtjes en andere sportactiviteiten, 
vakanties, etentjes en gezelligheid, of voor dat ze er gewoon waren voor ontspanning. 
Mijn (schoon) familie wil ik bedanken voor hun vertrouwen in mij en voor de 
stimulatie en steun om het beste uit jezelf te halen en het hoogst haalbare te bereiken. 
Mijn ouders wil ik speciaal bedanken voor de kansen die ze mij gegeven hebben en mijn 
schoonouders voor de gezellige etentjes (niet in het minste van de donderdagen). 
Caspar, voor jou de laatste bijzondere woorden in dit dankwoord. Zonder jouw 
liefde, vertrouwen, steun, hulp, en flexibiliteit was ik nooit zo ver gekomen als ik nu ben. 
Ook jouw relativeringsvermogen en stabiliteit zijn voor mij onmisbaar. De afgelopen 
jaren heb ik met spanning toegeleefd naar De dag, dus hopelijk begint na 19 september 
een tijd van ontspanning.  
 
Krista van den Broek, 








Papers included in thesis 
1. Van den Broek KC, Denollet J, Nyklícek I, van der Voort PH. Psychological reaction 
to potential malfunctioning of implantable defibrillators. Pacing Clin Electrophysiol 
2006;29:953-6. 
2. Van den Broek KC, Martens EJ, Nyklícek I, van der Voort PH, Pedersen SS. 
Increased emotional distress in type-D cardiac patients without a partner. J Psychosom 
Res 2007;63:41-9. 
3. Pedersen SS, Van den Broek KC, Sears SF. Psychological intervention following 
implantation of an implantable defibrillator: a review and future recommendations. Pacing 
Clin Electrophysiol 2007;30:1546-54. 
4. Van den Broek KC, Nyklíček I, Van der Voort P, Alings M, Denollet J. Shocks, 
personality, and anxiety in patients with an implantable defibrillator. Pacing Clin 
Electrophysiol, in press. 
5. Van den Broek KC, Nyklíček I, Denollet J. Anxiety predicts poor perceived health in 
patients with an implantable defibrillator. Psychosomatics, in press. 
 
Other papers 
1. Denollet J, Smolderen KG, Van den Broek KC, Pedersen SS. The 10-item 
Remembered Relationship with Parents (RRP
10
) scale: two-factor model and association 
with adult depressive symptoms. J Affect Disord 2007;100:179-89. 
2. Van den Broek KC, Smolderen KG, Pedersen SS, Denollet J. Type D personality 
mediates the relationship between remembered parenting and perceived health. 
Psychosomatics, in press. 
3. Pedersen SS, Van den Broek KC. ICD shocks and their adverse impact on patient-
centered outcomes: Fact or Fiction? J Am Coll Cardiol, in press. 
4. Smith ORF, Van den Broek KC, Renkens M, Denollet J. Fatigue levels in stroke 
patients as compared to end-stage heart failure patients: Application of the Fatigue 





About the author 
271 
About the Author 
Krista van den Broek was born on April 17
th
, 1978 in Zundert, the Netherlands. She 
completed her pre-university education at the Mencia de Mendoza Lyceum in Breda, the 
Netherlands, in 1996. From 1996 to 2001, she studied psychology at Tilburg University, 
with a specialization in clinical health psychology. Her research internship was conducted 
at the Cardiac Rehabilitation Center of the University Hospital of Antwerp, Belgium. 
From 2001 to 2004 she worked as a budget consultant for several Debt and Budget 
Advisory Units. In 2004, she returned to Tilburg University to start her PhD research on 
psychological factors in implantable defibrillator treatment. She published several papers 
in Pacing and Clinical Electrophysiology. In addition, she presented her research at 
international conferences, including the International Conference on the (Non)Expression 
of Emotions in Health and Disease in Tilburg, the Netherlands, and the Annual Scientific 
Meetings of the American Psychosomatic Society, for example, in Baltimore, MD, USA, 
where she won an APS scholar award. Currently, she is working as a postdoctoral 
researcher at the Center of Research on Psychology in Somatic diseases (CoRPS), Tilburg 
University, the Netherlands. 
 
 
